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Abstract
Pathogenic organisms express virulence factors that can inhibit immune signaling pathways. Thus, the
immune system is faced with the challenge of eliciting an effective inflammatory response to pathogens that
actively suppress inflammation. The mechanisms that regulate this response are largely undefined. Here, I used
the gram-negative extracellular bacterial pathogen Yersinia pseudotuberculosis to investigate anti-pathogen
responses, as the Yersinia virulence factor YopJ blocks NF-κB and MAPK signaling, resulting in reduced
cytokine production and target cell death. I set out to first, determine the molecular mechanism of Yersinia-
mediated cell death and second, examine the impact of cell death on immune responses in vivo. Multiple
caspases are activated during Yersinia infection, including caspase-1, which regulates pyroptosis, and caspase-3
and -8, which elicit apoptosis. I found that caspase-8 and receptor-interacting protein kinase-3 (RIPK3),
RIPK1 and FADD are required for Yersinia-induced cell death. My studies also showed that caspase-8 is
required for the activation of caspase-1 and -3 during Yersinia infection. Interestingly, mice lacking caspase-8
were severely susceptible to Yersinia infection and had defective pro-inflammatory cytokine production.
These findings highlight a possible mechanism of immune defense that can overcome pathogen inhibition of
cell-intrinsic pro-inflammatory immune responses.
Caspases are proteases that are best characterized for their abilities to regulate apoptotic or pyroptotic cell
death programs, both of which are critical for the proper operation of the mammalian immune system. Within
this family of proteins is caspase-8, which is unusual as it can promote both cell death, and inflammatory gene
expression induced by Toll-like Receptors. How these two dichotomous outcomes occur independently of the
other, is mysterious. Using mice that specifically ablate caspase-8 auto-processing, I have demonstrated that
caspase-8 enzymatic, but not autoprocessing activity, mediates induction of inflammatory cytokines by a wide
variety of TLR stimuli. Since uncleaved caspase-8 functions together with its homolog, cFLIP, our findings
implicate the activity of a caspase-8/cFLIP heterodimer in control of inflammatory cytokines during
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ABSTRACT  
  
CASPASE-­8  IN  CELL  DEATH  AND  INFLAMMATION  
  
Naomi  H.  Philip  
  
Igor  E.  Brodsky  
  
Pathogenic   organisms   express   virulence   factors   that   can   inhibit   immune  
signaling  pathways.  Thus,  the  immune  system  is  faced  with  the  challenge  of  eliciting  an  
effective   inflammatory   response   to  pathogens   that  actively  suppress   inflammation.  The  
mechanisms   that   regulate   this   response  are   largely  undefined.  Here,   I  used   the  gram-­
negative  extracellular  bacterial  pathogen  Yersinia  pseudotuberculosis  to  investigate  anti-­
pathogen   responses,   as   the   Yersinia   virulence   factor   YopJ   blocks   NF-­κB   and   MAPK  
signaling,  resulting  in  reduced  cytokine  production  and  target  cell  death.  I  set  out  to  first,  
determine   the   molecular   mechanism   of   Yersinia-­mediated   cell   death   and   second,  
examine   the   impact  of  cell  death  on   immune   responses   in  vivo.  Multiple  caspases  are  
activated  during  Yersinia  infection,  including  caspase-­1,  which  regulates  pyroptosis,  and  
caspase-­3  and  -­8,  which  elicit  apoptosis.  I  found  that  caspase-­8  and  receptor-­interacting  
protein  kinase-­3  (RIPK3),  RIPK1  and  FADD  are  required  for  Yersinia-­induced  cell  death.  
My  studies  also  showed  that  caspase-­8  is  required  for  the  activation  of  caspase-­1  and  -­3  
during   Yersinia   infection.      Interestingly,   mice   lacking   caspase-­8   were   severely  
susceptible  to  Yersinia  infection  and  had  defective  pro-­inflammatory  cytokine  production.  
These   findings  highlight  a  possible  mechanism  of   immune  defense   that   can  overcome  
pathogen  inhibition  of  cell-­intrinsic  pro-­inflammatory  immune  responses.  
Caspases  are  proteases  that  are  best  characterized  for  their  abilities  to  regulate  
apoptotic   or   pyroptotic   cell   death   programs,   both   of   which   are   critical   for   the   proper  
operation  of  the  mammalian  immune  system.    Within  this  family  of  proteins  is  caspase-­8,  
which   is  unusual  as   it  can  promote  both  cell  death,  and   inflammatory  gene  expression  
   v  
induced   by   Toll-­like   Receptors.     How   these   two   dichotomous   outcomes   occur  
independently  of  the  other,   is  mysterious.  Using  mice  that  specifically  ablate  caspase-­8  
auto-­processing,  I  have  demonstrated  that  caspase-­8  enzymatic,  but  not  autoprocessing  
activity,  mediates   induction  of   inflammatory  cytokines  by  a  wide  variety  of  TLR  stimuli.  
Since   uncleaved   caspase-­8   functions   together   with   its   homolog,   cFLIP,   our   findings  
implicate   the   activity   of   a   caspase-­8/cFLIP   heterodimer   in   control   of   inflammatory  
cytokines   during   microbial   infection,   and   provide   new   mechanistic   insight   into   how  
caspase-­8  regulates  gene  expression.  
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   1  
I.  INTRODUCTION1  
  
Innate  Immunity  and  Pattern  Recognition  
The   innate   immune   system   forms   the   first   line   of   defense   against   non-­self   or  
pathogenic   organisms.   Cells   of   the   myeloid   lineage   including   macrophages,   dendritic  
cells   (DCs)   and   neutrophils   express   germline-­encoded   receptors,   called   pattern  
recognition   receptors   (PRRs)   that   recognize   a   vast   range   of   ligands   including  
lipoproteins,   polysaccharides,   nucleic   acids,   conserved   microbial   proteins   and  
carbohydrate  structures  (2).  PRR  signaling  can  induce  a  vast  array  of  changes  in  the  cell  
from  activating  gene  expression  of  pro-­survival  and  inflammatory  proteins  to  eliciting  cell  
death.   Toll-­like   receptors   (TLRs)   and   C-­type   lectin   receptors   (CLRs)   are   membrane-­
bound  receptors  and  are  situated  on  the  plasma  membrane  or  on  endosomes,  enabling  
detection   of   extracellular   organisms   and   microbes   that   are   internalized   or   shuttled   to  
endocytic  compartments.  The  cytoplasm   is  patrolled  by  nucleotide-­binding  domain  and  
leucine   rich   repeat  containing  proteins   (NLRs),  AIM-­2   like   receptors   (ALRs)  and  RIG-­I-­
like  receptors  (RLRs).  RLRs  recognize  nucleic  acids  and  NLRs  sense  a  range  of  factors  
including  microbial  products  as  well  as  disturbances  in  cytosolic  homeostasis  (NLRs  are  
discussed  in  more  detail   in  the  cell  death  section).  There  are  a  number  of  mechanisms  
that   allow   for   preferential   detection   of   microbial   versus   host-­derived   PRR   ligands,  
including  sub-­cellular  localization  and  cleavage  of  TLR  ectodomains  for  activation.  
   TLR,  RLR  and  CLR  ligation  trigger  MAPK,  NF-­κB  and  IRF  signaling  that  
activate  anti-­microbial  programs  and  initiate  adaptive  immune  responses  (3).  There  are  
13   mammalian   TLRs   (10   in   humans   and   12   in   mice)   that   are   composed   of   an  
                                                                                                 
1  This  section  contains  excerpts  from  1.  Philip  NH  &  Brodsky  IE  (2012)  Cell  death  programs  in  
Yersinia  immunity  and  pathogenesis.  Front  Cell  Infect  Microbiol  2:149.    
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ectodomain,   containing   leucine-­rich   repeats,   and   a   cytosolic   Toll-­IL-­1   receptor   (TIR)  
domain   (4).   Sub-­cellular   localization   of   TLRs   by   sorting   adaptors,   regulates   signaling  
outcomes.  For  instance,  when  TLR4  binds  lipopolysaccharide  (LPS),  TLR4  is  shuttled  to  
lipid   rafts   by   the   sorting   adaptor  CD14  and   this   initiates   signaling   through   the   adaptor  
MyD88.  Likewise,  CD14-­mediated  endocytosis  is  necessary  to  activate  the  second  TLR4  
signaling  pathway,  via  the  adaptor  TRIF  (5).  When  MyD88  is  recruited  to  TLR4,  IL-­1R1-­
associated   protein   kinase   4   (IRAK4),   IRAK2   and   IRAK1   form   a   complex   termed   the  
myddosome   (6,   7).   The   myddosome   induces   TNFR-­associated   factor   6   (TRAF6)   to  
activate  the  TAK1  complex,  which  phosphorylates  IκB  kinase-­β  (IKKβ)  and  MAPKs.  The  
IKKβ  complex  phosphorylates   IκBα,   triggering  proteasomal  degradation  of   IκBα,  which  
mobilizes  NF-­κB  to  the  nucleus.  MAPK  kinases  (MKKs)  phosphorylate  p38  kinases,  Jun  
kinases   (JNK)   and   extracellular   signal   related   kinases   (ERK),   resulting   in   nuclear  
translocation   and   gene   expression.   Along   with   contributing   to   late-­phase   NF-­κB   and  
MAPK   activation,   TRIF   recruits   TRAF3,   which   activates   the   phosphorylation   of   IRF3  
through   TANK-­binding   kinase   1   (TBK1)   and   IKKi,   inducing   type   I   IFN.   TLR   signaling  
modulates  the  expression  of  many  genes,   including  those  involved  in  cell  survival,  pro-­
inflammatory  cytokine  and  anti-­microbial  peptide  production.  In  this  way,  innate  immune  
signaling   pathways   induce   important   changes   in   the   host   cell   that   are   essential   for  
activating  anti-­pathogen  responses.    
Cell   survival,   proliferation   and   gene   expression   are   important   anti-­pathogen  
responses.  However,   regulated  cell   death   is  an  alternative  outcome   that   can  be  either  
pathologic  or  protective  to  the  host.  The  next  sections  will  highlight  key  pathways  of  cell  
death  and  the  impact  of  cell  death  on  the  immune  response.     
   3  
Pathways  of  cell  death  downstream  of  Pattern  Recognition  Receptors  
From   plants   to   mammals,   cell   death   is   an   evolutionarily   conserved   host   cell  
response   to   pathogens.   Here,   I   discuss   the   three   major   types   of   cell   death   that   are  
activated  in  mammalian  cells,  apoptosis,  necroptosis  and  pyroptosis.  
Cell   death   plays   a   key   role   in   maintaining   tissue   homeostasis   by   eliminating  
stressed,  damaged,  and  infected  cells.  Distinct  cell  death  pathways  that  result  in  distinct  
downstream  outcomes  are  induced  under  different  circumstances  (8-­11)  (Figure  1).    
Apoptosis   is   traditionally   viewed   as   an   immunomodulatory   form   of   cell   death  
characterized   by   cell   shrinkage,   while   necrosis   and   pyroptosis   are   pro-­inflammatory  
forms   of   death   associated   with   rapid   loss   of   membrane   integrity   and   release   of  
intracellular   contents.   While   apoptosis   during   development   is   anti-­inflammatory,  
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apoptotic   cell   death   during   infection   has   been   associated  with   inflammation   (12).  How  
these   distinct   cell   death   pathways   contribute   to   host   defense   responses   remains   an  
important  unanswered  question.  
There   are   two   major   pathways   that   mediate   apoptosis,   intrinsic   and   extrinsic  
(Figure  2).  Intrinsic  apoptosis  is  mediated  by  caspase-­9,  which  is  activated  upon  release  
of   cytochrome   c   and   other   apoptotic   factors   from   the   mitochondria.   Bid   and   Bax,  
members   of   the   Bcl-­2   family   of   proteins,   form   pores   in   the   mitochondria,   which  
compromises   its   permeability.   Caspase-­9   is   activated   in   a   complex,   termed   the  
apoptosome   resulting   in   activation   of   caspase-­3   and   -­7   (13).   Receptors   of   the   TNFR,  
Fas  and  TLR  families,  also  called  death  receptors,  regulate  extrinsic  apoptosis  and  pro-­
survival  signaling.  Extrinsic  cell  death  programs  that  are  activated  through  TNFR1/2  are  
most   well-­characterized   and   have   informed  much   of   the   work   in   the   field.   Here,   I   will  
focus  on  the  pathways  of  cell  death  that  are  activated  downstream  of  TLRs.  TLR3  and  
TLR4   engage   extrinsic   cell   death   in   the   presence   of   pharmacological   or   microbial  
inhibitors  of  NF-­κB  (14-­16).  TLR3-­  or  TLR4-­dependent  apoptosis  requires  caspase-­8  or  
caspase-­10,   members   of   the   cysteine   protease   family   of   caspases.   Upon   receptor  
ligation,   caspase-­8   is   recruited   to  TRIF  by  RIPK1  via  RIP  homotypic   interaction  motifs  
(RHIM)  (17).  RIPK1  can  bind  FADD  through  shared  death  domains  (DD)  and  FADD  can  
engage   caspase-­8   via   their   respective   death   effector   domains   (DED),   resulting   in  
assembly   of   a   RIPK1-­FADD-­caspase-­8   Death   Inducing   Signaling   Complex   (DISC)   or  
Complex   II   (18,   19).   In   this   complex,   caspase-­8   undergoes   dimerization   and  
autoprocessing,  which  stabilizes   the  active  enzyme  and  activates   its  apoptotic   function  
(20).  Since  Bid   is  also  a   target  of   caspase-­8,   there  are  some  cells  where   intrinsic  and  
extrinsic  apoptosis  are  linked  (21).  
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TLR3   and   -­4   can   also   mediate   a   caspase-­independent   cell   death   pathway,  
termed   receptor-­interacting   serine/threonine   protein   kinase-­3   (RIPK3)-­dependent  
necroptosis  (22-­24)  (Figure  2).  During  homeostasis,  the  pro-­survival  activity  of  caspase-­
8,   mediated   by   heterodimers   of   caspase-­8   and   its   catalytically   inactive   homologue,  
cFLIP  represses  RIPK3.  However,  inhibition  of  caspase-­8  activity  or  deletion  of  caspase-­
8  derepresses  RIPK3-­dependent  necroptosis   (25,  26).  Consistent  with   this,  caspase-­8-­  
and   FADD-­deficient   mice   are   embryonic   lethal,   due   to   activation   of   RIPK3-­dependent  
necrosis  during  development  and  are  protected  by  RIPK3  deficiency   (27)   (28)   (25,  26,  
29-­32).  RIPK3-­regulated  necrosis  requires  the  pseudokinase  Mixed  Lineage  Kinase  Like  
(MLKL)   (33-­35),   and  with  RIPK1   and  RIPK3   forms   a   complex   termed   the   necrosome.  
RIPK3   phosphorylates   MLKL,   which   causes   plasma   membrane   permeability.   Current  
studies  offer   two  models:   the   first  model  suggests   that  MLKL  binds  negatively-­charged  
phosphatidylinositol  groups  on   the  plasma  membrane   inducing  pore   formation   (36-­38),  
and   the   second   model   proposes   that   MLKL   localization   to   the   plasma   membrane  
regulates  ion  channels,  resulting  in  osmolysis  (39,  40).  
Pyroptosis   is  a  caspase-­dependent  pathway  of  pro-­inflammatory  cell  death   that  
requires   the   formation   of   a   multiprotein   complex,   termed   the   inflammasome   (41,   42)  
(Figure   2).   The   assembly   of   NLRs   that   contain   a   leucine-­rich-­repeat   (LRR)   sensor  
domain,  a  nucleotide-­binding  oligomerization  domain  (NOD),  and  a  pyrin  domain-­  (PYD)  
or  caspase  activation  and  recruitment  domain-­  (CARD)  containing  signaling  domain  (43),  
with   caspase-­1   or   -­11   (caspase-­4   and   -­5   in   humans)   and   an   adaptor   protein   such   as  
ASC   that   bridges   the   NLR   with   the   caspase   creates   the   inflammasome   structure.  
Inflammasomes   form   a   platform   for   the   autoprocessing   and   activation   of   the   cysteine  
proteases   caspase-­1   and   caspase-­11,   resulting   in   caspase-­dependent   secretion   of   IL-­
1α,   IL-­1β   and   IL-­18,   and   a   caspase-­1/11-­dependent   cell   death   termed   pyroptosis   (41,  
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44-­48).   Inflammasome   activation   is   thought   to   require   two   signals,   the   first   signal  
induces  the  expression  of  certain   inflammasome  components  and  cytokines  of   the  IL-­1  
family,  and   the  second  signal  activates  assembly  of   the  multiprotein  complex   (41,  42).  
The  precise  structural  changes  that  occur  during  oligomerization  and  caspase  activation  
are   not   fully   elucidated,   but   studies   suggest   the   process   is   similar   to   the   proximity-­
induced  cleavage  model  of  caspase-­8/9  activation.  
   Inflammasomes  are  characterized  by  the  class  of  NLR  or  sensor  and  the  
type  of  signal.  They  are  generally  classified  as  the  canonical  caspase-­1   inflammasome  
and  non-­canonical  caspase-­11  inflammasome.  The  NLRP3,  NLRC4  (NLR  family,  CARD  
containing   4)   and   AIM2   (absent   in   melanoma   2)   inflammasomes   are   most   well  
characterized.  NLRC4,   together  with  NAIPs   (NLR   family,   apoptosis   inhibitory   proteins)  
responds  to  intracellular  flagellin,  and  components  of  type  III  and  IV  secretion  systems  of  
gram-­negative   bacteria   (49-­52).   Interestingly,   NLRP3   has   a   wide   range   of   agonists  
including   bacterial,   fungal   and   viral   proteins   or   nucleic   acids   that   gain   access   to   the  
cytosol,   protein   aggregates,   DAMPs   such   as   ATP,   pore-­forming   toxins,   as   well   as  
crystals   (41).   As   there   is   no   unifying   set   of   signals   or   outcomes   associated   with   the  
NLRP3  inflammasome,  multiple  hypotheses  have  been  proposed  for   the  mechanism  of  
NLRP3   activation   (41).   Similarly,   the   NLRP1   inflammasome   does   not   appear   to   be  
activated   via   a   ligand-­receptor   mode   (53).   Murine   NLRP1b   is   required   for   detecting  
Bacillus   anthracis   lethal   toxin   (54)   and   Toxoplasma   gondii   (55).   Since   inflammasome  
activation   results   in   IL-­18   and   IL-­1   release,   inflammasomes   indirectly   mediate   IFNγ  
production  from  lymphocytes.  For   instance,  AIM2,  which  senses  double-­stranded  DNA,  
contributes   to   NK-­cell-­dependent   IFNγ   production   against   the   DNA   virus,  
cytomegalovirus   (CMV)   (56).   Finally,   the   NLRP6   and   NLRP12   inflammasomes,   which  
are  among  the  least  well-­defined,  are  implicated  in  intestinal  disease  and  anti-­microbial  
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defense   respectively,   but   the   precise   stimuli   that   activate   them   are   unknown   (57-­61).  
Despite   differences   in   the   biochemical   mechanisms   of   activation,   NLR-­dependent  
inflammasomes  induce  caspase-­1/11-­mediated  pyroptosis  and  release  of  the  IL-­1  family  
of  cytokines.  
The   mechanism   of   pyroptosis   and   precise   contributions   of   caspase-­1   and  
caspase-­11   to   caspase-­1/11   inflammasome  activation   are   not   clear.  However,   it   is  
now  appreciated   that   caspase-­1   and   -­11   have   stimulus-­dependent   contributions   to  
pyroptosis  and  IL-­1  release.  For  gram-­negative  pathogens  such  as  Escherichia  coli,  
Vibrio  cholera  and  Citrobacter  rodentium,  pyroptosis  requires  caspase-­11,  and  IL-­1β  
and   IL-­18   release   require   caspase-­1   (46,   62).   Furthermore,   caspase-­11,   but   not  
caspase-­1,  IL-­1β  or  IL-­18,  is  a  crucial  mediator  of  endotoxic  shock,  providing  further  
evidence   for   individual   roles   for   these   caspases   (46,   63).   Caspase-­11   was  
subsequently  shown  to  be  a  sensor  for  the  hexa-­acylated  lipid  A  portion  of  LPS  (64,  
65),   which   explains   prior   studies   that   implicated   caspase-­11   in   inflammasome-­
dependent  responses  to  gram-­negative  bacteria  that  access  the  host  cytosol  (44,  62,  
66-­69).  
In  vivo  consequences  of  cell  death  on  inflammation  
Every  second,  millions  of  cells  undergo  cell  death  and  are  removed  in  a  manner  
that  generates  minimal  inflammation.  Conversely,  cell  death  in  the  context  of  infection  or  
certain   cancer   therapeutics   can   be   highly   inflammatory.   For   sessile   organisms   lacking  
circulatory  systems,  such  as  plants,  cell  death  provides  a  cell-­autonomous  host  defense  
response  (70).   In  mammalian  cells,   immunogenic  cell  death   is  characterized  by  certain  
hallmarks,   such   as   the   release   of   damage-­associated   molecular   patterns   (DAMPs),  
which   include  HMGB1  (high  mobility  group  box  1),   IL-­33  and  ATP.  Cell  death  has  also  
been   proposed   to   enhance   cross-­presentation,   whereby   extracellular   antigens   are  
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phagocytosed  and  presented  on  major  histocompatibility   complex   I   (MHC   I)   to  T  cells.  
But   how   cell   death   affects   cross   presentation   is   poorly   understood.   Moreover,   the  
precise   requirements   for   individual   DAMPs   in   inflammatory   responses   are   not   known.  
Finally,  the  factors  that  determine  whether  cell  death  is  beneficial  or  pathological  to  the  
host  are  not  well-­defined.    
Apoptotic   cell   death   is   generally   viewed   as   non-­inflammatory   or  
immunosuppressive.   While   this   is   true   during   development   and   tissue   homeostasis,  
apoptotic   cell   death   can   also   promote   immune   responses.   For   example,   anthracyclin  
treatment  of   tumor  cells  causes  apoptosis   that   leads   to  exposure  of   calreticulin  on   the  
surface,  which   acts   as   a   signal   to   induce   phagocytosis   and   promote   anti-­tumor   T   cell  
responses   in  vivo   (71,  72).  Similarly,   the  dendritic  cell  C-­type   lectin   receptor,  DNGR-­1,  
can  promote  cross-­presentation  of  apoptotic  cell  antigens  by  CD8α+  DCs  to  CD8+  T  cells  
in  both  non-­infectious  and   infectious  settings   (73,  74).  HMGB1   release  by  dying   tumor  
cells   is   recognized   by   TLR4   on  DCs   and   enhances   antigen   presentation   (75).   Finally,  
DCs   that   phagocytose   bacterially-­infected   apoptotic   cells   produce   both   the  
immunoregulatory   cytokine   TGFβ,   and   the   inflammatory   cytokine   IL-­6,   which   together  
promote  the  differentiation  of  naïve  CD4+  T  cells  into  TH17  cells  (12).  These  cells  play  a  
critical   role   in   anti-­bacterial   immunity   and   pathological   inflammatory   responses   at  
mucosal   barrier   surfaces   (76-­78).   Together,   these   studies   argue   that   under   specific  
circumstances,   namely   microbial   infection   or   stimuli   that   promote   DAMP   release,  
apoptosis  can  be  immunostimulatory  (Figure  1).    
Caspase-­1/11-­mediated  pyroptosis  is   inherently   lytic,  but   is  also  associated  with  
the   release   of   pro-­inflammatory   cytokines.   Therefore,   recent   work   in   the   field   has  
stressed   the   importance   of   distinguishing   the   role   of   cell   death   on   inflammation  
independently   of   inflammatory   gene   expression.   Indeed,   caspase-­1-­dependent  
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pyroptosis   can   promote   antibacterial   responses   against   intracellular   pathogens  
independent  of  production  of   the  caspase-­1  dependent  cytokines   IL-­1β  and   IL-­18   (79).  
Consistently,  caspase-­11-­deficient  mice  are  resistant  to  LPS-­induced  septic  shock,  while  
IL-­1-­deficient  mice   are   still   susceptible,   suggesting   that   pyroptosis   is   a  major   driver   of  
inflammatory   disease   (46).   In   murine   models   of   spontaneous   cryopyrin-­associated  
periodic  syndromes  (CAPS),  where  missense  mutations  in  NLRP3  induce  high  systemic  
levels   of   IL-­1β   and   IL-­18,   deficiency   in   IL-­1R   and   IL-­18   did   not   completely   abrogate  
disease  (80).  However,  mice  lacking  caspase-­1  were  protected  from  CAPS,  suggesting  
a  role  for  cytokine-­independent,  likely  pyroptosis-­mediated  pathology.    
RIPK3-­regulated   necrosis   is   also   lytic   in   nature,   implying   necroptosis   can  
generate  local  and  systemic  inflammation.  In  fact,  RIPK3-­dependent  necrosis  promotes  
control   of   Vaccinia   and   CMV   viral   infections   (81).   Furthermore,   pyroptosis   and  
programmed   necrosis   may   promote   pathologies   that   are   not   directly   associated   with  
microbial   infections,   such   as   gout,   experimental   autoimmune   encephalomyelitis   and  
intestinal   barrier   function   (32,   48,   82).   Using   a   reductionist   approach,   Yatim   and  
colleagues   utilized   a   drug-­inducible   cell   death   system,   to   trigger   cell   death   in   the  
absence  of   any   other   source   of   inflammation   (81,   83).   The  authors   demonstrated   that  
RIPK3/RIPK1-­dependent  death,  activated  RIPK1  signaling  within  necroptotic  cells,  which  
was   necessary   for   cross-­priming   CD8+   T   cells.   However,   how   different   cell   death  
pathways  contribute   to   inflammation,  and  orchestrate  activation  of   innate  and  adaptive  
cells  during  bacterial   infections  remains  a  major  unresolved  question  for  understanding  
of  anti-­bacterial  immunity.  
Yersinia  as  a  useful  model  to  study  the  mechanisms  and  role  of  death  
Cell  death  is  an  evolutionarily  conserved  immune  response  to  microbial  infection,  
as  it  prevents  pathogen  replication  and  can  provide  pro-­inflammatory  signals  necessary  
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for  an  effective  immune  response.  Infection  with  the  pathogenic  Yersiniae  species  elicits  
host   cell   death.   There   are   three   pathogenic   species   of   Yersinia;;   Y.   pestis,   Y.  
pseudotuberculosis,   and   Y.   enterocolitica   share   a   virulence   plasmid   encoding   a  
conserved   Type   Three   Secretion   System   (T3SS)   and   virulence   factors,   known   as  
Yersinia  outer  proteins  (Yops)  (84).  T3SS-­mediated  injection  of  Yops  into   infected  cells  
enables  Yersinia  to  modulate  host  signaling  pathways  and  suppress  innate  and  adaptive  
immunity   (85).   YopJ   of   Y.   pestis   and   Y.   pseudotuberculosis,   termed   YopP   in   Y.  
enterocolitica,  blocks  NF-­κB  and  MAPK  signaling,  thereby  inhibiting  cytokine  production  
and  triggering  death  of  Yersinia-­infected  cells  (86-­88).  Among  the  sequenced  strains  of  
pathogenic  Yersiniae,  YopJ  and  YopP  share  95-­98%  identity  across  the  full  length  of  the  
protein   sequence,   but   key   polymorphisms   have   been   identified   that   impact   both  
enzymatic  activity  and  translocation  of  the  protein,  which  affect  the  outcome  of  Yersinia  
infection  (89-­92).    
Interestingly,  Yersinia-­infected  cells  can  exhibit  features  of  apoptosis,  pyroptosis,  
or  necrosis,  depending  on  the  relative  amounts  of  host  cell  death  regulators  and  Yersinia  
virulence   factors   (87,   88,   93-­96).   However,   whether   Yersinia-­induced   cell   death  
promotes  host  defense  or  bacterial  virulence  during  infection   in  vivo  remains  unclear.  A  
number   of   studies   have   revealed   key   players   in   cell   death   pathways   during   Yersinia  
infection,   providing   some   insight   into   mechanisms   of  Yersinia-­induced   cell   death,   but  
very  little  is  known  about  the  nature  and  role  of  Yersinia  death  in  vivo.  Yersinia  is  thought  
to   primarily   replicate   as   an   extracellular   pathogen   that   evades   phagocytosis   by  
neutrophils   and   monocytic   cells   in   lymphoid   tissues.   Cell   death   has   therefore   been  
viewed  as  a   strategy   for  Yersinia   to  eliminate  host   phagocytes   (97).  However,   several  
studies  suggest  that  host  cell  death  during  Yersinia  infection  may  promote  anti-­Yersinia  
immunity,   although   the   precise   mechanisms   are   poorly   understood   (89,   98,   99).   An  
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alternative   possibility   is   that   if  Yersiniae   are   capable   of   intracellular   replication   in   vivo,  
host   cell   death   may   eliminate   a   replicative   niche   (100).   Since   cell   death   is   a  
characteristic  feature  of  Yersinia  infection  both  in  vitro  and  in  vivo,  and  because  Yersinia  
is  genetically  tractable,  it  is  a  powerful  tool  to  study  the  mechanisms  and  consequences  
of  cell  death.       
Mechanisms  of  Yersinia-­induced  cell  death    
Early  studies  observed  that  macrophages  and  dendritic  cells  infected  by  Yersinia  
exhibit   characteristics   of   apoptotic   cells,   specifically   membrane   blebbing,   nuclear  
condensation,  DNA  fragmentation,  and  formation  of  large  cytoplasmic  vacuoles  (87,  95).  
Apoptosis   has   been   viewed   as   immunologically   silent,   but   growing   evidence   suggests  
that   during   infection,   apoptosis   may   promote   inflammatory   responses   (8,   12).  
Furthermore,   apoptotic   cells   can   be   phagocytosed,   and   their   associated   microbial  
antigens  used  to  prime  CD8+  T  cell  responses  (101).  Therefore,  while  cell  death  during  
Yersinia  infection  is  thought  to  be  apoptotic,  it  may  not  be  immunologically  silent.  Below,  
I   discuss   the   nature   of   Yersinia-­induced   cell   death   and   its   contribution   to   bacterial  
virulence  or  host  defense.    
The  cysteine  protease  YopJ  induces  cell  death  during  Yersinia  infection  (86,  87,  
97).   YopJ   is   a   potent   inhibitor   of   MAPK   and   NF-­κB   signaling,   and   blocks  
proinflammatory  cytokine  production  by  infected  cells  (88,  94,  102,  103)  (Figure  3).  YopJ  
has   been   reported   to   function   as   a   ubiquitin-­like   protein   protease   (102),   and   as   a  
deubiquitinase  (104,  105).  YopJ  is  also  reported  to  be  an  acyl  transferase  that  acetylates  
serine  residues  in  the  activation  loop  of  MKK  family  proteins  and  prevents  their  activation  
(106,   107).   The   sensitivity   of   NF-­κB   signaling   pathways   to   YopJ-­mediated   inhibition  
occurs   at   the   level   of   TAK1   and   is   evolutionarily   conserved   from   Drosophila   to  
mammalian  cells  (108).  
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Macrophages   stimulated   with   LPS   in   the   presence   of   inhibitors   of   protein  
synthesis   or   components   of   NF-­κB   signaling   undergo   cell   death   (15,   109).   Consistent  
with   this,  Tlr4-­/-­   macrophages   are   resistant   to   YopJ-­dependent   apoptosis,   as   are   cells  
deficient   in   the   TLR3/4   adaptor   TRIF,   but   not   MyD88   (14-­16).   Moreover,   infection   of  
dendritic  cells  with  Yersinia   leads  to   the   formation  of  a  FADD/caspase-­8/RIP1  complex  
and   caspase-­8   activation   (110).   Cytochrome-­c   release   and   caspase-­9   cleavage   were  
observed   downstream   of   Yersinia-­induced   cleavage   of   the   pro-­apoptotic   Bid   protein  
(111).   Additionally,   treatment   with   broad-­spectrum   caspase   inhibitors   reduced   the  
number  of  TUNEL+  cells  during  Yersinia  infection,  suggesting  Yersinia  induces  caspase-­
dependent   cell   death   (97,   111).   Whether   these   proteins   are   required   for   Yersinia-­
induced  cell  death   is  unclear.   Interestingly,  Yersinia   infection  of  dendritic  cells  exposed  
to   a   pan-­caspase   inhibitor   still   induced   a   cell   death   that   is   presumably   caspase-­
independent   and   exhibited   morphological   features   of   necrosis   (112),   likely   RIPK3-­
regulated  necrosis.  But  how  this  pathway  functions  during  Yersinia  infection  and  the  link  
between  programmed  necrosis  and  other  forms  of  Yersinia-­induced  death  is  not  known.    
Pathogens   express   pore-­forming   toxins   and   virulence   proteins   that   disrupt  
membrane   integrity  and  modulate  signaling  networks   (113).  Consequently,  mammalian  
hosts   have   evolved   mechanisms   that   detect   these   virulence   activities,   such   as   the  
activation  of  a  multiprotein  complex  called  the  inflammasome  (114).  Yersinia  expresses  
a   conserved   T3SS   that   activates   the   NLRP3   and   NLRC4   inflammasomes,   triggering  
pyroptosis   (115).   However,   the   virulence   factor   YopK   prevents   this   inflammasome  
activation,   and   promotes   bacterial   replication   and   dissemination   in   vivo   (115).   In   the  
presence  of  YopJ,  YopK-­sufficient  bacteria  still  induce  cell  death.  Thus,  a  key  question  is  
how   these   two   seemingly   contradictory   outcomes   are   controlled   during   Yersinia  
infection.  Yersinia   expressing   YopK   but   lacking   YopJ,   do   not   induce   T3SS-­dependent  
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inflammasome  activation  or  cell  death.  Thus,  YopK  likely  limits  inflammasome  activation  
under   conditions   where   YopJ   expression   or   translocation   is   reduced,   as  may   happen  
during  infection  of  systemic  sites  (discussed  further  below).  Thus,  specific  Yops,  such  as  
YopJ  and  YopK,  can  control  the  mechanisms  of  host  cell  death.  However,  the  activation  
state   of   host   cells   is   also   an   important   factor   in   the   cell   death   response.   Previous  
encounter  with  a  pathogen  or  PAMP  is  most  relevant  in  vivo,  where  PAMPs  such  as  LPS  
are  shed  by  bacteria.    
Macrophages   that   are   treated  with   LPS   prior   to   infection,   also   called   “primed”,  
respond   to   pathogens,   such   as   Yersinia,   differently   than   unprimed   or   naïve  
macrophages.   LPS   priming   upregulates   an   array   of   pro-­survival   proteins   and  
inflammasome  components,  such  as  NLRP3  (116),  and  may  set   the  threshold  for  Yop-­
dependent   cell   death.   For   instance,   macrophages   primed   by   inflammatory   stimuli  
undergo  pyroptosis  in  response  to  YopJ-­deficient  Yersinia  infection  (93),  which  is  greatly  
enhanced   in   the   additional   absence   of   YopK   or   YopM   (115,   117,   118).   Interestingly,  
YopM  inhibits  caspase-­1  and  inflammasome  activation  in  LPS-­primed  macrophages,  by  
preventing   the   association   of   pro-­caspase-­1   with   ASC   (119,   120).   These   studies  
demonstrate   how   prior   exposure   to   PAMPs   sensitizes   macrophages   to   YopJ-­
independent   cell   death.   Nevertheless,   naïve   macrophages   undergo   cell   death   that  
requires  YopJ.  
Interestingly,   YopJ-­dependent   apoptosis   is   also   associated   with   caspase-­1  
activation   (92,   115,   121),   and   the   extent   of  YopJ-­mediated  NF-­κB   inhibition   correlates  
with  the  degree  of  caspase-­1  activation  (92),  consistent  with  the  finding  that  deletion  of  
IKKβ   in   macrophages   induces   spontaneous   inflammasome   activation   (122).   Although  
NLRP3  and  the  adaptor  ASC  are  required  for  YopJ-­dependent  secretion  of  IL-­1β  and  IL-­
18   (92),   the  mechanism   by  which   YopJ   activates   caspase-­1   is   unclear,   as   caspase-­1  
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processing  and  YopJ-­dependent   cell   death   still   occur   in   cells   lacking  ASC,  NLRC4,  or  
NLRP3   (115,   123,   124)   (Figure   2).   Distinct   inflammasome   complexes   with   different  
functions   have   been   identified,   and   could   potentially   account   for   these   observations.  
Caspase-­1  could  be  recruited  to  an  NLRP3/ASC  complex  that  regulates  IL-­1β  and  IL-­18  
production,   and   to   a   separate   complex   that   activates   cell   death.   Indeed,   during  
Salmonella   infection,  a   complex  containing  catalytically  active   caspase-­1,  but  not  ASC  
triggers   cell   death   but   not   cytokine   secretion,   while   a   distinct   ASC-­containing   focus  
mediates  caspase-­1  processing  and  cytokine  secretion  (125).  NLRP12  was  also  recently  
found   to   induce   inflammasome   activation   in   response   to  Y.   pestis   infection,   and   both  
NLRP3   and   NLRP12   contributed   to   host   defense   against   Yersinia,   presumably   via  
induction  of  caspase-­1-­dependent  IL-­1β  and  IL-­18.  (60).  YopJ  may  activate  an  NLRP12  
inflammasome,   although   this   remains   to   be   demonstrated.   Finally,   a   non-­canonical  
inflammasome  pathway  involving  caspase-­11,  TRIF,  and  type  I   IFN  signaling  has  been  
described   that   responds   to   gram-­negative   intracellular   bacteria   independently   of   T3SS  
activity   (46,   66,   68,   69,   126).   Whether   this   pathway   contributes   to   anti-­Yersinia   host  
defense  remains  unknown.    
The  role  of  YopJ-­induced  death  in  vivo    
A   number   of   studies   indicate   that   YopJ/P   promotes   Yersinia   virulence.   Oral  
infection   with   Y.   pseudotuberculosis   and   Y.   enterocolitica   demonstrate   that   YopJ/P  
contributes   to   systemic   disease   and   barrier   dysfunction   (97,   127,   128).   YopJ   is  
dispensable  for  colonization  of  the  Peyer’s  patches  (PPs)  and  mesenteric   lymph  nodes  
(mLNs),   especially   at   higher   infectious   doses;;   however,   YopJ-­deficient   Yersinia   had  
significantly   reduced   levels  of  spleen  colonization  after  oral   infection  (97).  Spleens  and  
mLNs  from  mice  infected  with  YopJ-­sufficient  bacteria  had  a  higher  percentage  of  Mac1+  
TUNEL+  and  total  TUNEL+  cells  compared  to  YopJ-­deficient  bacteria,  consistent  with  the  
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role  of  YopJ  in  apoptosis   in  vivo.  Furthermore,  in  competitive  index  experiments,  YopJ-­
deficient  Yersinia  showed  colonization  defects  in  PPs,  mLNs  and  spleen.  YopJ-­deficient  
Yersinia   were   not   defective   for   splenic   replication   following   intraperitoneal   infection,  
indicating  that  YopJ  primarily  regulates  dissemination  from  mucosal  tissues,  rather  than  
replication  at  systemic  sites   (97).  Consistently,  YopJ-­deficient  Y.  pestis  are  still  able   to  
cause  systemic  infection  in  an  intradermal  rat  model  of  bubonic  plague,  despite  a  defect  
in   induction   of   apoptosis   and   higher   levels   of   TNF   compared   to   wild   type   Y.   pestis  
infection   (129).      These   findings   imply   that   apoptosis   may   be   utilized   by   Yersinia   to  
eliminate   immune   cells   at   mucosal   surfaces   resulting   in   barrier   dysfunction   and  
dissemination.  An  alternative  explanation   is   that  YopJ-­dependent  cytokine  suppression  
weakens  barrier  integrity  and  promotes  bacterial  spread.  Thus,  it  is  important  that  future  
studies   distinguish   the   roles   of   cell   death   versus   cytokine   expression   on   disease  
progression.  
Paradoxically,  ectopic  expression  of  a  hypercytotoxic  YopP  from  Y.  enterocolitica  
in  Y.  pseudotuberculosis  results  in  its  attenuation  in  oral  mouse  infection  (89)  (Figure  3).  
While   both   Y.   pseudotuberculosis   and   Y.   enterocolitica   cause   cell   death   in   cultured  
macrophages   and   infected   tissues,   infection   with   YopP-­expressing   Y.  
pseudotuberculosis   showed   a   significant   increase   in   TUNEL+   CD11b+,   CD11c+   and  
B220+   cells   in   mLNs   relative   to   mice   infected   with   the   YopP-­expressing   strain   (89).  
Similarly,  Y.   pestis   strains   expressing  YopP   had   higher   cytotoxic   potency   than   strains  
expressing  YopJ,  both  in  vitro  and  in  tissues  of  infected  mice;;  furthermore,  expression  of  
YopP   in   Y.   pestis   also   resulted   in   lower   virulence   following   subcutaneous,   but   not  
intranasal   or   intravenous   routes   of   infection   (99).   Interestingly,   subcutaneous  
administration  of  Y.  pestis  expressing  YopP  protected  against   infection  with  virulent  Y.  
pestis,   regardless   of   the   route   of   challenge.   These   observations   suggest   that   YopJ  
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contributes  to  dissemination  of  Yersinia  from  barrier  surfaces,  but  may  be  less  important  
once   bacteria   have   spread   to   systemic   sites.   Whether   YopJ   or   additional  
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immunosuppressive   virulence   mechanisms   play   a   role   in   dampening   the   early  
inflammatory  response  to  Yersinia   infection   in  pneumonic  plague  (130)  also  remains  to  
be  determined.    
Consistent   with   observations   that   YopJ   promotes   systemic   dissemination  
following  oral  infection,  YopJ  contributes  to  gut  barrier  disruption  (127,  128).  Specifically,  
YopJ   can   induce   TLR2-­dependent   IL-­1β   secretion   in   PPs,   which  was   associated  with  
increased   barrier   permeability,   suggesting   that   TLR2   signaling   mediates   YopJ-­
dependent  gut  disruption  (127).  Conversely,  TLR2-­deficient  mice  have  been  reported  to  
be  more  susceptible   to   oral   infection   by  Yersinia   pseudotuberculosis,   due   to   a   loss   of  
TLR2-­dependent  Reg3β  expression  in  the  gut  epithelium  (131).  Thus,  the  precise  role  of  
TLR2  in  Yersinia   infection  remains  to  be  further  dissected.  Notably,   IL-­1α  is  associated  
with   pathological   intestinal   inflammation   and   increased   dissemination   of   Yersinia  
enterocolitica  (132),  but  the  role  of  YopP  or  TLR2  in  this  context  has  not  been  examined.    
In   contrast   to   cell   death   induced   by   the   activity   of   a   bacterial   virulence   factor,  
CD8+  cytotoxic  T  cells  also  induce  death  of  Yersinia-­infected  cells,  and  are  important  for  
control   of  Yersinia   infection,   as   demonstrated   by   the  more   severe   disease   in   infected  
β2m-­/-­,  anti-­CD8α-­treated,  or  perforin-­deficient  mice  (98).  CD8+  T  cell-­mediated  killing  of  
bacteria-­associated   cells   targeted   them   for   phagocytosis   by   uninfected   macrophages,  
and   could   bypass   the   anti-­phagocytic   activity   of  Yersinia  Yops   (98).   Notably,   CD8+   T  
cells  were  not   responsible   for   resistance   to  YopP-­expressing  Y.  pestis,   (99).  The  more  
cytotoxic  YopP  may  bypass  the  requirement  for  CD8+  T  cell-­mediated  killing  due  to  the  
elevated   cytotoxicity   induced   by   the   bacteria.   These   studies   collectively   suggest   that  
regulation  of  cytotoxicity  during  Yersinia   infection  impacts  virulence,  and  that  a  balance  
between   the   cytokine-­blocking   and   death-­inducing   functions   of   YopJ   is   required   for  
optimal  virulence.  Specifically,  absence  of  YopJ  results  in  failure  of  Yersinia  to  suppress  
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cytokine  production  or  induce  cell  death  and  causes  a  defect  in  dissemination.  However,  
Y.   pseudotuberculosis   expressing   YopP,   which   enables   stronger   inhibition   of   cytokine  
production   and   elevated   levels   of   cell   death,   are   also   significantly   attenuated   in   vivo.    
Thus,  while   the   relative  contributions  of  bacteria-­induced  and  T  cell-­induced  cell   death  
during  Yersinia  infection  in  vivo  are  not  yet  defined,  activation  of  cell  death  in  vivo  either  
in   response   to  YopJ  activity,  or  as  a  consequence  of  T-­cell-­mediated  cytotoxicity   likely  
promotes   immune   responses   against   Yersinia.   Finally,   the   precise   pathways   of   cell  
death  that  may  be  activated  in  a  cell  type  specific  manner  in  vivo,  is  still  unclear.    
Caspase-­8  and  its  homolog  cFLIP  
Caspases  belong  to  a  family  of  cysteine  proteases  that  recognize  four  contiguous  
amino  acids  and  cleave  their  substrates  after  an  aspartate  residue.  Apoptotic  caspases  
can   be   segregated   into   initiator   caspases,   caspase-­2,   -­8,   -­9   and   -­10,   and   executioner  
caspases,   caspase-­3,   -­6,   and   -­7.   Most   caspases   are   inactive   zymogens   that   need   to  
undergo   cleavage,   either   by   initiator   caspases   or   by   themselves,   to   be   activated.    
Although   the   first   caspase,   IL-­1beta   converting   enzyme   (ICE),   now   called   caspase-­1,  
was   identified   in   humans   (133,   134),   the   critical   studies   that   uncovered   the   role   of  
caspases   in  apoptosis  were  performed   in   the  nematode  worm,  Caenorhabditis  elegans  
(135).  Since  then,  14  caspases  have  been  identified  in  mammals  and  11  in  humans.  The  
homologs  caspase-­8  and  -­10  are  executioner  caspases  that  are  activated  by  proximity-­
induced   dimerization   and   cleavage.   Caspase-­8   and   -­10   are   considered   to   have  
branched-­off  from  their  ancestor  caspase-­810  sometime  after  the  split  between  fish  and  
tetrapods,   but   the   gene   for   caspase-­10   is   lost   in   rodents,   suggesting   overlapping  
functions   (136)   (137).   Although   caspase-­8   and   caspase-­10   share   substrate   specificity  
(138),   whether   they   have   similar   roles   in   non-­apoptotic   pathways   remains   to   be  
discovered.   Interestingly,   another   member   of   this   family,   caspase-­18,   is   suggested   to  
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have   originated   from   a   duplication   event   of   caspase-­8   or   -­10   in   the   split   of   the  
amphibians   from   the   amniotes.   As   such,   caspase-­18   is   conserved   among   birds,  
prototherian  (egg-­laying)  and  metatherian  (marsupials)  mammals,  but  appears  to  be  lost  
among  eutherian  (placental)  mammals  (137).  As  I  have  used  murine  models  to  examine  
the  role  caspase-­8  in  immunity,  this  section  will  focus  on  caspase-­8.    
Regulation  of  caspase-­8  activation  
The  current  model  for  caspase-­8  activation  describes  two  cleavage  steps  (139).  
For  human  caspase-­8,  which  has  been  studied  in  more  depth,  caspase-­8  first  undergoes  
self-­cleavage   between   the   large   and   small   catalytic   subunits   at   Asp384   (or  Asp387   in  
mice).  Then,  a  second  cleavage  event  takes  place  between  the  second  DED  and  large  
subunit,   at   Asp210,   Asp216,   or   Asp223,   and   just   downstream   the   large   subunit   at  
Asp374,  releasing  the  active  p182-­p102  heterotetramer  (Figure  4).    
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In  mice,  the  equivalent  cleavage  at  Asp374  is  not  thought  to  occur,  suggesting  potential  
differences   in  substrate  specificity  between  human  and  mouse  caspase-­8.  Additionally,  
the  cleavage  at  one  site  does  not  affect  self-­processing  at  another  site   (140),   implying  
different  cleavage  products  may  have  distinct  functions.  The  precise  roles  of  caspase-­8  
cleavage  and  dimerization  in  its  activation  will  be  discussed  below.  
In   vitro   experiments   with   recombinant   proteins   have   shown   that   non-­cleavable  
caspase-­8   undergoes   dimerization   in   high   salt   solutions   and   can   hydrolyse   substrates  
(139,   141,   142).   Since   cleavage   alone   was   insufficient   to   activate   caspase-­8   in   vitro  
(142),   these   studies  proposed  an  early  model,  whereby   caspase-­8   cleavage   stabilizes  
the  dimer  but  is  not  necessary  for  activation.  However,  other  experiments  suggested  that  
when  caspase-­8  is  cleaved  by  Granzyme  B  or  upon  addition  of  cytochrome  c/ATP,  as  is  
the   case   during   intrinsic   apoptosis,   dimerization   in   the   context   of   the   DISC   is   not  
necessary   for   caspase-­8-­mediated   substrate   processing   (143,   144)   (145,   146).  
Therefore,  whether   dimerization  and   cleavage  was  necessary   for   caspase-­8  activation  
remained  unresolved.    
Subsequent   work   demonstrated   that   dimerization   of   non-­cleavable   caspase-­8,  
using  modified  caspase-­8  expressing  drug-­inducible  dimerizable  domains,  is  insufficient  
for   caspase-­8   activation   in   cellular   conditions   (20,   147,   148).   Interestingly,   addition   of  
non-­physiological   levels  of  sodium  citrate  overcomes  the  requirement  for  self-­cleavage,  
consistent   with   the   findings   above   (148).   Therefore,   noncleavable   caspase-­8  
homodimers  can  be  active  under  certain  conditions,  but  whether  this  occurs  in  vivo  is  not  
clear.   The   requirement   for   caspase-­8   homodimerization   and   subsequent   self-­cleavage  
for   activation   may   be   a   cell-­type   specific   phenomenon,   that   depends   on   the   relative  
abundance  of  caspase-­8,  its  homolog  cFLIP  and  other  components  of  the  DISC.  
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cFLIP  is  a  key  regulator  of  caspase-­8  activation  
FLIPs   (Fas-­associated   death   domain-­like   IL-­1β-­converting   enzyme   inhibitory  
proteins)  are  cellular  (cFLIP)  and  viral  (vFLIP)  proteins  that  are  homologs  of  caspase-­8,  
but   possess   no   enzymatic   activity   on   their   own   (149-­157).   There   are   many   splice  
variants   of   cFLIP:   the   long   isoform   cFLIPL/cFLIPα   expresses   the   two   DEDs   and  
caspase-­like   domain   of   caspase-­8,   the   short   isoform   cFLIPS/cFLIPδ   (cFLIPR   in   mice)  
consists   of   the   two   caspase-­8  DEDs,   and   cFLIPβ   and   cFLIPγ   express   two  DEDs   and  
part  of   the  caspase-­like  domain.  The  DEDs  of  cFLIPS  engage   the  DEDs  of  caspase-­8,  
thereby  preventing  caspase-­8  homodimerization  and  apoptosis  via  a  dominant  negative  
fashion   (150,   154).  Viral   FLIPs,  which  are   analogous   to   cFLIPS,   are   nonessential   viral  
genes   that  are  expressed   in  pox  viruses  and   lymphotropic  gamma-­herpes  viruses  and  
also   block   caspase-­8-­dependent   apoptosis   (149,   157).   In   addition,   cFLIPL   has   a  
prosurvival   role,   as   cFLIPL-­deficient  mice  are  embryonic   lethal   and  suffer   from  cardiac  
developmental  defects  at  E10.5  similar  to  caspase-­8  and  FADD-­deficient  mice  (27,  158,  
159).   cFLIP   represses   apoptosis   and   necrosis:   the   caspase-­8/cFLIP/FADD   complex  
inhibits   RIPK3-­regulated   necrosis   and   caspase-­8/cFLIP   blocks   caspase-­8-­dependent  
apoptosis  (26,  160)  (161).  
The  function  and  activity  of  cFLIP  has  been  examined  in  the  context  of  caspase-­
8.   Paradoxically,   experiments   using   kosmotropic   salts   to   force   dimerization   between  
cFLIP  and  non-­cleavable  or  wild   type  caspase-­8  demonstrate   that   cFLIPL  can  activate  
caspase-­8  under  these  cell-­free  conditions  (162).  The  caspase-­8/cFLIP  heterodimer  has  
one   catalytic   site,   while   caspase-­8   homodimers   have   two   sites.   One   plausible  
explanation   is   that   cFLIP/caspase-­8  heterodimers  at   superphysiological   concentrations  
contain  the  sufficient  number  of  active  sites  necessary  for  apoptotic  substrate  cleavage  
(147).   Nevertheless,   upon   Fas   ligation,   caspase-­8/cFLIPL   heterodimers   undergo  
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proteolytic   processing   between   the   small   and   large   subunits,   producing   43   kDa  active  
subunits  (163).  Additionally,   in  vitro  studies  suggest  that  processing  of  cFLIPL  occurs  in  
the  caspase-­8/cFLIPL  heterodimer  and  not  as  a  consequence  of  caspase-­8  homodimer  
activity  (164).  The  cFLIP/caspase-­8  p43  subunit  does  not  mediate  any  known  apoptotic  
functions   of   caspase-­8,   however   p43   caspase-­8/cFLIPL   may   control   non-­apoptotic  
signaling.    
Non-­apoptotic  roles  for  caspase-­8  and  cFLIP  
In   the   Drosophila   immune   deficiency   (imd)   pathway,   the   caspase-­8   homolog,  
Dredd,   activates   Relish,   the   p100/105   NF-­κB   homolog   in   Drosophila   via   cleavage  
between  its  IκB  and  Rel  homology  domains  (165).  However,  the  roles  of  caspase-­8  and  
cFLIP   on   NF-­κB   signaling   in   mammalian   cells,   is   under   debate.   There   is   a   sizeable  
literature  suggesting  that  caspase-­8  and  cFLIP  control  NF-­κB  and  MAPK  signaling  (166-­
172),  but   there  are  also  studies  showing  no  connection  between  these  pathways  (173-­
175).  As  caspase-­8  represses  RIPK3-­necrosis,  caspase-­8  inhibition  may  have  released  
the  break  on  necroptosis,   confounding   the   interpretation   that   caspase-­8  affects  NF-­κB  
independently   of   cell   death.   It   is   also   possible   that   certain   conditions   in   vitro   may  
promote  interactions  between  caspase-­8,  cFLIP  and  NF-­κB.  Future  studies  will  need  to  
examine  this  interaction  in  a  cell-­,  stimulus-­  and  dose-­specific  manner  to  shed  more  light  
on  these  mechanisms.  
In   addition   to   their   well-­described   roles   in   regulating   cell   death,   caspases  
(especially  caspase-­3  and  -­9)  are  also  implicated  in  regulating  non-­apoptotic  functions  in  
glial  cell  development,  erythroid  maturation  and  skeletal  muscle  differentiation  (176-­178).  
Recent  studies  have  implicated  a  role  for  caspase-­8  in  anti-­microbial  responses,  but  the  
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extent   and  mechanisms   of   this   regulation   remain   poorly   defined   (123,   124,   173,   179-­
182).  
Caspases  regulate  cell  death  and  survival  during  homeostasis  and  disease.  How  
cells  die,  and  how  neighboring  cells  respond  to  dying  cells  are  critical  factors  that  control  
the   pathogenesis   of   disease.   Cell   death   can   be   beneficial   under   some   circumstances  
and  pathological  under  others.  Therefore,  understanding   the  mechanisms  of  cell  death  
and   how   cell   death   impacts   immune   responses   will   shed   light   on   how   the   balance  
between   protective   and   pathological   inflammation   is   regulated.   In   this   work,   using  
Yersinia  as   a  model,   I  will   investigate   the  molecular   requirements   of   cell   death   during  
Yersinia   infection.  Once   I  have   identified   the  mechanisms  by  which  host  cells  undergo  
Yersinia-­induced  cell  death,  I  will  study  the  role  of  cell  death  during  Yersinia  infection  on  
the  immune  response.  These  findings  will  aide  in  the  development  of  novel  therapeutics  
that  modulate  inflammation  during  infection,  cancer  and  autoimmunity.  
Appropriate   regulation   of   innate   and   adaptive   immune   responses   is   necessary  
when   the   host   encounters   potentially   dangerous   stimuli.   PRRs   are   a   family   of   innate  
immune   receptors   that   sense   conserved   microbial   features   activating   innate   and  
consequently   adaptive   immune   responses.   Modulating   gene   expression   is   a   critical  
outcome  of  PRR  signaling.  Since  the  initial  discovery  of  TLRs,  many  of  the  factors  that  
are  necessary  for  PRR  signaling  are  now  well-­characterized.  However,  TLR  signaling  is  
not  a  bimodal  switch.  The  concentration  of  input  can  control  the  magnitude  of  the  output,  
suggesting   that   signal   strength   is   an   important   factor   that   can   modulate   outcome.  
Furthermore,  signaling  networks  consisting  of  core  regulators  and  fine-­tuners  that  define  
the   nature,   magnitude   and   specificity   of   the   response.   But,   the   precise   cell-­intrinsic  
circuits  that  modulate  the  specificity  of  signaling  outcomes  are  poorly  defined.  Here,  I  will  
examine   the   role   of   caspase-­8   in   TLR   signaling   and   in   host   defense   against   bacterial  
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and   viral   infections.   Understanding   the   factors   that   control   TLR   signaling   will   provide  
rational  targets  that  can  be  hyperactivated  or  repressed  to  manipulate  disease  outcomes  
in  autoimmunity,  infection,  vaccines  and  cancer.     
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II.  MATERIALS  AND  METHODS  
Mice  
C57BL/6.SJL   mice   were   obtained   from   Jackson   Laboratories.   Ripk3-­/-­   mice   were  
provided  by  Vishva  M.  Dixit  (Genentech)  and  are  N7  and  N10  generation  backcrossed.  
The  Ripk3-­/-­Casp8-­/-­    mice  were  provided  by  Doug  Green  (St.  Jude  Children’s  Research  
Hospital).   Casp8f/-­   mice   were   provided   by   Rasq   Hakem   (University   Health   Network),  
Fadd-­/-­   mice   were   provided   by   Tak  W.  Mak   (University   Health   Network),  Ripk1-­/-­  mice  
were  provided  by  Michele  Kelliher   (University  of  Massachusetts),  and  Mlkl-­/-­  mice  were  
provided  by  Warren  Alexander  (The  Walter  and  Eliza  Hall  Institute  of  Medical  Research).  
Casp8+/-­   mice   that   were   used   to   generate   the  Mlkl-­/-­Casp8-­/-­     mice   were   provided   by  
Steve  Heddrick   (UCSD).  Ripk3-­/-­Casp8-­/-­  mice   in   these   studies  were  backcrossed  6-­10  
times  and  a  detailed  SNP  analysis  of  Ripk3-­/-­Fadd-­/-­  mice   indicated   that  90-­94%  of   loci  
are  B6  in  any  given  mouse.  Bones  from  Casp3-­/-­  and  Casp7-­/-­  mice  were  provided  by  T.  
Devi-­Kanneganti   (St.   Jude   Children’s   Research   Hospital)   or   purchased   from   Jackson  
Laboratories.   Bones   from   Trif-­/-­   mice   were   provided   by   Sankar   Ghosh   (Columbia  
University)   and   bones   from  MyD88-­/-­   mice   were   provided   by   Ruslan   Medzhitov   (Yale  
University).   Casp8fl/flxLysM-­Cre   bones   were   provided   by   Stephen   Hedrick  
(UCSD).Casp3fl/flTie2-­Cre+  and  Casp7-­/-­  mice  were  previously  described  (183,  184).  Six-­  
to   eight-­week-­old  C57BL/6.SJL  mice  were   lethally   irradiated  with   1100   rads  and  2-­5   x  
106   Ripk3-­/-­,   Ripk3+/-­Casp8+/-­,   Ripk3+/-­Casp8-­/-­,   Ripk3-­/-­Casp8-­/-­   or   C57BL/6   (Jackson  
Laboratories)  congenic  bone  marrow  (BM)  cells  were  transferred  i.v.  BM  chimeras  were  
allowed   to   reconstitute   for  eight   to   ten  weeks.  For  other  animal  experiments,  age-­  and  
sex-­matched   six-­to-­eight-­week   old   mice   were   used.   All   experiments   were   performed  
under  Institutional  Animal  Care  and  Use  Committee  (IACUC)  approved  protocols  and  in  
accordance  with  the  guidelines  of  the  IACUC  of  the  University  of  Pennsylvania.  
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Generation  of  Casp8DA/DA  mice  
Casp8DA/DA  mice  were  generated  using  the  reagents  and  protocol  described  by  Henao-­
Mejia   and   colleagues   (185).   Briefly,   single   guide   RNA  
(gRNA:ACAGAACCACACTTTAGAAGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAA
GGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTT)   and  
Cas9  RNA  were  in  vitro  transcribed,  purified  and  injected  into  B6xSJL  F1  embryos  with  
repair   oligoDNA   containing   50   base   pairs   of   flanking   regions   on   each   side  
(TTGCCTCATCATCTCACAAGAACTATATTCCGGATGAGGCAGAT).   The  
complementary   gRNA   sequence   is   in   blue,  mutated   base   pairs   are   in   red,   and   codon  
changes   for   D387A   are   highlighted   in   green.   Embryos   were   transferred   to  
pseudopregnant   females   and   pups   were   screened   for   mutagenesis   using   Surveyor  
Mutation  Detection  Kit   (IDT).  Founders  were   identified  by  cloning  PCR  products  of   tail  
DNA   (primer   F:   TTCACTGGTTCAAAGTGCCC,   primer   R:  
ACTTTGCCAGAGCCTGAGGG)  according  to  manufacturer’s  instructions  (M13  primers,  
TOPO  TA  Cloning  Kit  for  Sequencing,  ThermoFisher),  followed  by  sequencing  using  T3  
and   T7   primers.   Mice   were   backcrossed   onto   C57BL/6J   for   5   generations   until   a  
minimum  of  95%  B6  was  achieved  by  SNP  analysis   (Jax  Genome  Scanning  Service).  
Casp8DA/+  x  Casp8DA/+  mice  were  crossed  and  littermates  were  used  for  experiments.          
Animal  Infections  
For  Yersinia   infections,  mice  were  fasted  for  12-­16  hours  and   infected  orally  with  1-­4  x  
108  Yersinia   (32777).  Mice  were  sacrificed  and  tissues  were  harvested  on  days  3,  5,  6  
and   7   post-­infection,   as   indicated.   Tissues   were   processed   and   plated   on   LB   plates  
containing   irgasan   (2   μg/mL)   to   determine   bacterial   loads   (CFU/g).   Levels   of   serum  
cytokines  were  assayed  by  Luminex.  Cells   from  spleens  and  mesenteric   lymph  nodes  
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were  cultured   in   the  presence  of  BFA  and  monensin   for  5  hrs,  stained   for  surface  and  
intracellular  cytokines  and  analyzed  by   flow  cytometry  as  described  below.  Spleen  and  
liver  sections  were   fixed  and  stained  for  H&E.  For   in  vivo  Sendai  virus   infections,  mice  
were  anaesthetized  using  ketamine  and  infected  with  104  of  SeV  strain  52  (low  defective  
viral  genomes)  per  mouse  (186).  Mice  were  weighed  every  one  to  two  days.  On  days  3  
and  10,  lungs  were  harvested  and  homogenized  in  Trizol  for  RT-­qPCR  analysis.  
Histopathology  
Spleens   and   livers  were   fixed   and   stained   for   haematoxylin   and   eosin.   Sections  were  
quantified  by  a  blinded  pathologist  (Louise  Fitzgerald,  PennVet)  according  to  the  metric  
in  Table  S1.    
Table  S1.  Histopathology  scoring  scheme.  Rubric  that  describes  scoring  scale  for  
lesion  size  and  number  of  lesions  in  spleens  and  livers  of  mice.  
Score   #  Lesions   Size  of  Lesions   Bacterial  Colonies  
0   None   None   None  
1   0  –  9     Small     Rare,  small  
2   10  –  19     Medium    
Infrequent,  small  to  
medium    
3   20  –  30  
Medium  to  large,  infrequent  
confluence  
Frequent,  small  to  
medium  
4  
>30  or  marked  
confluence  
Medium  to  large,  frequent  
confluence  
Frequent,  large  or  
coalescing    
  
Detection  of  germline  single  nucleotide  variations  (SNVs)  and  small  
insertion/  deletion  (indels)    
We   downloaded   Whole-­genome   sequencing   (WGS)   data   from   the   Mouse   Genomes  
Project  of  WELLCOME  TRUST  SANGER   INSTITUTE  (187).  Using  a  pipeline   that  was  
initially  developed  for  detecting  somatic  mutations  using  paired  tumor/normal  sample,  we  
identified   the   germline   single   nucleotide   variations   (SNVs)   of   the   three   129   strains  
(129P2,  129S1,  129S5)  by  running  a  paired  SNV  analysis  using  C57B6  as  the  reference  
sample.   The   initial   variant   calls   were   generated   using   variation   detection   module   of  
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Bambino   (188)   with   the   following   parameters:   -­min-­flanking-­quality   15   -­min-­alt-­allele-­
count   2   -­min-­minor-­frequency   0   -­broad-­min-­quality   10   -­mmf-­max-­hq-­mismatches   15   -­
mmf-­min-­quality   15   -­mmf-­max-­any-­mismatches   20   -­unique-­filter-­coverage  2   -­min-­mapq  
1.   A   post-­process   pipeline   filters   SNVs   in   regions   with   low   quality   regions,   re-­maps  
(using   the  program  BLAT)  and  re-­aligns  (using   the  program  SIM)   the  reads  harbouring  
variant   allele   to   the   mouse   mm10   genome   to   remove   additional   false   calls.   The  
validation   rate   for   human   cancer   genome   analysis   is   about   95%   (189)   while   that   of   a  
mouse  exome  sequencing  data  is  ~  90%  (190).      
Flow  cytometry  
For   animal   studies,   mesenteric   lymph   nodes   were   isolated   and   plated   in   complete-­
DMEM  containing  brefeldin  A  (Sigma)  and  monensin  (BD)  in  a  37°C  humidified  incubator  
for  5  hrs.  For  BMDMs,  cells  were  plated   in  48-­  or  12-­well   suspension  dishes  and  pre-­
treated   with   zVAD-­fmk   (100   μM)   for   1   hr   prior   to   PAMP   stimulation,   where   indicated.  
BFA  and  monensin  were  added  1  hr  later  and  samples  were  harvested  for  analysis  4-­5  
hrs   later.  BMDMs  were  harvested  using  PBS  with  EDTA  (2mM)  prior   to  staining.  Cells  
were  washed  with   PBS,   stained   for   viability   (Zombie   Yellow,   BioLegend   or   Aqua   Live  
Dead,  Invitrogen)  and  then  stained  with  the  following  antibodies  from  BioLegend:  Ly6G  
(clone  1A-­8  PE-­Cy7),  IL-­6  (MP5-­20F3  APC/FITC),  F4/80  (clone  BM8  Pacific  Blue),  CD3ε  
(clone  17A2  AF700),  NK1.1  (clone  PK136,  Pacific  Blue),  BD  Biosciences:  CD45.1  (clone  
A20  APC-­Cy7),  CD45.2   (clone  104  FITC),  MHCII   (clone  M5/114  BV650),  B220   (clone  
RA3-­6B2  PETexasRed),  NK1.1  ThermoFisher:  CD11b  (clone  M1/70.15  PE-­Texas  Red),  
eBioscience:  Ly6C  (clone  HK1.4  PerCPCy5.5),  CD11c  (clone  N418  AF700),  F480  (clone  
BM8  APC-­eF780),  TNF  (clone  MP6-­XT22  eF450),  IL-­12p40  (clone  C17.8  PE),  proIL-­1β  
(clone   NJTEN3   APC/FITC),   CD19   (clone   MB19-­1   APC),   IFNγ   (clone   XMG1.2  
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AF700/APC)  or  cleaved  caspase-­3  (Asp  175,  Cell  Signaling  Technologies).  Inflammatory  
monocytes   and   neutrophils   were   gated   as   follows   live   CD45.1+2+/CD45.2+,   CD11c-­,  
CD11bhi,  Ly6Chi  or  Ly6G+.  BMDMs  were  gated  on  Live/dead-­,  singlets,  and   in  Figure  7  
also  CD11b+F480+.  Resident  peritoneal  exudate  cells   (PECs)  were   isolated   from  naïve  
six-­  to  eight-­week-­old  sex-­matched  mice  with  cold  PBS.  PECs  were  incubated  with  LPS  
(10   ng/mL),   BFA   and  monensin   for   4hrs   and   large   peritoneal   macrophage   responses  
were   examined  based  on  gating   strategy   as   published  by  Ghosn  et   al.   (191).  Surface  
staining  was   performed   in   FACS   buffer   (PBS  with   1%  BSA,   2mM  EDTA)   and   sample  
fixation  and  permeabilization  prior   to   intracellular  staining  were  all  performed  according  
to  manufacturer’s  instructions  (BD).  Samples  were  run  on  an  LSRFortessa  and  analyzed  
using  FlowJo  Treestar  software.    
Cell  Culture  and  Infection  Conditions  
Bone  marrow-­derived  macrophages  (BMDMs)  were  grown  as  previously  described  (115)  
in  a  37°C  humidified  incubator  in  DMEM  supplemented  with  10%  FBS,  HEPES,  sodium  
pyruvate  (complete-­DMEM)  and  30%  L929  supernatant  for  7-­9  days.  Fetal  liver-­derived  
macrophages   (FLDMs)   were   grown   from   E12-­14   livers   in   complete-­DMEM   and   50%  
L929  supernatant  for  7-­9  days.  16-­20  hrs  prior  to  infection  cells  were  re-­plated  into  96-­,  
48-­,   24-­   or   12-­well   dishes   in   complete-­DMEM   containing   10%   L929   supernatant.  
Necrostatin-­1,   zVAD-­fmk,   QVD-­oph   and   GSK’872   were   added   1-­3   hours   prior   to  
infection  or  treatment  with  PAMPs  (30  μM  or  60  μM  Necrostatin-­1  Calbiochem,  100  μM  
zVAD-­fmk-­001   R   &   D   Systems   or   SMBiochemcials,   3uM   GSK’872   Calbiochem,   0.5  
μg/mL  Cytochalasin-­D  Sigma,  25  mM  N-­acetylcysteine  Sigma).  IKKβ  and  p38  inhibitors  
were  added  1  hr  prior  to  infection  (BMS  345541,  SB202190  Millipore).  
Bacterial  and  viral  infections:  Bacterial  strains  are  described  in  Table  S2.  Yersinia  were  
grown  overnight  with  aeration  in  2xYT  broth  at  26°C.  The  bacteria  were  diluted  into  fresh  
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2xYT   containing   20  mM   sodium  oxalate   and   20  mM  MgCl2   (inducing  media).   Bacteria  
were  grown  with  aeration   for  1  hr  at  26°C   followed  by  2  hrs  at  37°C.  Salmonella  were  
grown  overnight  in  LB  medium  at  37°C  with  aeration,  diluted  into  fresh  LB  containing  300  
mM  NaCl,  and  grown  standing  at  37°C  for  3  hrs.  Bacteria  were  washed  three  times  with  
pre-­warmed  DMEM,   added   to   the   cells   at   an  MOI   of   20:1   unless   otherwise   indicated,  
and   spun  onto   the   cells   at   1000   rpm   for   5  min.  Cells  were   incubated  at   37°C   for   1  hr  
post-­infection   followed   by   addition   of   100   μg/mL   gentamicin.   For   in   vitro   Sendai   virus  
infections,   cells   were   washed   twice   with   warm   PBS,   and   infected   with   Sendai   virus  
Cantell  (high  defective  viral  genomes)  in  a  low  volume  of  serum-­free  media  as  previously  
described  (192).  
4-­OHT   treatment:   4-­OHT   (50  nM,   98%  pure  Z-­form,  Sigma)  was  added  on  day  3   and  
day   5   to   indicated   BMDMs   in   complete-­DMEM   supplemented   with   30%   L929  
supernatant.  Cells  were  replated  on  day  7  and   infections  were  performed  as  described  
above  on  day  8.  
Table  S2.  Bacterial  strains  used  in  this  work.  A  description  of  strain  name  or  
genotype,  abbreviations  and  source  or  reference  information  for  all  strains  used.    
Strain  name  or  
genotype  
Description   Source  or  Reference  
IP2666  (Yp)   Wild  type  Yersinia  pseudotuberculosis  
serogroup  O:3  strain  
(193)  
IP26  (ΔYopJ)   IP2666  YopJ-­deficient  strain   (121)  
32777   Wild  type  Yersinia  pseudotuberculosis  
serogroup  O:1  strain  (previously  known  
as  IP2777)  
(194)  Provided  by  Jim  
Bliska.  
327     YopJ-­deficient  Yersinia  
pseudotuberculosis  serogroup  O:1  
strain  
This  work.  
YopJC172A   32777  mutant  YopJ  C172A     (195)  
T3SS/mCD1   Yp  cured  of  virulence  plasmid,  
reconstituted  with  modified  virulence  
plasmid  from  Y.  pestis  lacking  all  known  
effectors  but  expressing  function  type  III  
secretion  system  
(115)  
8081  (Ye)   Wild  type  Yersinia  enterocolitica  
serogroup  O:8  
(196)  
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8081c-­  (YeP-­)   8081  virulence  plasmid  cured   (89,  196)  




Generation  of  immortalized  cell  line  
Freshly   isolated   Ripk3-­/-­Casp8-­/-­   bone   marrow   was   infected   with   the   v-­myc/v-­raf  
expressing  J2-­Cre  retrovirus  (198)  and  differentiated  in  15%  L929  supernatant.  After  20  
days  in  culture  macrophages  were  weaned  off  L929  and  passaged  in  complete-­DMEM.    
Viral  transductions  
WT  C8  expression  was  accomplished  by   cloning   full-­length  murine   caspase-­8   into   the  
pBabe-­Puro  retroviral  vector  upstream  of  the  T2A  ribosomal  skipping  sequence  followed  
by   enhanced  GFP.  Mutations   in  murine  D3A  C8  were   inserted   at  D387A,  D397A   and  
D400A   using   the   QuikChange   Site   Directed   Mutagenesis   kit   (Agilent).      D3A   C8   was  
cloned   into   the   pRRL-­Puro   lentiviral   vector   upstream   of   the   T2A   ribosomal   skipping  
sequence   followed   by   enhanced   GFP.   Stable   expression   was   achieved   by   retro-­   or  
lentiviral   transduction   of   iR3-­/-­C8-­/-­   cells   followed   by   two   rounds   of   sorting   by   FACS   to  
enrich   for   GFP+   cells.   Plasmids   were   a   kind   gift   from   Andrew   Oberst   (University   of  
Washington,  Seattle).  
Western  Blotting  
All  Yersinia   infections,  unless  otherwise   indicated  were  performed  with   IP2666   (Yp)  or  
IP26   (ΔYopJ).  Whole  cell   lysate  western  blotting  was  adapted   from  (115).  Briefly,  cells  
were   lysed   in   20   mM   HEPES,   150  mM   NaCl,   10%   glycerol,   1%   Triton   X-­100,   1   mM  
EDTA,  1mM  NaF,  1mM  activated  Na3VO4  and  protease   inhibitors.  Lysates  were  mixed  
with  protein   loading  buffer,   boiled,   centrifuged,   and  20%  of   the   total   cell   lysate   loaded  
onto  4%–12%  NuPAGE  gels  (Invitrogen).  Proteins  were  transferred  to  PVDF  membrane  
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(Millipore)   and   blotted  with   rabbit   anti-­mouse   caspase-­1   antibody   (sc-­514,   Santa  Cruz  
Biotechnology),   rabbit   anti-­mouse  MAPK  and   phospho-­MAPK  antibodies   (all   from  Cell  
Signaling   Technologies),   rat   anti-­mouse   caspase-­8   (clone   1G12,   ALX   804-­447-­C100,  
Enzo   Life   Sciences),   mouse   anti-­mouse   β-­actin   (Sigma),   mouse   anti-­mouse   β-­tubulin  
(Sigma),   anti-­IRAK2   (ProSci   3595   rabbit   anti-­mouse),   anti-­HDAC1   (Cell   Signaling  
Technologies).   Secondary   antibodies   were   goat   anti-­rabbit,   goat   anti-­rat   (Jackson  
Immunoresearch)  or  horse  anti-­mouse  HRP  (Cell  Signaling  Technology).    
Immunoprecipitations  
Myddosome  isolation  assays  were  adapted  from  (Bonham  et  al.,  2014).  Briefly,  BMDMs  
were   treated  with  LPS  (100  ng/mL)  and  harvested   in  cold  PBS.  4x106  cells  were  used  
per  IP  condition.  Cells  were  lysed  in  1%  NP-­40  (IGEPAL®  CA-­630  Sigma),  50  mM  Tris-­
HCl  (pH  7.4),  150  mM  NaCl,  10%  glycerol,  and  protease/phosphatase  inhibitors  (Roche)  
for   20   minutes   on   ice   and   spun   at   high   speed   for   20   minutes.   1/7   of   lysates   was  
aliquoted   for   inputs,   the   remaining   lysate  was   incubated   at   4°C  with   1   μg   anti-­MyD88  
(R&D   LifeSciences,   AF3109   goat   anti-­mouse)   or   control   goat   IgG   (R&D  Normal   Goat  
IgG   Control,   AB-­108-­C).   The   following   day,   50   μl   of   protein   G   Dynabeads  
(ThermoFisher)  was  added  for  1  hr  at  4°C.  Beads  were  washed  3  times  with  lysis  buffer,  
proteins   were   extracted   by   adding   Laemmli   buffer,   boiled,   electrophoresed,   and  
immunoblotted  with  the  indicated  antibodies  using  standard  conditions.  
Nuclear  Extractions  
5x106   cells   per   condition   were   treated   as   desccribed   and   harvested   with   cold   PBS.  
Pellets  were  resuspended  in  100  μl  cold  NAR  A  (10  mM  HEPES  pH  7.9,  10  mM  KCl,  0.1  
mM  EDTA  pH  8,  protease/phosphatase  inhibitors,  1mM  DTT,  1mM  β-­glycerophasphate  
and  1mM  NaF)  and   incubated  on   ice   for  20  minutes.  10  μl  1%  NP-­40  was  added  and  
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lysates  were  incubated  at  room  temperature  for  2-­5  minutes.  Lysates  were  vortexed  for  
10-­30  seconds,  centrifuged  for  1.5  min  at  6000  rpm.  Supernatants  containing  the  crude  
cytoplasmic  extract  were  transferred  to  new  microcentrifuge  tubes.  Cytoplasmic  extracts  
were   spun   for   60   minutes   at   full   speed   at   4°C   and   supernatants   containing   purified  
cytoplasmic  extracts  were  recovered.  Nuclear  pellets   from  first  wash  were  washed  four  
times  in  100  μl  cold  NAR  A.  Pellets  were  resuspended  in  50  μl  NAR  C  (20  mM  HEPES  
pH   7.9,   0.4   M   NaCl   pH   8,   1   mM   EDTA   pH   8,   protease/phosphatase   inhibitors,   1mM  
DTT,  1mM  β-­glycerophasphate  and  1mM  NaF).  Tubes  were  vortexed  at  4°C  for  1  hr  at  
full   speed.   Supernatants   containing   nuclear   extracts   were   recovered   after   max   speed  
spin   for   20   minutes.   All   lysates   were   quantified,   run   on   SDS-­PAGE   and   analyzed   by  
western  blotting.  
Cell  Death  Assays  
Lactate   dehydrogenase   (LDH)   release:   All   Yersinia   infections,   unless   otherwise  
indicated  (as  in  Figure  1g,  S.  Figure  1b  and  Extended  Data  Fig.  6)  were  performed  with  
IP2666  (Yp)  or  IP26  (ΔYopJ).  BMDMs  were  seeded  into  96-­well  plates  at  a  density  of  7  x  
104  cells/well  in  complete-­DMEM  containing  10%  L929  supernatant.  Cells  were  infected  
as  described  above  and  supernatants  harvested  at   indicated   times  post-­infection.  LDH  
release   was   quantified   using   the   Cytotox96   Assay   Kit   (Promega)   according   to   the  
manufacturer's   instructions.   Cytotoxicity   was   normalized   to   Triton   (100%)   and   LDH  
release  from  uninfected/untreated  cells  was  used  for  background  subtraction.  
Propidium  iodide  (PI)  uptake  was  analyzed  by  flow  cytometry  and  confocal  microscopy:  
Cells  were  seeded  in  12-­well  suspension  dishes  at  a  density  of  5  x  105  cells/well  16-­20  
hrs   priot   to   infection.   Cells   were   harvested   with   cold   PBS   at   indicated   times,   washed  
twice  with  PBS,  and  stained  with  PI   (Calbiochem),  washed   twice  with  PBS,   run  on  an  
LSR  Fortessa  and  analyzed  using  FlowJo  Treestar  software.  
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Kinetics   of  PI   uptake  was  analyzed  by   time-­lapse   confocal  microscopy  as   follows:   12-­
well   chamber  slides   (IBIDI)  were  coated  with  1  mg/mL  poly-­L-­lysine   (Sigma)  at  4°C,  1  
day  prior  to  seeding  cells.  Cells  were  seeded  at  a  density  of  8-­10  x  104  cells/well,  16-­20  
hrs  prior  to  infection.  4  hours  prior  to  infection,  cells  were  loaded  with  Cell  Tracker  Green  
(Invitrogen)  according  to  manufacturer’s  instructions,  washed  once  and  replenished  with  
fresh  media.  At   time  of   infection,  PI  was  added  and  PI  uptake  was  analyzed  using   the  
inverted  Leica  DMI4000  based  Yokagawa  CSUX-­1  spinning  disk  confocal  microscope  in  
a  37°C  humidified  chamber  (Penn  Vet  Imaging  Core)  over  indicated  time  points.  
Caspase-­8  Activity  Assay  
BMDMs  were  seeded  into  96-­well  white-­walled  plates  at  a  density  of  7  x  104  cells/well  in  
complete-­DMEM   containing   10%   L929   supernatant.   Cells   were   infected   as   described  
above   with   Ye   or   YeP-­   for   2   hrs.   Media   was   aspirated   and   a   1:1   mix   of   PBS   and  
Caspase-­Glo   8   reagent+buffer   (Promega)   was   added   as   per   the   manufacturer’s  
protocol.  Plates  were  allowed   to  shake  at  300rpm   for  40  minutes  before   luminescence  
was  read.    
ELISAs  and  Luminex  
BMDMs  were   pretreated  with   50   ng/mL  E.   coli   LPS   (Sigma)   for   3   hr   prior   to   bacterial  
infection  as  described  above,  and  supernatants  were  harvested  4  hrs  post-­infection.   In  
experiments   without   bacterial   infections,   BMDMs  were   treated   with   100   ng/mL  E.   coli  
LPS  (Sigma),  1  μg/mL  Pam3CSK4  (Invivogen),  1  μg/mL  CpG  (Invivogen),  or  50  μg/mL  
HMW   Poly(I:C)   (Invivogen).   Release   of   proinflammatory   cytokines   was   measured   by  
enzyme-­linked   immunosorbent   assay   (ELISA)   using   capture   and   detection   antibodies  
against   IL-­6   (BD),   IL-­12p40   (BD),   IL-­1α   (BD   Pharmingen),   IL-­1β   (e-­Bioscience)   or   or  
TNFα  (BioLegend).  To  detect  IL-­18  by  ELISA  (MBL  International)  from  Yersinia-­infected  
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cells,  BMDMs  were  infected  (with  LPS  priming  where  indicated)  and  supernatants  were  
harvested  4  hrs  post-­infection.  Magnetic  20-­plex  Luminex  (Invitrogen)  was  performed  at  
the   University   of   Pennsylvania   Human   Immunology   Core   to   quantify   cytokines   and  
chemokines  in  mouse  serum.  
RT-­qPCR  
1x106  BMDMs/well  were  plated  in  6-­well  tissue  culture-­treated  dishes  16  hrs  before  the  
experiment.  Cells  were   treated  with   10   ng/mL  mTNFa   (BioLegend)   for   6hrs.   For  RNA  
stability  experiments,  BMDMs  were  stimulated  with  LPS  (100  ng/mL)  for  2  hrs,  and  then  
treated   with   Actinomycin   D   (Sigma,   5   μg/mL).   Samples   were   lysed   in   Trizol   Reagent  
(Invitrogen/ThermoFisher)   and   RNA   was   extracted   using   phenol/chloroform   method.  
RNA  was  resuspended  in  RNAse-­free  water  and  cDNA  synthesis  was  performed  using  
High   Capacity   RNA   to   cDNA   kit   (ThermoFisher)   as   per   manufacturer’s   instructions.  
qPCR  was   run  using  Power  Sybr  Green  Master  Mix   (ThermoFisher)  on  a  QuantStudio  
Flex6000  (ThermoFisher).  Primer  sequences  used  are  listed  in  Table  S3.  
  
Table  S3:  Primer  sequences  for  ChIP  and  RT-­qPCR.  A  description  of  gene  and  primer  
names,  primer  sequences,  assay  conducted  and  reference  information  of  all  primers  
used  in  this  work.  
Gene   Primer  Name   Primer  Sequence   Type   Reference  
Gapdh     GapdF   GGTCCAAAGAGAGGGAGGAG     ChIP   (199)  
Gapdh     GapdR   GCCCTGCTTATCCAGTCCTA     ChIP   (199)  
Cxcl2   Cxcl2F   GGGCTCTGTGCTTCCTGAT     ChIP   (199)  
Cxcl2   Cxcl2R   TCCCGAGAGCTCCTTTTATG     ChIP   (199)  
Il1beta   Il1betaF   CCCACCCTTCAGTTTTGTTG     ChIP   (199)  
Il1beta   Il1betaR   CTTGTTTTCCCTCCCTTGTTT     ChIP   (199)  
Ccl5   Ccl5F   CTGCTACCCTGGCTCCCTAT     ChIP   (199)  
Ccl5   Ccl5R   TGGGAGATGCATGTGCTGT     ChIP   (199)  
Il6   Il6F   AATGTGGGATTTTCCCATGA     ChIP   (199)  
Il6   Il6FR   GCTCCAGAGCAGAATGAGCTA     ChIP   (199)  
Tnf   TnfF   GATTCCTTGATGCCTGGGTGTC     ChIP   (199)  
Tnf   TnfR   GAGCTTCTGCTGGCTGGCTGT     ChIP   (199)  
Il12b   Il12bF   GGGGAGGGAGGAACTTCTTA     ChIP   (199)  
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Il12b   Il12bR   CTTTCTGATGGAAACCCAAAG     ChIP   (199)  
Hbbs   HbbsF   GCATGGAAGACAGGACAATC   ChIP   This  study  
Hbbs   HbbsR   GTGGGAGGAGTGTACAAGGA   ChIP   This  study  
Ifnb   IfnbF   AGATGTCCTCAACTGCTCTC   Transcript   (192)  
Ifnb   IfnbR   AGATTCACTACCAGTCCCAG   Transcript   (192)  
Il1b   Il1bF   CCTCTGATGGGCAACCACTT   Transcript   (200)  
Il1b   Il1bR   TTCATCCCCCACACGTTGAC   Transcript   (200)  
Il12b   Il12bF   TTGAAAGGCTGGGTATCGGT   Transcript   (186)  
Il12b   Il12bR   GAATTTCTGTGTGGCACTGG   Transcript   (186)  
Il6   Il6F   ACAGAAGGAGTGGCTAAGGA   Transcript   (186)  
Il6   Il6R   CGCACTAGGTTTGCCGAGTA   Transcript   (186)  
SeV  NP   SeV  NPF   TGCCCTGGAAGATGAGTTAG   Transcript   (192)  
SeV  NP   SeV  NPR   GCCTGTTGGTTTGTGGTAAG   Transcript   (192)  
Cxcl2   Cxcl2F   GATACTGAACAAAGGCAAGGC   Transcript   This  study  
Cxcl2   Cxcl2R   ATCAGGTACGATCCAGGCT   Transcript   This  study  
Ccl22   Ccl22F   GGCCATACAAAGTGATACCT   Transcript   This  study  
Ccl22   Ccl22R   GGAAGCAAGAATGGGTTCTA   Transcript   This  study  
  
Chromatin  Immunoprecipitation  
Bone   marrow-­derived   macrophages   (BMDMs)   were   stimulated   with   LPS   (50ng/mL,  
Sigma)   for   2   hrs.   Cells   were   cross-­linked   with   disuccinimidyl   glutarate   (2mM,   Thermo  
Fisher)  for  30  min,  then  formaldehyde  (1%,  Sigma)  for  10  min  and  quenched  with  glycine  
(0.125M)   for  5  min.  Nuclear   lysis  was  performed  with   the   truChIP  Chromatin  Shearing  
Reagent   KIT   (Covaris)   and   nuclei   were   sonicated   using   the   Covaris   S220   sonicator.  
Chromatin  was   immunoprecipitated  using  anti-­p65  antibody   sc-­372X   (Santa  Cruz)  and  
protein  G  agarose  beads  (Millipore).  All  samples  were  column  purified  with  the  QIAquick  
PCR  purification  Kit   (Qiagen).  qPCR  was  performed  using  SYBER  Green  PCR  Master  
Mix  (Thermo  Fisher).  Primer  pairs  were  designed  to  amplify  80-­250  bp  fragments  of  the  
promoter  region  of  each  gene  (Table  S3)  and  melt  curve  analysis  was  used  to  confirm  
the  amplification  of  unique  products.  All  samples  were  normalized  to  a  5%  input  control  
and   fold   enrichment   calculated   using   percent   enrichment   of   treated   over   percent  
enrichment  for  untreated  samples.    
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RNA-­seq  
BMDMs  were  prepared  as  described  above  and  1x106  BMDMs/well  were  plated  in  6-­well  
tissue   culture-­treated   dishes   and   placed   in   a   5%   CO2   37   °C   incubator   for   16   hours.  
BMDMs  were   stimulated  with  LPS   (100  ng/mL)   for   6  hrs.  RNA  was   isolated  using   the  
RNeasy  Mini  Kit  (Qiagen)  and  processed  as  per  manufacturer’s  instructions.  mRNA-­seq  
libraries   were   prepared   using   the   TruSeq   Stranded   Total   RNA   LT   Kit   with   Ribo-­Zero  
Gold,   according   to   the   manufacturer’s   instructions.   Samples   were   run   on   Illumina  
NextSeq  500  to  generate  between  151  base-­pair,  paired-­end  reads  with  a  Q30  score  of  
~80%,   resulting   in   25-­50  million   fragments/sample.      All   data   processing   and   analyses  
were   carried   out   using   the   R   programming   language   (Version   3.2.2)   and   the   RStudio  
interface  (Version  0.99.489),  as  described  previously  (201)  and  can  be  reproduced  using  
the  supplementary  code  file.    Briefly,  raw  fastq  files  were  aligned  to  version  79  of  mouse  
reference  genome  GRCm38  using  the  Subread  aligner  (202)  in  the  RSubread  package.  
BAM   files   were   summarized   to   genes   using   the   featureCounts   algorithm   (203).     Raw  
data   is   available   on   the   Short   Read   Archive   (SRA)   and   Gene   Expression   Omnibus  
(GEO)   (accession  #  pending).     Differentially  expressed  genes  were   identified  by   linear  
modeling  and  Bayesian  statistics  using  the  VOOM  function  (204)  in  the  Limma  package  
(205).     Gene   Ontology   (GO)   was   performed   using   the   Database   for   Annotation,  
Visualization  and  Integration  of  Data  (DAVID)  (206,  207).  Gene  Set  Enrichment  Analysis  
(GSEA)   (208)   was   performed   against   the   Molecular   Signatures   Database   (MSigDB)  
(209)  using  the  C2  canonical  pathways  collection.    
Statistics  
All   statistical   analyses   were   performed   using   the   two-­tailed   unpaired   Student’s   t-­test,  
two-­way  ANOVA  with  Bonferonni  correction  or  Mann-­Whitney  U  test,  where  indicated.    
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III.  CASPASE-­8  MEDIATES  CASPASE-­1  PROCESSING  AND  
INNATE  IMMUNE  DEFENSE  IN  RESPONSE  TO  BACTERIAL  
BLOCKADE  OF  NF-­κB  AND  MAPK  SIGNALING2    
  
Background  
   The   innate   immune   response   forms   the   first   line   of   defense   against  
pathogens.   Microbial   infection   triggers   the   activation   of   pattern   recognition   receptors  
(PRRs),   such   as   Toll-­like   receptors   (TLRs)   on   the   cell   surface   or   cytosolic   Nucleotide  
binding  domain  Leucine  Rich  Repeat  family  proteins  (NLRs)  (210).  TLRs  induce  NF-­κB  
and   mitogen-­activating   protein   kinase   (MAPK)   signaling   to   direct   immune   gene  
expression,  whereas  certain  NLRs  direct  the  assembly  of  multi-­protein  complexes  known  
as   inflammasomes   that  provide  platforms   for  caspase-­1,  or   -­11  activation   (211).  Active  
caspase-­1  and  -­11  mediate  cleavage  and  secretion  of   the  IL-­1  family  of  proteins  and  a  
pro-­inflammatory   cell   death   termed   pyroptosis.   However,   microbial   pathogens   can  
interfere   with   various   aspects   of   innate   immune   signaling,   and   the   mechanisms   that  
mediate  effective  immune  responses  against  such  pathogens  remain  poorly  understood.  
Pathogenic   Yersiniae   cause   diseases   from   gastroenteritis   to   plague,   and   inject   a  
virulence  factor  known  as  YopJ,  which  inhibits  NF-­κB  and  MAPK  signaling  pathways  in  
target   cells   (107,   212,   213).   YopJ   activity   inhibits   proinflammatory   cytokine   production  
(213)   and   induces   target   cell   death   (87).   YopJ   activity   induces   processing   of  multiple  
caspases,   including   caspases-­8,   -­3,   -­7,   and   -­1   (93,   111,   121).  Nevertheless,  Yersinia-­
infected   cells   exhibit   properties   of   both   apoptosis   and   necrosis   (96,   112),      and   no  
specific   cellular   factors   have   been   identified   as   being   absolutely   required   for   YopJ-­
induced  caspase  activation  and  cell  death.  We  previously  found  that  the  inflammasome  
                                                                                                 
2  This  chapter  is  reprinted  from  Philip  NH,  et  al.  (2014)  Caspase-­8  mediates  caspase-­1  processing  and  innate  immune  
defense  in  response  to  bacterial  blockade  of  NF-­kappaB  and  MAPK  signaling.  Proc  Natl  Acad  Sci  U  S  A  111(20):7385-­
7390.  
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proteins   NLRC4,   NLRP3,   and   ASC   are   dispensable   for   YopJ-­induced   caspase-­1  
processing  and  cell  death  (115).  Thus,  additional  pathways  likely  mediate  YopJ-­induced  
caspase-­1  activation  and  cell  death.    
Death  receptors,  such  as  TNF  receptor  and  Fas,  mediate  caspase-­8-­dependent  
apoptosis  via  a  death-­inducing  signaling  complex  (DISC)  containing  receptor-­interacting  
serine/threonine   kinase   1   (RIPK1),   caspase-­8,   and   Fas-­associated   death   domain  
(FADD)  (214,  215).  Whether  these  proteins  are  required  for  Yersinia-­induced  cell  death,  
and  whether  this  death  contributes  to  anti-­bacterial  immune  responses  is  not  known.  The  
Ripoptosome  complex,  which  contains  RIPK1,  FADD,  caspase-­8,  as  well  as  RIPK3  and  
cFLIP,   regulates  apoptosis,   programmed  necrosis,   and  survival   in   response   to   various  
stimuli   including   signaling   by   the   TLR   adaptor   TRIF   (22,   216).   As   YopJ-­induced   cell  
death   is   inhibited   in   the  absence  of  either  TLR4  or  TRIF   (16),  we  sought   to  determine  
whether  YopJ-­dependent  cell  death  and  caspase-­1  activation  is  regulated  by  caspase-­8  
or  RIPK3,  and  to  define  the  role  of  YopJ-­dependent  cell  death  in  host  defense.  Here,  we  
describe  a  previously  unappreciated  requirement  for  RIPK1,  FADD,  and  caspase-­8,  but  
not   RIPK3,   in   YopJ-­induced   caspase-­1   activation   and   cell   death.   Critically,   loss   of  
caspase-­8  in  the  hematopoietic  compartment  resulted  in  a  failure  of  innate  immune  cells  
to   produce   pro-­inflammatory   cytokines   in   response   to  Yersinia   infection,   and   severely  
compromised   resistance   against  Yersinia   infection.   Our   data   suggest   that   caspase-­8-­
mediated   cell   death   in   response   to   blockade   of   NF-­κB/MAPKs   by   YopJ   allows   for  
activation  of  host  defense  against  Yersinia  infection.  This  cell  death  may  thus  enable  the  
immune  system  to  override  inhibition  of  immune  signaling  by  microbial  pathogens.    
Results  
RIPK1  is  required  for  Yersinia-­induced  cell  death  and  caspase-­1  activation  
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Activation  of  multiple  caspases,   including  caspase-­1,   -­3,   -­7,  and   -­8,   is   triggered  
due  to  YopJ  activity  in  Yersinia-­infected  cells  (93,  110,  111,  115).  Casp1-­/-­Casp11-­/-­  bone  
marrow-­derived   macrophages   (BMDMs)   exhibit   a   significant   delay   in   cell   death   in  
response  to  Yersinia  pseudotuberculosis  (Yp),  whereas  both  Yp-­induced  cell  death  and  
caspase-­1   activation   are   indistinguishable   between   B6   and   Casp11-­/-­   or   129SvImJ  
BMDMs   (Figure   5A-­C).   These   data   suggest   that   caspase-­1   plays   a   functional   role   in  
YopJ-­induced   cell   death.   Surprisingly,   NLRC4,   NLRP3,   ASC,   and   type   I   IFN   receptor  
alpha   are   dispensable   for   Yersinia-­induced   caspase-­1   processing   and   cell   death,  
suggesting  that  these  events  occur  via  a  distinct  pathway  (Figure  5D-­H  and  (115)).  
RIPK1,   RIPK3,   caspase-­8   and   FADD   regulate   cell   survival   and   death   fate  
decisions  downstream  of  TRIF  as  a   result   of  RIP  Homotypic   Interaction  Motif   (RHIM)-­
driven   interactions   between  TRIF  and  RIPK1   (216,   217).   This   interaction   can  promote  
apoptosis  through  a  RIPK1/FADD/caspase-­8  complex  (17),  or  programmed  necrosis  via  
RIPK1  and  RIPK3  (23).  We  therefore  investigated  the  potential  involvement  of  RIPK1  in  
Yersinia-­induced   cell   death.   Necrostatin-­1   (Nec-­1)   inhibits   RIPK1   kinase   activity   and  
prevents  TLR-­induced  necrosis   (23,  218),  but  was  previously   reported   to  not   inhibit  Y.  
pestis-­induced   cell   death   (96).   Surprisingly,   we   observed   that   both   RIPK1-­deficient  
BMDMs   and   B6   BMDMs   treated   with   Nec-­1,   exhibited   reduced   levels   of   Yp-­induced  
caspase-­1   and   -­8   processing   (Figure   6A-­D),   and   cell   death   (Figure.   6E   and  F).  Tlr4-­/-­  
BMDMs   are   partially   protected   from  Yersinia-­induced   death   (16),   and   TLR4   signaling  
induces  programmed  necrosis   in  cells   treated  with  the  pan-­caspase  inhibitor  zVAD-­fmk  
via  a  TRIF-­  and  RIPK3-­dependent  pathway  (23).  Interestingly,  zVAD-­fmk  still  sensitized  
Trif-­/-­   BMDMs   to   cell   death   in   response   to   wild-­type   Yp,   but   not   YopJ-­deficient   Yp  
(ΔYopJ)   infection,  whereas  B6  BMDMs  were  sensitized   to  both   (Figure  6E  and  F,  and  
Figure   7A).   In   contrast,  Ripk1-­/-­   cells   were   not   sensitized   to   death   in   the   presence   of  
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zVAD-­fmk   in   response   to  either  ΔYopJ  or  Yp  (Figure  6E  and  F  and  Figure  7B).  These  
data  indicate  that  YopJ  induces  cell  death  through  RIPK1  via  both  TRIF-­dependent  and  -­
independent   pathways.   Notably,   although   Nec-­1   treatment   protects   Yp-­infected   cells  
from  death,  expression  of  NF-­κB-­dependent  cytokines  were  not  restored  (Figure  7D-­E).  
These   data   demonstrate   that   YopJ-­mediated   blockade   of   cytokine   production   is  
independent  of  YopJ-­induced  cell  death,  and   implies   that   this  cell  death  may  serve  an  
alternative  function.  Nec-­1  did  inhibit  YopJ-­induced  secretion  of  IL-­18,  consistent  with  its  
effect   on   caspase-­1   activation   (Figure   6G).   Altogether,   these   data   demonstrate   a   key  
role  for  RIPK1  in  Yersinia-­induced  death  and  caspase-­1  activation,  and  suggest  that  this  
cell   death   functions   as   a   host   defense   against   pathogen   blockade   of   inflammatory  
signaling  pathways.  
Caspase-­8   activity   is   required   for   YopJ-­induced   cell   death   and   caspase-­1  
processing    
TLR   signaling   can   trigger   RIPK1-­mediated   cell   death   either   via   caspase-­8   or  
RIPK3   (22,   23).   The   observation   that   zVAD-­fmk-­treatment   did   not   protect   B6   BMDMs  
from  Yp-­induced   death   suggests   either   caspases   are   not   required   for   Yp-­induced   cell  
death,   or   blocking   caspase   activity   in   Yp-­infected   cells   triggers   cell   death   via   RIPK3-­
mediated   necrosis.   Caspase-­8   catalytic   activity   prevents   a   lethal   RIPK3-­dependent  
programmed   necrosis   that   occurs   in   early   embryonic   development   (26).   Notably,   we  
found   that  Ripk3-­/-­   BMDMs   had   no   defect   in   Yp-­induced   caspase-­1   processing   or   cell  
death,   whereas   Ripk3-­/-­Casp8-­/-­   BMDMs   failed   to   process   caspase-­1   or   undergo   cell  
death  in  response  to  Yp  infection,  in  contrast  to  STm  or  LPS+ATP  treatment  (Figure  8A-­
C).  This   failure  was  not   the   result   of   insufficient  back-­crossing  of   these  mice,  as   there  
were  no  single  nucleotide  variants   (SNVs)  between  B6  and   three  different   lines  of  129  
mice   in   caspase-­8,   cFLIP,   FasL   or   RIPK3,   and   the   polymorphic   genes   immediately  
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flanking  caspase-­8  are  not  linked  to  these  cell  death  pathways  (Figure  9).  Importantly,  in  
Ripk3-­/-­   BMDMs,   zVAD-­fmk   abrogated   Yp-­induced   death   (Figure   8C).   These   data  
demonstrate  that  caspase  inhibition  induces  RIPK3-­dependent  programmed  necrosis  in  
Yp-­infected  cells,  and  that  RIPK3  is  not  required  for  YopJ-­induced  caspase-­1  processing  
or   cell   death   in   the   presence   of   caspase-­8.   RIPK3   can   activate   caspase-­1   in   the  
absence   of   caspase-­8   in   response   to   LPS   (219)   or   cIAP   inhibitors   (220).   Therefore,  
caspase-­8  and  RIPK3  might  play   redundant   roles   in  caspase-­1  activation  or  cell  death  
during  Yp   infection.   Intriguingly,   conditional   deletion   of   caspase-­8   by   inducible   (ERT2-­
Cre),   or   developmental   (LysM-­Cre)   approaches   significantly   reduced   YopJ-­mediated  
processing  of  caspase-­1   in  RIPK3-­sufficient  cells,   indicating  that  caspase-­8  and  RIPK3  
play  a  non-­redundant  role  in  YopJ-­induced  caspase-­1  processing  (Figure  8D  and  Figure  
10A).  This  caspase-­8-­dependent  processing  of  caspase-­1  was  functionally  important,  as  
IL-­18   secretion   was   significantly   reduced   in   Ripk3-­/-­Casp8-­/-­,   but   not   Ripk3-­/-­   BMDMs  
(Figure   8E).   However,   conditional   deletion   of   caspase-­8   was   not   sufficient   to   protect  
BMDMs  from  Yp-­induced  cell  death  (Figure  10B  and  C),  in  keeping  with  the  finding  that  
zVAD-­fmk  leads  to  programmed  necrosis  in  RIPK3-­sufficient  cells.  Importantly,  caspase-­
1   activation   in   response   to   STm   was   completely   unaffected   in   caspase-­8   conditional  
BMDMs,   indicating   that   these   cells   retained   the   ability   to   undergo   inflammasome  
activation  (Figure  10D).  We  also  observed  an  apparent  synergy  between  zVAD-­fmk  and  
Nec-­1  in  protection  from  LPS+ATP-­treated  cell  death  in  B6  cells  (Figure  8C).  However,  
this  is  most  likely  because  zVAD-­fmk-­pretreated  cells  that  are  then  exposed  to  LPS+ATP  
undergo   programmed   necrosis,   as   Ripk3-­/-­   cells   treated   with   zVAD-­fmk   followed   by  
LPS+ATP  are  protected  from  cell  death  (Figure  8C).  
To   dissect   how   caspase-­8   mediates   activation   of   caspase-­1,   we   reconstituted  
immortalized   Ripk3-­/-­Casp8-­/-­   (iR3-­/-­C8-­/-­)   macrophages   with   either   wild-­type   caspase-­8  
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(WT  C8),  or  mutant  caspase-­8   lacking   the   three  critical  aspartate   residues  required   for  
autoprocessing  (D3A  C8).  Critically,  expression  of  WT  C8  but  not  D3A  C8  restored  both  
Yp-­induced  cell  death  and  processing  of  caspase-­1   in   iR3-­/-­C8-­/-­  cells   (Figure  8F).  Both  
forms  of   caspase-­8  were  expressed  at   similar   levels   in   the   reconstituted   cells,   but   the  
D3A   mutant   lacked   catalytic   activity,   consistent   with   observations   that   non-­cleavable  
forms  of  caspase-­8  do  not  exhibit  catalytic  activity  in  the  absence  of  forced  dimerization  
(142)   (Figure  11A  and  B).  Noncleavable  caspase-­8  nonetheless  retains  some  function,  
as   it   interacts  with   cFLIP   to   inhibit   programmed   necrosis   and  mediate   protection   from  
embryonic  lethality  (26,  28).  Consistently,  zVAD-­fmk-­treatment  abolished  both  caspase-­
8  and  caspase-­1  processing   in   response   to  Yersinia   infection,  but  not   in  STm-­infected  
cells   (Figure   11C-­E).   These   data   indicate   that   zVAD-­fmk   does   not   block   the  
autoprocessing   of   caspase-­1   that   occurs   in   canonical   inflammasomes,   but   inhibits  
caspase-­8-­mediated   caspase-­1   processing.   Altogether,   these   data   indicate   that   the  
cleaved  active  caspase-­8  homodimer  mediates  YopJ-­induced  processing  of  caspase-­1.  
Inhibition  of  NF-­κB  and  MAPK  signaling  by  YopJ  is  necessary  for  Yp-­induced  cell  
death   (109),   but   whether   this   is   responsible   for   RIPK1-­   and   caspase-­8-­mediated  
caspase-­1   activation   is   not   known.   Intriguingly,   inhibition   of   both   IKKβ  and  p38  MAPK  
induced  RIPK1-­dependent  processing  of  caspase-­8  and  -­1,  and  RIPK1-­dependent  death  
of  ΔYopJ-­infected  cells  (Figure  12).  Similarly  to  the  outcome  of  WT  Yp  infection,  this  cell  
death  was  largely  unaffected  in  Ripk3-­/-­  cells,  but  was  abrogated  in  the  absence  of  both  
RIPK3  and  caspase-­8.  Together,  these  data  demonstrate  that  YopJ-­dependent  inhibition  
of  NF-­κB  and  MAPK  signaling  triggers  RIPK1/caspase-­8-­mediated  caspase-­1  activation.  
FADD  is  required  for  Yp-­induced  caspase-­1  processing  and  cell  death  
These  findings,  together  with  previous  observations  that  YopP  induces  formation  
of  a  caspase-­8,  RIPK1,  FADD  complex  (110),  and  that  FADD  plays  a  role   in  apoptosis  
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downstream   of   TRIF   (22)   suggested   that   FADD   might   play   a   role   in   YopJ-­induced  
caspase-­1   activation   and   cell   death.   Fadd-­/-­   mice   exhibit   embryonic   lethality   that   is  
reverted  with   loss  of  RIPK3   (160).  As  anticipated,  YopJ-­induced  caspase-­1  processing  
was   indeed   abrogated   in   Ripk3-­/-­Fadd-­/-­   cells   but   not   in   Ripk3-­/-­   cells   (Figure   13A),  
whereas   STm-­infected   cells   exhibited   robust   caspase-­1   processing   in   the   absence   of  
RIPK3  and  FADD  (Figure  13A  and  B).  Consistent  with  the  recent  study  by  Gurung  et  al.  
(179),  Ripk3-­/-­Fadd-­/-­  BMDMs  also  showed  a  noticeable   reduction   in  LPS+ATP-­induced  
caspase-­1   processing   and   cell   death   (Figure   13B   and  C).  Moreover,   pro-­inflammatory  
cytokine   production   in   response   to   LPS   was   reduced   in   BMDMs   lacking   RIPK3   and  
caspase-­8  or  FADD  (Figure  14),  consistent  with  recent  findings  that  pro-­IL1β  expression  
is   reduced   in   these   cells   (179,   180,   221).      Whereas   Gurung   et   al.   observed   that  
caspase-­8   contributes   to   LPS+ATP-­induced   canonical   inflammasome   activation   (179),  
unlike   with   FADD   deficiency,   we   did   not   observe   a   consistent   reduction   in   caspase-­1  
processing  in  Ripk3-­/-­Casp8-­/-­  macrophages  treated  with  LPS+ATP,  and  we  were  unable  
to  detect  caspase-­8  processing  in  LPS+ATP-­treated  cells.  The  contribution  of  FADD  and  
caspase-­8  to  LPS+ATP-­induced  caspase-­1  activation  may  relate  to  differential  effects  on  
NLRP3  inflammasome  priming.  
YopJ-­induced   caspase-­8   activation   promotes   anti-­Yersinia   immune   defense   in  
vivo    
YopJ   promotes   dissemination   of   Yersinia   to   systemic   tissues   (97).   However,  
increasing   YopJ-­mediated   cytotoxicity   paradoxically   enhances   immune   clearance   and  
reduces   virulence   (89).  How   this   cytotoxicity   contributes   to   host   defense   in   vivo   is   not  
known.   We   therefore   infected   bone   marrow   chimeric   mice   lacking   both   RIPK3   and  
caspase-­8   in   the   hematopoietic   compartment,   as   these   cells   cannot   undergo   YopJ-­
inducd  cell  death.  Critically,  in  contrast  to  littermate  control,  B6,  or  Ripk3-­/-­  BM  chimeras,  
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mice   with   a   caspase-­8-­deficient   hematopoietic   compartment   rapidly   succumbed   to  
infection  with   a  Yp   strain   that   is   non-­lethal   to  WT  mice   (222),   (Figure   15A   and  Figure  
16A).  Surprisingly,  Ripk3-­/-­Casp8-­/-­   chimeric  mice  were  deficient   in  production  of   serum  
IFNγ,  IL-­6  and  IL-­1β  despite  a  several-­log   increase  in  bacterial  CFU  in   infected  tissues  
on  day  6  post-­infection,  (Figure  15B,  C  and  Figure  16B).  Both  innate  and  adaptive  Ripk3-­
/-­Casp8-­/-­  cells  failed  to  produce  cytokines,  as  inflammatory  monocytes  in  the  mLNs,  and  
splenic  NK  and  T  cells  were  all  defective  in  production  of  TNFα,  and  IFNγ  at  day  6  post-­
infection   (Figure   15D-­H   and   Figure   16C).   In   contrast,   the   chemokine  MCP-­1   was   not  
affected  in  Ripk3-­/-­Casp8-­/-­  chimeric  mice  (Figure  15B).  On  day  3  post-­infection.,  Ripk3-­/-­
Casp8-­/-­  chimeras  had  a  higher  proportion  of  TNF-­producing  inflammatory  monocytes  in  
the  spleen  (Figure  17B)  suggesting  that  caspase-­8  deficiency  in  vivo  does  not  lead  to  a  
failure   of   cell-­intrinsic   cytokine   production   per   se.   However,   in   contrast   to   caspase-­8-­
sufficient   animals,   Ripk3-­/-­Casp8-­/-­   chimeras   failed   to   maintain   or   upregulate   cytokine  
production   in   the   spleen   over   the   course   of   infection,  while   cytokine   production   in   the  
mLNs,  where  bacterial   burdens  were   similar   across   genotypes,  was  defective   on  both  
days  3  and  5  (Figure  17A-­C).  
These   findings   demonstrate   that   combined   deficiency   of  RIPK3  and   caspase-­8  
results  in  severe  susceptibility  to  WT  Yp  infection,  but  whether  this  is  due  to  a  failure  to  
respond   to   the   activity   of   YopJ,   or   due   to   a   more   global   failure   to   induce   immune  
responses   was   not   clear.   Importantly,   Ripk3-­/-­Casp8-­/-­   bone   marrow   chimeric   animals  
were   capable   of   surviving   infection   with   ΔYopJ   Yp,   had   significantly   lower   bacterial  
burdens   of   ΔYopJ   in   their   spleen   and   liver,   and   partially   recovered   production   of  
intracellular   TNF   (Figure   18A-­C).   Despite   elevated   bacterial   burdens,   in   the   Ripk3-­/-­
Casp8-­/-­  chimeras,  these  mice  had  smaller  splenic  lesions  that  lacked  close  association  
of   neutrophils   with   bacteria,   as   compared   with   control   caspase-­8-­sufficient   chimeras,  
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which   had   extensive   lesions   containing   bacterial   colonies   surrounded   by   visible   cell  
debris   and  neutrophilic   infiltrates   (Figure  18D   and  Figure  17D   and  E).   These  data  are  
consistent   with   reduced   levels   of   in   vivo   death   of   Ripk3-­/-­Casp8-­/-­   cells.   Intriguingly,  
ΔYopJ-­infected   Ripk3-­/-­Casp8-­/-­   chimeras   showed   significantly   elevated   numbers   and  
extent   of   liver   lesions   as   compared   with   Yp-­infected   animals,   suggesting   that   in   the  
absence  of  NF-­κB  blockade,  Ripk3-­/-­Casp8-­/-­  cells  can  generate  protective   inflammatory  
responses   that   correlate   with   increased   cell   death   in   vivo   (Figure   18E-­G).   Together  
these  findings  demonstrate  that  YopJ-­dependent  triggering  of  caspase-­8  plays  a  critical  
role   in   mediating   anti-­Yersinia   immune   defense   in   vivo,   and   that   loss   of   RIPK3   and  
caspase-­8   results   in   dysregulated   inflammatory   responses   and   failure   to   control  
Yersinia.  
Discussion  
Caspase-­1  and  caspase-­8  activation  are  generally  induced  by  distinct  stimuli.  In  
contrast   to   caspase-­1,   which   causes   pyroptosis   independently   of   other   caspases,  
caspase-­8   induces  apoptosis   through  caspases-­3  and  -­7.  Caspase-­8  can  also  mediate  
cleavage   and   secretion   of   IL-­1β   and   IL-­18   downstream   of   Fas/FasL   signaling   or   ER  
stress   (182,   223),   and  was   recently   reported   to   regulate   expression   of   pro-­IL1β   (180,  
221).   We   now   demonstrate   that   caspase-­8,   RIPK1   and   FADD   mediate   caspase-­1  
activation   in   response   to   the   Yersinia   virulence   factor   YopJ,   thus   revealing   an  
unanticipated   integration   of   caspase-­1   and   caspase-­8   death   pathways   in   response   to  
Yersinia  infection.    
We   cannot   currently   exclude   the   possibility   that  RIPK3  and   caspase-­8   function  
redundantly   to  mediate  cell  death,  or   that  RIPK3-­mediated  necrosis  contributes   to  host  
defense   against   Yersinia.   Nevertheless,   in   caspase-­8-­sufficient   cells,   RIPK3   is  
dispensable   for   YopJ-­induced   cell   death   or   caspase-­1   activation,   and   in   caspase-­8  
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conditional   knockout   cells,   RIPK3   does   not   contribute   to   YopJ-­induced   caspase-­1  
processing.  Under  certain  conditions,  RIPK3  can  mediate  caspase-­1  activation  and  cell  
death   in   response   to   LPS   (219)   or   cIAP   inhibitors   (220).   Thus,   while   TLR   stimulation  
alone   triggers   RIPK3-­dependent   necrosis   in   caspase-­8-­deficient   cells,   our   data  
demonstrates  that  YopJ  triggers  cell  death  and  caspase-­1  processing  through  caspase-­
8.   Engagement   of   caspase-­1   by   both   of   these   pathways   may   enable   the   release   of  
caspase-­1-­dependent   inflammatory   signals   by   dying   cells,   even   when   this   caspase-­1  
activation   does   not   occur   in   a   canonical   inflammasome   platform.   Our   data   suggest   a  
model   (Figure   19)   whereby   RIPK1,   caspase-­8,   and   FADD   engage   a   cell   death   and  
caspase-­1-­activation  pathway  that  promotes  anti-­microbial  immune  defense  in  response  
to  pathogen-­mediated  interference  with  innate  immune  signaling  pathways.  
In  addition  to  controlling  cell-­extrinsic  death,  caspase-­8  also  plays  a  role  in  NF-­κB  
signaling  and  gene  expression   (170,   172,   180,   221),   potentially   via   cleavage  of   cFLIP  
(120,  169).  However,  YopJ-­induced  caspase-­1  activation  and  cell   death  via  caspase-­8  
and  FADD  are  independent  of  LPS-­induced  priming,  because  they  are  triggered  by  NF-­
κB   inhibition,   and   are   independent   of   ASC,  NLRP3,   and   IFNAR.   Indeed,   LPS   priming  
prevents   YopJ-­driven   cell   death   (93,   115),   either   due   to   upregulation   of   NF-­κB-­
dependent  survival  genes,  or  inhibition  of  caspase-­1  by  YopM  in  LPS-­primed  cells  (120).  
A  related  study  by  Weng  et  al.  observes  a  role  for  ASC  in  caspase-­1  activation  in  
Y.   pestis-­infected   cells,   in   contrast   to   our   studies   here   (124).   YopJ   isoforms   from  
different  Yersinia   isolates  exhibit  different  degrees  of  NF-­κB   inhibitory  activity,  and   this  
also   correlates   with   their   degree   of   ASC/NLRP3   inflammasome   activation   (92).   An  
alternative   possibility   is   that  Weng  et   al.,   examine   cleaved   caspase-­1   in   supernatants  
(124),   whereas   we   measure   caspase-­1   processing   in   cell   lysates.   Future   studies   will  
dissect  the  underlying  basis  for  this  apparent  difference.    
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Finally,   whether   cell   death   or   dysregulated   cytokine   production   or   both   are  
directly   responsible   for   the   inability   of   caspase-­8-­deficient   animals   to   clear   Yersinia  
infection  remains  to  be  determined.  The  drop   in  cytokine  production  over  the  course  of  
Yp   infection   in   Ripk3-­/-­Casp8-­/-­   chimeric   mice   may   be   due   to   increased   blockade   of  
signaling   pathways   as   a   consequence   of   progressively   greater   bacterial   burden   over  
time.  Caspase-­8-­mediated  cell  death  and  caspase-­1  activation  in  response  to  blockade  
of  innate  signaling  may  thus  mobilize  bystander  cells  for  rapid  cytokine  production  and/or  
phagocytosis  of  pathogen-­associated  cell  debris.  
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Figure   6.   RIPK1   is   required   for  Yersinia-­induced   caspase-­1   processing   and   cell  
death.  
(A,   B)   B6   BMDMs   were   either   left   uninfected   (UI),   LPS-­primed   (50   ng/mL)   for   3   hrs  
followed  by  ATP  (2.5  mM)   for  1  hr   (LPS+ATP),   infected  with  wild   type  Yersinia   (Yp)  or  
YopJ-­deficient   Yp   (ΔYopJ)   for   2   hrs   or  Salmonella   (STm)   for   1   hr.   Cell   lysates   were  
probed  for  caspase-­1  or  -­8  processing  by  western  analysis.  (C,  D)  Ripk1+/+  and  Ripk1-­/-­  
FLDMs   were   infected   as   in   (A,   B).   (E)   %   Cytotoxicity   was   measured   by   lactate  
dehydrogenase   (LDH)   release   from   B6   BMDMs   (left)   and  Ripk1+/+   or  Ripk1-­/-­   FLDMs  
(right)  that  were  uninfected  or  infected  with  ΔYopJ,  Yp  or  LPS  +  ATP  for  4  hrs,  or  STm  
for  1  hr.  (F)  Flow  cytometry  for  propidium  iodide  uptake  (%  PI+  cells)  by  cells  as  treated  
in  (E).  (G)   IL-­18  assayed  by  ELISA,  and  LDH  release  on  cells  treated  as  in  (E).  30  μM  
necrostatin-­1   (Nec-­1)   and  100  μM  zVAD-­fmk  were  used  3   hrs   prior   to   infection  where  
indicated.  Error  bars  indicate  mean  ±  s.e.m  of  triplicates  and  are  representative  of  three  
or  more  independent  experiments.  ***  p  <  0.0001,  **  p  <  0.001,  *  p  <  0.01.  
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Figure   8.   Caspase-­1   activation   and   IL-­18   secretion   in   response   to   Yersinia  
infection  require  caspase-­8.    
(A,  B)  Lysates  from  BMDMs  left  uninfected  (UI),  infected  with  Yp  for  2  hrs,  STm  for  1  hr  
or   LPS-­primed   for   3   hrs   and   ATP   for   1   hr   (LPS+ATP)   were   probed   for   caspase-­1  
processing   by  western   analysis.   (C)  %  Cytotoxicity   (LDH   release)   of   BMDMs   infected  
with  Yp  for  4  hrs,  STm  for  1  hr  or  treated  with  LPS+ATP  as  in  (A).  (D)  4-­OHT-­treated  (50  
nM)  BMDMs  infected  as  in  (A).  (E)  IL-­18  assayed  by  ELISA  from  BMDMs  left  uninfected  
(UI),  infected  with  isogenic  Yp  32777,  YopJ  C172A  or  STm  or  LPS-­primed  for  4  hrs.    (F,  
G)  iR3-­/-­C8-­/-­  BMDMs  were  reconstituted  with  empty  vector,  wild  type  caspase-­8  (WT  C8)  
or  non-­cleavable  mutant  caspase-­8  (D3A  C8).  (F)  LDH  release  4  hrs  post-­infection.  (G)  
caspase-­1   processing   by  western   analysis,  MOI   of   50:1.   30   μM   necrostatin-­1   (Nec-­1)  
and   100   μM   zVAD-­fmk   were   used   3   hrs   prior   to   infection   where   indicated.   N.D.,   not  
detected.  Error  bars  indicate  mean  ±  s.e.m  of  triplicates  and  are  representative  of  three  
or  more  independent  experiments.  ***  p  <  0.0001.  
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Figure   17.   RIPK3/caspase-­8-­deficient   mice   experience   faster   bacterial  
dissemination   and   dysregulated   cytokine   production   even   at   early   time   points  
during  Yersinia  infection.    
Lethally-­irradiated  B6.SJL  mice  were  reconstituted  and  infected  as  in  Figure  4.  (A)  
Bacterial  loads/gram  tissue  on  days  3  (top)  and  5  (bottom)  post-­infection.  (B,  C)  %TNF+  
inflammatory  monocytes  in  (B)  spleens  and  (C)  mesenteric  lymph  nodes  were  analyzed  
by  flow  cytometry.  (D)  Representative  images  of  spleen  in  naïve  and  Yersinia-­infected  
Ripk3-­/-­Casp8+/-­  and  Ripk3-­/-­Casp8-­/-­  chimeric  mice  at  days  3  and  5,  showing  lesions  of  
necrosuppurative  splenitis  (dashed  white  lines)  and  extracellular  bacterial  colonies  
(arrows)  in  infected  mice.  Hematoxylin  and  eosin  staining.  scale  bars  =  50  μm.  (E)  
Quantification  of  lesion  severity  in  spleens.  “†”  denotes  3  dead  mice  not  harvested  for  
CFUs.  Dotted  lines  represent  limit  of  detection.  Solid  lines  represent  geometric  means.  
Flow  cytometry  plots  were  gated  on  live  CD45.2+,  CD11c-­,  CD11bhi,  Ly6Chi.  R3C8  =  
Ripk3Casp8.       
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IV.  CELL-­INTRINSIC  ACTIVITY  OF  UNCLEAVED  CASPASE-­8  
CONTROLS  EXPRESSION  OF  TLR-­INDUCED  INFLAMMATORY  
RESPONSES  
Background  
Pattern  recognition  receptors  such  as  Toll-­like  receptors  (TLRs)  sense  conserved  
microbial   structures   including   lipopolysaccharide   (LPS)   or   peptidoglycans   (2).   TLR  
ligation   triggers   MyD88-­   and   TRIF-­dependent   MAPK   and   NF-­κB   signaling,   which  
induces   the   expression   of   cell   survival   and   inflammatory   programs   that   are   critical   for  
host   defense   (224).   TLR3   and   TLR4   can   also   engage   extrinsic   death   pathways,   as  
TLR3/4   activation   in   the   presence   of   pharmacological   or  microbial   inhibitors   of   NF-­κB  
results  in  cell  death  that  is  mediated  by  the  cysteine  protease  caspase-­8  (14-­16).  Upon  
receptor   ligation,  caspase-­8  is  recruited  to  a  TRIF/RIPK1/FADD-­containing  complex  via  
specific  homotypic  protein-­protein   interaction  motifs   (17).  RIPK1   interacts  with  TRIF  by  
means  of  RIP  homology   interaction  motifs   (RHIM)  and  can  bind  FADD  through  shared  
death  domains  (DD),  which  in  turn  engages  caspase-­8  via  death  effector  domains  (DED)  
(18,   19).   Upon   recruitment   to   this   complex,   caspase-­8   undergoes   dimerization   and  
autoprocessing,  which  stabilizes  the  active  enzyme,  and  initiates  the  proteolytic  cascade  
that  ultimately  results  in  apoptotic  disassembly  of  the  cell  (20).  
Interestingly,   spontaneous   mutations   in   human   caspase-­8   that   render   it  
catalytically   inactive   are   linked   with   primary   immunodeficiency   and   recurrent  
sinopulmonary   and   mucocutaneous   infections   (225,   226).   Similarly,   individuals   with  
mutations   in   the   adaptor   FADD   suffer   from   recurrent   infections   and   liver   pathology,  
suggesting  a   role   for   caspase-­8  and  FADD   in  antimicrobial   responses   (227).  Whereas  
initial   studies  observed   that  T,  B  and  NK  cells   from  patients  with  caspase-­8  deficiency  
displayed  defects   in  activation  (172,  225),  subsequent  work  revealed   that  caspase-­8   is  
critical   for   lymphocyte  survival  and  that  rescuing  this  survival  defect  restored  the  ability  
   69  
of  T  cells  to  respond  to  viral  infection  (25,  228).  These  studies  suggested  the  possibility  
that   the   effect   of   caspase-­8   on   activation,   at   least   in   lymphocytes,   may   relate   to   its  
control  of  cell  death.  
The   prosurvival   function   of   caspase-­8   serves   to   limit   receptor-­interacting  
serine/threonine   protein   kinase-­3   (RIPK3)-­dependent   necroptosis,   which   occurs   in   the  
context   of   developmental   and   inflammatory   cues   (25,   26,   29-­32).  During  homeostasis,  
RIPK3   is   repressed   by   heterodimers   of   caspase-­8   and   its   catalytically   inactive  
homologue,   cFLIP.   However,   inhibition   of   caspase-­8   activity   or   deletion   of   caspase-­8  
releases   the   brake   on  RIPK3-­dependent   necroptosis   (25,   26).   TLR   signaling   normally  
prevents   caspase-­8-­,   FADD-­   and   RIPK3-­dependent   cell   death   pathways   both   through  
transcriptional   upregulation   of   pro-­survival   genes   and   through   post-­translational  
modification  of  key  signaling  proteins  such  as  RIPK1  (229).   Induction  of  cell  death  and  
inflammatory  gene  expression  are  therefore  thought  to  be  mutually  exclusive  programs.  
However,   a   number   of   recent   studies   including   our   own   have   demonstrated   that  
caspase-­8  nonetheless   regulates   anti-­microbial   innate   responses   (123,   124,   173,   179-­
182).  
Specifically,  combined  deficiency  of  RIPK3  and  caspase-­8  or  RIPK3  and  FADD  
result  in  significant  reduction  in  the  secretion  of  a  number  of  pro-­inflammatory  mediators  
as   well   as   loss   of   inflammasome   priming   and   activation   in   response   to   some   stimuli  
(123,   124,   173,   179).   Interestingly,   while   many   of   these   inflammatory   mediators   are  
regulated  by  the  NF-­κB  signaling  pathway,  whether  caspase-­8  regulates  proximal  NF-­κB  
signaling,   and   even   whether   caspase-­8   acts   as   a   negative   or   positive   regulator   of  
inflammatory   gene   expression   remains   unresolved,   due   to   the   coupling   of   caspase-­8  
deficiency  with  induction  of  programmed  necrosis.  Thus,  these  studies  take  place  either  
under   conditions   where   RIPK3   is   ablated   (123,   124,   173,   179),   or   under   conditions  
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where  programmed  necrosis  may  be  occurring  due  to  conditional  deletion  of  caspase-­8  
(170,   172,   174,   230).   Thus,   how   caspase-­8  might   function   to   regulate   both   cell   death  
and   inflammatory   gene   expression,   and  whether   enzymatic   activity   plays   a   role   in   the  
latter  response  is  currently  unknown.      
We  now  demonstrate  that  caspase-­8  is  necessary  for  cell-­intrinsic  control  of  key  
inflammatory   cytokine   gene   expression   in   response   to   gram-­negative   bacterial  
pathogens  as  well  as  multiple  TLR  agonists.  Notably,  caspase-­8  controls  expression  of  a  
specific  subset  of  genes  critical  for  controlling  inflammation  and  host  defense.  Moreover,  
regulation   of   gene   expression   by   caspase-­8   was   independent   of   cell   death   and   the  
known   apoptotic   caspases   that   are   targets   of   caspase-­8   cleavage.   Surprisingly,   the  
catalytic  activity  of  caspase-­8  was  crucial   for   its  control  of  optimal  cytokine   responses.  
As   caspase-­8  enzymatic   activity   is   essential   for   both   the  apoptotic   function  of   cleaved  
caspase-­8  homodimers  and  the  cell  survival   function  of  caspase-­8/cFLIP  heterodimers,  
we   generated   CRISPR-­based   caspase-­8   knock-­in   mice   in   which   the   self-­cleavage   of  
caspase-­8   was   abrogated   due   to   a   mutation   in   aspartate   387   to   alanine   (Casp8DA).  
Intriguingly,   Casp8DA   macrophages   were   unable   to   undergo   caspase-­8-­dependent  
apoptosis,   but   displayed   no   loss   of   caspase-­8-­dependent   control   of   gene   expression.  
These   findings   implicate   a   novel   function   for   the   caspase-­8/cFLIP   heterodimer   in  
induction   of   innate   inflammatory   gene   expression   and   provide  mechanistic   insight   into  
how  caspase-­8  controls  antimicrobial  host  defense.    
Results  
Caspase-­8   plays   a   cell-­intrinsic   role   in   inflammatory   cytokine   production   during  
bacterial  infection  in  vivo  
Ripk3-­/-­Casp8-­/-­  mice  exhibit  severely  diminished  cytokine   responses   following  a  
number   of   bacterial   infections,   in   contrast   to  Ripk3-­/-­   mice,   which   have   no   discernible  
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defect  (123,  124,  179).  This  could  be  due  to  a  role  for  caspase-­8-­dependent  apoptosis  in  
the   release   of   intracellular   alarmins   that   promote   inflammatory   cytokine   production   by  
bystander   cells,   or   a   cell-­intrinsic   contribution   of   caspase-­8   to   inflammatory   gene  
expression.   To   distinguish   between   these   possibilities,   we   generated   mixed   bone  
marrow  chimeras  using  transfer  of  congenically  marked  WT,  Ripk3-­/-­,  and  Ripk3-­/-­Casp8-­/-­    
donor   bone   marrow   at   1:1   ratios   into   lethally-­irradiated   wild-­type   (B6.SJL)   recipients  
(Figure   20A   and   Figure   21A).   Eight   weeks   post-­reconstitution,   these   mixed   chimeric  
animals  were  infected  with  Yersinia  pseudotuberculosis  (Yp),  a  gram-­negative  bacterial  
pathogen   that   causes   a   rapid   and   lethal   bacteremia   in   animals   with   hematopoietic  
caspase-­8   deficiency   (123,   124).   Strikingly,   five   days   post-­infection,   Ripk3-­/-­Casp8-­/-­  
inflammatory  monocytes  isolated  from  the  mesenteric  lymph  nodes  (mLN)  of  mixed  BM  
chimeras  had  a  significant  defect  in  intracellular  TNF  and  IL-­6  production  compared  with  
either  wild-­type  or  Ripk3-­/-­   cells   from   the  same  animal   (Figure  20B,  C  and  Figure  21B,  
C).  Moreover,  this  defect  was  equivalent  to  monocytes  from  recipients  that  received  only  
Ripk3-­/-­Casp8-­/-­   BM,   indicating   that   the   presence   of   caspase-­8-­sufficient   cells   did   not  
restore  cytokine  production  in  cells   lacking  it  (Figure  21B,  C).   Interestingly,  not  only  did  
Ripk3-­/-­Casp8-­/-­   cells   have   a   lower   frequency   of   cytokine-­producing   cells,   the   mean  
fluorescence   intensity   of  Ripk3-­/-­Casp8-­/-­   cytokine   positive   cells   was   significantly   lower  
than  Ripk3-­/-­   or   B6   cells   from   the   same  mouse,   indicating   a   reduced   level   of   cytokine  
production  per  cell   (Figure  20D).  We  also  observed  that  a  significantly   lower   frequency  
of   Ripk3-­/-­Casp8-­/-­   neutrophils   produced   TNF   compared   to   either  Ripk3-­/-­   or   wild   type  
control  neutrophils,  indicating  a  broader  cytokine  defect  that  extended  to  other  innate  cell  
types  (Figure  20E,  F).  Importantly,  the  percent  chimerism  of  these  cell  types  was  similar  
across  all   the  genotypes,   indicating   that   there  were  no  differences   in   the  generation  or  
maintenance  of  Ripk3-­/-­Casp8-­/-­  monocytes  or  neutrophils   in  a  competitive  environment  
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at   these   timepoints   (Figure  21D).  Ripk3-­/-­Casp8-­/-­  chimeras  cannot  control  Yersinia  and  
harbor   much   higher   bacterial   burdens   in   their   lymph   nodes   and   spleen   (123,   124).  
Importantly,   however,   the   presence   of   congenically  marked  WT  or  Ripk3-­/-­   cells   in   the  
Ripk3-­/-­Casp8-­/-­   mixed   BM   chimeras   provided   significant   protection   from   Yersinia  
infection,   as   the   Ripk3-­/-­Casp8-­/-­   mixed   BM   chimeras   had   similar   bacterial   burdens  
compared  to  chimeric  mice  that  contained  only  wild-­type  or  a  mixture  of  Ripk3-­/-­  and  wild-­
type   bone  marrow   (Figure   20G   and   Figure   21D).   Together,   these   data   provide   direct  
evidence  for  a  key  cell-­intrinsic  role  for  caspase-­8  in  cytokine  gene  expression  in  innate  
immune  cells  in  response  to  bacterial  infection.  
Caspase-­8   regulates   inflammatory   cytokine   production   downstream   of   multiple  
TLRs  
We  next  sought  to  determine  the  contribution  of  caspase-­8  to  cytokine  production  
in  response  to  bacterial  infection  and  individual  pathogen-­associated  molecular  patterns  
(PAMPS)  in  an  in  vitro  system  as  a  means  to  further  define  this  response.  We  observed  
that  Ripk3-­/-­Casp8-­/-­  BMDMs  showed  dramatically  reduced  IL-­6  and  IL-­12p40  production  
compared  with  B6  or  Ripk3-­/-­  cells  in  response  to  either  Yersinia  or  Salmonella  infection  
(Figure  22A).  Consistent  with  this,  Ripk3-­/-­Casp8-­/-­  BMDMs  also  produced  lower  levels  of  
secreted  IL-­6,  IL-­12p40,  and  TNF,  as  well  as  intracellular  pro-­IL-­1β  in  response  to  LPS  
treatment   (Figure  22B,  C).   Interestingly,  Ripk3-­/-­Casp8-­/-­  BMDMs  did  not   have  a  global  
defect  in  all  responses  to  LPS  stimulation,  as  Ifnb  transcript  levels  were  not  decreased,  
suggesting   a   more   selective   effect   of   caspase-­8   deficiency   (Figure   22D).   Importantly,  
peritoneal  macrophages   isolated   from  Ripk3-­/-­Casp8-­/-­  mice  and  stimulated  ex  vivo  with  
LPS   also   showed   a   significant   defect   in   TNF   production   relative   to   B6   and   Ripk3-­/-­  
peritoneal  macrophages  (Figure  22E),  further  supporting  a  role  for  caspase-­8  in  cytokine  
production  by  innate  cells  following  TLR  stimulation.    
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TLR4-­mediated   apoptosis   requires   both   TRIF   and   caspase-­8.   Therefore,   we  
hypothesized   that   caspase-­8   could   be   coupled   to   TLR-­mediated   gene   expression   via  
TRIF,  and  that  TLRs  that  signal  through  MyD88  would  not  require  caspase-­8  for  cytokine  
expression.   Surprisingly,   RIPK3/caspase-­8-­deficient   BMDMs   exhibited   reduced  
production  of   the  cytokines   IL-­6,   IL-­12p40,  and  TNF   in   response   to  not  only   the  TRIF-­
dependent   TLR3   agonist   Poly(I:C),   but   also   the   MyD88-­dependent   TLR2   ligand  
Pam3CSK4  and  the  TLR9  ligand  CpG  (Figure  22F).  These  data  suggest  that  caspase-­8  
mediates  gene  expression  downstream  of  both  TRIF-­  and  MyD88-­dependent  pathways.    
These  cytokines  depend  on  NF-­κB  and  AP-­1  transcription  factor  family  members,  
and  previous  studies  have  suggested   that  caspase-­8   regulates   the  activation  of  NF-­κB  
activation   (124,   170,   172).   At   what   step   and   how   caspase-­8  might   regulate   NF-­κB   is  
nevertheless   unclear.   TLR   signaling   induces   assembly   of  MyD88   into   a   complex   with  
proteins   of   the   IRAK   family   called   the  myddosome   (6,   7),  which   initiates   the   signaling  
events   that   lead   to   the   activation   of   NF-­κB   transcription   factors   to   mediate   NF-­κB-­
dependent  cytokine  and  chemokine  gene  expression  (6,  7).  However,  we  did  not  detect  
caspase-­8   in   the  myddosome,   and   caspase-­8   did   not   affect   IRAK2   localization   to   the  
myddosome  in  response  to  LPS-­treatment  (Figure  23A,  B),  suggesting  that  caspase-­8  is  
not   involved   in   TLR-­proximal   signaling   events.   Initial   studies   had   observed   a   role   for  
caspase-­8   in   regulating   the   NF-­κB   pathway   in   lymphocytes   (170,   172).   We   therefore  
examined  whether  caspase-­8  regulates  NF-­κB  in  macrophages.  Consistent  with  a  recent  
report   (173),   degradation  and   resynthesis  of   IκBα  was  similar   among  B6,  Ripk3-­/-­,  and  
Ripk3-­/-­Casp8-­/-­   BMDMs   in   response   to   LPS   stimulation   (Figure   23C).  We  also   did   not  
observe   a   difference   in   phosphorylation   of   AKT,   p38   or   ERK   in   LPS-­treated   Ripk3-­/-­
Casp8-­/-­   BMDMs   compared   to   B6   and   Ripk3-­/-­   BMDMs   (Figure   23D,   E   and   data   not  
shown).  Moreover,   recruitment   of   the   NF-­κB   p65   subunit   to   caspase-­8-­inducible   gene  
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promoters  was  unaffected  in  Ripk3-­/-­Casp8-­/-­  BMDMs  (Figure  23F).  Together,  these  data  
suggest  that  the  role  of  caspase-­8  in  control  of  gene  expression  likely  does  not  occur  via  
receptor-­proximal  effects  on  classical  NF-­κB  or  MAPK  signaling  pathways.  
To   test   whether   caspase-­8   regulates   inflammatory   cytokine   production   at   the  
transcriptional   level,   we   examined   mRNA   levels   of   representative   cytokines.   Indeed,  
LPS-­stimulated   Ripk3-­/-­Casp8-­/-­   BMDMs   produced   significantly   less   Il1b,   Il12b   and   Il6  
mRNA  compared   to  either  Ripk3-­/-­   or  wild   type  BMDMs   (Figure  22G).   Importantly,   this  
reduction  in  cytokine  mRNAs  was  likely  due  to  decreased  transcriptional  induction  rather  
than  transcript  instability,  as  Ripk3-­/-­Casp8-­/-­  BMDMs  did  not  exhibit  a  more  rapid  decline  
of  mRNA  levels  following  treatment  with  the  transcription  synthesis  inhibitor  actinomycin  
D  (ActD)  2  hours  after  LPS  stimulation  (Figure  24A,  B).    
Caspase-­8-­regulated  genes  are  enriched  for  cytokine  signaling  pathways  
These  findings  support  a  role  for  caspase-­8  in  the  expression  of  TLR-­dependent  
inflammatory  cytokines,  but   the  extent   to  which  caspase-­8   impacts   the  TLR-­dependent  
transcriptional   program   is   unclear.   To   define   the   breadth   of   the   caspase-­8-­dependent  
transcriptional   response,   we   performed   genome-­wide   transcriptional   profiling   of   B6,  
Ripk3-­/-­,   and   Ripk3-­/-­Casp8-­/-­   BMDMs   following   LPS   treatment.   Based   on   our  
observations   that   maximal   differences   between   Ripk3-­/-­Casp8-­/-­   and   B6   or   Ripk3-­/-­  
BMDMs   occurred   at   6   hours   post-­infection,   we   stimulated   these   three   genotypes   of  
macrophages  with  LPS  for  6  hours  and  performed  RNA-­Seq  analysis  (Figure  25  A).  This  
timepoint   also   allowed   for   detection   of   both   primary   and   secondary   response   genes  
(231).   To   define   the   contribution   of   caspase-­8   to   the   TLR4-­induced   transcriptional  
program,  we  analyzed  the  LPS-­induced  genes  by  Principle  Component  Analysis  (PCA),  
Gene  Set  Enrichment  Analysis  (GSEA),  and  performed  hierarchical  clustering  and  Gene  
Ontology  (GO)  analysis  (Figure  25B).  The  PCA  analysis  revealed  that,  as  expected,  LPS  
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treatment   accounted   for   almost   96%   of   the   variance   among   the   samples   (PC1),  
demonstrating  that  neither  RIPK3  deficiency  alone,  nor  combined  deficiency  of  caspase-­
8  and  RIPK3  resulted  in  a  global  impact  on  LPS-­induced  gene  expression.  Interestingly,  
RIPK3/caspase-­8-­deficiency  contributed  to  the  second  highest  variance  (PC2),  implying  
a   role   for   caspase-­8   in   LPS-­induced   gene   expression.   To   determine   the   precise  
contribution  of  caspase-­8   to   the  LPS  response,  we   identified  LPS-­regulated  genes  that  
were  altered   in  either  Ripk3-­/-­Casp8-­/-­  or  Ripk3-­/-­  BMDMs.   Interestingly,  527  of   the  6379  
(8.3%)   genes   were   RIPK3/caspase-­8-­dependent,   whereas   only   62   of   6379   (less   than  
1%)  were  RIPK3-­dependent   (Appendix   I).   Importantly,   479   (or   91%)  of   the  527  genes  
affected  in  Ripk3-­/-­Casp8-­/-­  BMDMs  were  unaffected  by  RIPK3  deficiency  alone,  implying  
a  specific   role   for  caspase-­8   in   induction  of   these  genes.  Hierarchical  clustering  of   the  
caspase-­8-­dependent   genes   by   Pearson   correlation   revealed   two   major   clusters   of  
coordinately   regulated   genes   (Figure   25C).   Genes   in   cluster   1   were   more   highly  
expressed   in   response   to   LPS   in   Ripk3-­/-­Casp8-­/-­   BMDMs,   whereas   cluster   2   was  
composed   of   genes   that   were   not   as   strongly   induced   by   LPS   stimulation   in  Ripk3-­/-­
Casp8-­/-­  BMDMs  compared   to  B6  or  Ripk3-­/-­  BMDMs.   Interestingly,  and  consistent  with  
previous  findings  suggesting  that  caspase-­8  regulates  inflammatory  cytokine  production,  
functional   enrichment  of   cluster   2  genes  using  Gene  Ontology   (GO)  analysis   revealed  
genes   associated   with   immune   defense   and   transcriptional   regulation   (Figure   25D).  
Genes   belonging   to   the   category   of   transcriptional   regulation   included   JunB,  Rel   and  
Stat5a   (Figure   25E),  while   the   category   of   immune   defense   included   Il1a,   Il1b,  Ccl17,  
Il12b,  and  Tnf  (Figure  25E).  Although  this  subset  of  genes  was  still  upregulated  by  LPS  
stimulation  in  Ripk3-­/-­Casp8-­/-­  BMDMs,  the  degree  of  induction  was  significantly  reduced  
relative  to  control  cells  (Figure  26A).  Intriguingly,  Il1a,  Il1b,  Ccl17  and  Il12b  were  among  
the   top   20   most   differentially   expressed   genes.   Furthermore,   Gene   Set   Enrichment  
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Analysis   (GSEA),   which   provides   an   unbiased  way   to   identify   coordinated   changes   in  
gene  expression,  demonstrated  that  genes  involved  in  cytokine  and  chemokine  signaling  
were  significantly  enriched   in  wild   type  BMDMS  compared   to   caspase-­8-­deficient   cells  
(Figure  25F).  These   findings  demonstrate   that   caspase-­8  deficiency   is  associated  with  
altered   transcriptional   responses   of   a   subset   of   LPS-­induced   genes   that   play   a  
particularly  important  role  in  inflammatory  responses  to  infection.  
Caspase-­8   has   been   reported   to   localize   to   the   nucleus   of   B   cells,   raising   the  
possibility  that  nuclear  caspase-­8  might  play  a  role  in  gene  expression  (232).  However,  
we   did   not   observe   caspase-­8   in   the   nucleus   of   either   untreated   or   LPS-­treated  
macrophages,   suggesting   that   caspase-­8   does   not   play   a   direct   role   in   transcriptional  
activation   of   these   target   genes   (Figure   26B).   Furthermore,   both  Ripk3-­/-­   and  Ripk3-­/-­
Casp8-­/-­  BMDMs  phagocytosed   and   degraded  Salmonella  and  Yersinia  equivalently   to  
wild-­type  cells,  indicating  that  direct  killing  mechanisms  of  macrophages  were  still  intact  
(Figure  26C).  Together,  these  data  indicate  that  the  loss  of  caspase-­8  is  associated  with  
altered   expression   of   a   significant   number   of   TLR-­induced   genes   involved   in  
inflammation   and   transcription,   potentially   providing   an   explanation   for   the   profound  
susceptibility  of  caspase-­8-­deficient  animals  to  bacterial  infections.  Interestingly,  despite  
the  key  role  of  caspase-­8  in  regulating  cell  death  and  survival  decisions  in  the  context  of  
TNFR   signaling   (233),   the   role   of   caspase-­8   in   gene   expression   in   macrophages   is  
specific   to  TLRs,  as  caspase-­8  deletion  did  not  affect   the  expression  of  Cxcl2  or  Ccl22  
chemokine  genes   in   response   to  TNF,  despite   the   clear   impact  of   caspase-­8  on  LPS-­
dependent  induction  of  these  genes  (Figure  26D,  E).      
Sendai  virus-­induced  cytokine  production  does  not  require  caspase-­8  
Our  observations  imply  a  specific  contribution  of  caspase-­8  to  TLR  signaling.  To  
test  the  possibility  of  a  more  general  role  for  caspase-­8  in  other  innate  immune  signaling  
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pathways,   we   employed   Sendai   virus   (SeV),   which   induces   innate   immune   cytokine  
responses   primarily   via   the   RIG-­I   and   MDA-­5   pathways   (234,   235).   In   contrast   to  
bacterial   infection   and   TLR   stimulation,   caspase-­8   was   dispensable   for   SeV-­induced  
expression   of   IL-­6   and   IL-­12p40   in  BMDMs   (Figure   27A).  Moreover,   consistent  with   a  
robust   innate   response   to   SeV   in   vitro,   Ripk3-­/-­Casp8-­/-­   mice   also   showed   similar   or  
reduced   levels   of   weight   loss   in   response   to   SeV,   and   controlled   and   cleared   SeV  
infection   similarly   to   WT   and   Ripk3-­/-­   mice   (Figure   27B   and   C).   Importantly,   Ripk3-­/-­
Casp8-­/-­  mice  also  expressed  similar   levels  of   Ifnb,   Il6  and   Il1b   in   the   lung  during  SeV  
infection   relative   to   WT   and   Ripk3-­/-­   mice   (Figure   27D).   Thus,   while   caspase-­8   is  
important  for  maximal  inflammatory  gene  expression  in  response  to  bacterial  infection,  it  
is  dispensable  for  innate  responses  and  clearance  of  SeV  infection.    
Caspase-­8   is   necessary   for   optimal   inflammatory   cytokine   production  
independent  of  RIPK3  
Caspase-­8  and  RIPK3  are  present   in   the   same  complex  as  FADD  and  RIPK1.  
While   caspase-­8   inhibits   RIPK3-­regulated   necrosis   via   a   caspase-­8/cFLIP   complex,  
mutation   or   inhibition   of  RIPK3   kinase   activity   can   also   promote   caspase-­8-­dependent  
apoptosis   (19,   236-­238).   Given   this   close   link   between   caspase-­8   and   RIPK3,   we  
considered  the  possibility  that  the  observed  effect  of  caspase-­8  on  gene  regulation  could  
be  due  to  combined  loss  of  both  RIPK3  and  caspase-­8.  However,  due  to  the  embryonic  
lethality   of   caspase-­8-­deficient   animals   because   of   unrestrained   RIPK3-­mediated  
necrosis,  the  effect  of  single  deficiency  in  caspase-­8  has  been  difficult  to  separate  from  
its  effect  on  programmed  necrosis.  Conditional  deletion  of  caspase-­8  in  vitro  also  results  
in  significant   toxicity  due   to   induction  of  RIPK3-­mediated  necrosis   in   response   to   tonic  
signaling  (24).  RIPK3  induces  programmed  necrosis  through  Mixed  Lineage  Kinase  Like  
(MLKL)   (33-­35).   Importantly,   while   caspase-­8-­deficient   mice   are   embryonic   lethal,  
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deletion  of  MLKL  also  rescues  this  embryonic  lethality,  analogous  to  deletion  of  RIPK3.  
Intriguingly,  Mlkl-­/-­Casp8-­/-­   BMDMs   also   produced   significantly   lower   levels   of   IL-­6,   IL-­
12p40   and   TNF   in   response   to   LPS,   Pam3CSK4   and   CpG,   relative   to  Mlkl-­/-­   BMDMs  
(Figure   28).   These   data   demonstrate   that   caspase-­8   controls   cytokine   expression  
independently  of  RIPK3.  
Caspase-­8  catalytic  activity,  but  not  auto-­processing,  is  required  for  optimal  TLR-­
induced  cytokine  production  
Caspase-­8   homodimerization   results   in   activation   of   apoptosis,   whereas  
heterodimerization   of   caspase-­8   with   its   catalytically   inactive   homolog   cFLIP   prevents  
both   apoptosis   and   regulated   necrosis   (26,   154).   Conditions   that   trigger   extrinsic  
apoptosis   induce  assembly  of  caspase-­8  homodimers  or  oligomers,  wherein  caspase-­8  
undergoes   autoprocessing   (141,   239).  While   homodimerization   is   sufficient   to   activate  
the  enzyme,  subsequent  autoprocessing  stabilizes  the  cleaved  dimer,  and  is  required  for  
caspase-­8  to  cleave  its  downstream  apoptotic  substrates  such  as  Bid,  caspase-­3  and  -­7  
(20).   In   contrast,   the   caspase-­8/cFLIP   heterodimer   does   not   require   caspase-­8  
processing,   but   does   require   catalytic   activity   to   prevent   necrosis   (26).   Thus,   blocking  
caspase  activity  in  the  context  of  TNF  or  TLR  stimulation  leads  to  programmed  necrosis  
that   depends   on   RIPK3   (240).   In   order   to   test   whether   caspase-­8   catalytic   activity   is  
responsible   for   the   effect   of   caspase-­8   on   TLR-­induced   gene   expression,   we   treated  
RIPK3-­deficient   cells   with   the   pan-­caspase   inhibitor   zVAD-­fmk.   Notably,   zVAD-­fmk  
significantly   reduced   production   of   IL-­12p40,   IL-­6   and   IL-­1β   in   LPS-­treated   Ripk3-­/-­  
BMDMs   (Figure   29A-­C).   As   expected,   Ripk3-­/-­Casp8-­/-­   BMDMs   exhibited   significantly  
blunted   responses   to   LPS,  which  were   not   substantially   altered   by   inhibitor   treatment.  
QVD-­oph   is  another  widely  used  pan-­caspase   inhibitor   that  does  not  display   the  same  
cytotoxicity  as  zVAD-­fmk  (241).  Critically,  QVD-­oph  also  significantly   reduced   IL-­12p40  
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and   IL-­6   production   following   LPS   treatment   in   both   B6   and  Ripk3-­/-­   BMDMs   (Figure  
29D).  Notably,  QVD-­oph  did  not  induce  cytotoxicity  in  either  B6  or  Ripk3-­/-­  BMDMs,  and,  
Ripk3-­/-­   cells   did   not   undergo   cell   death   in   response   to   zVAD-­fmk,   demonstrating   that  
caspase  activity  contributes  to  LPS-­induced  gene  expression  independently  of  cell  death  
(Figure  29E).  Importantly,  cells  deficient   in  both  caspase-­3  and  -­7  were  fully  competent  
to  induce  expression  of  cytokines  following  LPS  treatment,  demonstrating  that  caspase-­
8   activity   regulates   TLR-­induced   gene   expression   independently   of   these   apoptotic  
caspases  (Figure  30).  
To   further   define   how   caspase-­8   regulates   TLR-­induced   gene   expression,   we  
generated  a  caspase-­8  mutant  knock-­in  mouse,   termed  Casp8DA/DA,   in  which  aspartate  
387   is   replaced   with   an   alanine,   thereby   rendering   it   non-­cleavable   (Figure   31A).  
Although   caspase-­8   deficiency   is   embryonically   lethal,   mice   expressing   non-­cleavable  
caspase-­8   are   viable,   due   to   the   enzymatic   activity   of   caspase-­8   in   the   context   of   a  
caspase-­8/cFLIP   heterodimer   (26,   160,   242).   Self-­cleavage   at   D387   releases   the  
catalytically  active  p20  subunit,  and  under  most  cellular  conditions,   this  self-­processing  
is  necessary   for  caspase-­8-­dependent  apoptosis  (20).  However,  catalytic  activity  of   the  
caspase-­8/cFLIP   heterodimer   prevents   RIPK3-­mediated   necrosis   (26),   but   can   also  
mediate   the   processing   of   substrates   (148,   162).   Therefore,   the   Casp8DA/DA   mouse  
provides   a  means   to   distinguish   the   roles   of   the   caspase-­8   homodimer   and   caspase-­
8/cFLIP   heterodimer   in   gene   expression.   Notably,  Casp8DA/DA   BMDMs  were   unable   to  
process  caspase-­8  in  response  to  Yersinia,  which  induces  caspase-­8  cleavage  and  cell  
death   in   wild   type   or   Casp8DA/+   macrophages   that   depend   on   the   Yersinia   effector  
protein   YopJ   (110)   (Figure   31B-­D).   Importantly,  Yersinia-­induced   caspase-­3   cleavage,  
which   is   caspase-­8-­dependent   (123)   is   specifically   abrogated   in   Casp8DA/DA   BMDMs  
(Figure   31C).   Surprisingly,   despite   the   absence   of   caspase-­3   cleavage,   Casp8DA/DA  
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macrophages  exhibited  equivalent   levels  of  cell  death   in   response   to  Yersinia   infection  
(Figure   31D).   We   therefore   considered   the   possibility   that   Yersinia   infection   of   these  
macrophages   might   induce   RIPK3-­dependent   necrosis.   Indeed,   while   Casp8+/+,  
Casp8DA/+  and  Casp8DA/DA  BMDMs  exhibited  similar  levels  of  Yersinia-­induced  cell  death,  
only  Casp8DA/DA   BMDMs   were   protected   from   this   cell   death   upon   treatment   with   the  
RIPK3   inhibitor,   GSK’   872   (Figure   31D).   Together,   these   data   demonstrate   that  
caspase-­8  cleavage  is  necessary  for  apoptosis   in  macrophages,  and  in  the  absence  of  
this  cleavage,  Yersinia-­infected  Casp8DA/DA  BMDMs  undergo  RIPK3-­dependent  necrosis.  
These  data  imply  that  caspase-­8  D387A  does  not  activate  apoptosis,  but   likely  forms  a  
heterodimer  with  cFLIP  in  macrophages.    
Critically,   Casp8DA/DA   and   Casp8DA/+   BMDMs   responded   equally   well   to  
stimulation  with  LPS,  Pam3CSK4  or  CpG  as  compared  to  littermate  control  WT  BMDMs,  
as  we  observed  similar  frequencies  of  IL-­12p40+,  IL-­1β+  and  IL-­6+  cells  among  Casp8+/+,  
Casp8DA/+   and   Casp8DA/DA   BMDMs   (Figure   31E-­G).   Consistently,   Casp8DA/DA   BMDMs  
produced  WT  levels  of  TNF  in  response  to  LPS,  Pam3  or  CpG  (Figure  31H).  Altogether,  
our  findings  indicate  that  caspase-­8  enzymatic  but  not  its  auto-­processing  activity  plays  
an   important   role   in  optimal  production  of  TLR-­dependent   inflammatory   cytokines,  and  
implicate  the  activity  of  the  caspase-­8/cFLIP  heterodimer  in  this  response.  
Discussion  
Caspase-­8   and   caspase-­8-­containing   protein   complexes   have   emerged   as  
central   regulators   of   cell   fate   decisions   in   the   context   of   infection   and   inflammatory  
stimuli.   Caspase-­8   interacts   with   a   number   of   key   adaptors   and   signaling   proteins,  
including   cFLIP,   RIPK1,   RIPK3   and   FADD.   The   precise   nature   of   the   interactions  
between  caspase-­8  and   these  components   in   the  context  of  specific  extracellular  cues  
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determine   whether   the   cell   initiates   inflammatory   gene   expression,   or   undergoes  
apoptosis   or   RIPK3-­dependent   programmed   necrosis.   While   the   molecular   and  
biochemical   mechanisms   of   caspase-­8-­induced   apoptosis   and   caspase-­8-­dependent  
control   of   RIPK3   necrosis   have   been   extensively   characterized,   how   caspase-­8  might  
control  cell-­intrinsic  gene  expression  is  not  clear.  
Germline   mutations   in   human   caspase-­8   or   FADD   cause   a   primary  
immunodeficiency   associated   with   severe   recurrent   bacterial   and   viral   infections,  
encephalopathy   and   hepatopathy   (225,   227).   While   initial   studies   proposed   that  
caspase-­8   regulates   NF-­κB   signaling   in   lymphocytes   following   antigen   receptor  
activation   (170,  172),  Ripk3-­/-­Casp8-­/-­  T  cells  did  not  exhibit  defects   in  NF-­κB  activation  
or,  antigen-­specific  IFNγ  production  (25,  173,  175,  228).  This  suggested  that  caspase-­8  
regulates  T  cell  responses  by  limiting  RIPK3-­dependent  necrosis  rather  than  controlling  
T  cell  activation  itself.  Nevertheless,  several  recent  studies  examining  macrophages  and  
dendritic  cells   from  Ripk3-­/-­Casp8-­/-­  animals  have   linked  caspase-­8   to   the  production  of  
innate  cytokines  as  well  as   to   inflammasome  activation   (124,  170,  172,  173,  175,  182,  
221,   223,   243-­245).   The   role   of   caspase-­8   in   NF-­κB   signaling   in   innate   cells   is   not  
precisely   defined,   as   recent   studies   have   come   to   opposite   conclusions   about   the  
contribution   of   caspase-­8   to   activation   of   the   IKK   complex   and   IκB   degradation   (124,  
173).   Moreover,   while   caspase-­8   mediates   apoptosis   and   prevents   RIPK3-­necrosis  
downstream   of   the   TLR4-­   or   TLR3-­TRIF   axes   (14-­16,   23,   24),   the   extent   to   which  
caspase-­8  regulates  TLR-­induced  gene  expression  has  not  been  defined.    
Here,  we  report  a  pleiotropic  role  for  caspase-­8  in  the  control  of  gene  expression  
downstream  of  multiple  TLRs,   including   those   that   signal   through  TRIF   (TLR3,   4)   and  
those  that  signal  through  MyD88  (TLR2,  4,  9).  We  have  now  defined  the  contribution  of  
caspase-­8   to  LPS-­induced  gene  expression,  and   find   that  caspase-­8   regulates  a  small  
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but  critical  subset  of  genes  that  play  an  important  role  in  inflammation  and  anti-­microbial  
immune  defense.  Caspase-­8  acts  as  an   important  modifier  of  gene  expression,  as   it   is  
necessary  for  the  maximal  induction  of  particular  genes,  rather  than  absolutely  required  
for   their   expression.   Notably,   IL-­12,   IL-­6,   pro-­IL-­1α,   pro-­IL-­1β,   as   well   as   multiple  
chemokine  genes  were  among  the  527  LPS-­induced  genes  that  required  caspase-­8  for  
optimal  induction,  which  collectively  constitutes  8.3%  of  total  LPS-­induced  genes  in  WT  
cells.  Mechanistically,  our  data  also  demonstrate  that  caspase-­8  enzymatic  activity,  but  
not  auto-­processing,  plays  a  key  role  in  the  induction  of  gene  expression  independently  
of   apoptotic   caspases   or   any   other   effects   on   cell   death   signaling   (Figure   32).   These  
data   provide   new   insight   into   the   susceptibility   phenotypes   associated  with   caspase-­8  
deficiency.    
Our   findings   imply   that  caspase-­8  has  an  apoptosis-­independent   function   in   the  
context  of  TLR  engagement  because  TLR  stimulation  alone  does  not   induce  cell  death  
under   the   conditions  employed  here.  The  precise   targets  of   this  activity   remains   to  be  
defined,  but  do  not  involve  the  known  apoptotic  substrates  caspase-­3  and  -­7.  Moreover,  
our   findings   that   the  gene  expression  defect  of  caspase-­8-­deficient  cells   is  cell-­intrinsic  
exclude   a   model   in   which   the   diminished   cytokine   production   by   caspase-­8-­deficient  
cells   results   from   the   lack  of   release  of   intracellular  alarmins   in   the  absence  of  RIPK3  
and  caspase-­8.    
It   is   possible   that   some   of   the   effects   we   observe   are   the   result   of   the   dual  
deletion  of  RIPK3  and  caspase-­8.  RIPK3  has  been  implicated  in  inflammatory  responses  
independent  of  cell  death,  as  RIPK3  itself  can  promote  IL-­1β  expression  in  dendritic  cells  
via  induction  of  mitochondrial  ROS  (245).  Similarly,  conditional  deletion  of  caspase-­8  in  
dendritic   cells   resulted   in   elevated   production   of   IL-­1β   due   to   RIPK3-­dependent  
activation  of   the  NLRP3   inflammasome  (219),  and   led   to  systemic  autoimmunity   (246).  
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Caspase-­8  and  RIPK3  may  play  cell  type-­specific  roles  in  regulating  inflammatory  gene  
expression.  However,   the   increased   inflammatory   responses  observed   in   the  setting  of  
conditional   deletion   of   caspase-­8   or   FADD   in   vivo   are   likely   due   to   de-­repression   of  
RIPK3-­dependent  necrosis  (30,  32,  247).  We  did  not  observe  a  contribution  of  RIPK3  to  
the  caspase-­8-­dependent  gene  expression  program,  in  that  loss  of  RIPK3  alone  did  not  
substantially  affect  expression  of  pro-­IL-­1β  or  other  inflammatory  cytokines,  either  in  vitro  
in   BMDMs,   or   in   vivo   in   monocytes   or   neutrophils   in   response   to   bacterial   infection.  
Furthermore,  several   lines  of  evidence  support  a   role   for  caspase-­8   in   regulating  gene  
expression   independent   of   RIPK3:   first,   Mlkl-­/-­Casp8-­/-­   but   not   Mlkl-­/-­   BMDMs   have   a  
significant  defect  in  production  of  pro-­inflammatory  cytokines  in  response  to  multiple  TLR  
agonists,   despite   having   functional   RIPK3.   Second,   treatment   of   RIPK3-­sufficient   B6  
BMDMs  with  the  caspase  inhibitor  QVD-­oph  prior  to  TLR  stimulation  did  not  induce  any  
detectable  cytotoxicity,  but  still  significantly   reduced  cytokine  production   in   response   to  
TLR   stimulation.   Cumulatively,   these   data   imply   a   key   role   for   caspase-­8   activity  
independent  of  RIPK3  in  TLR-­induced  inflammatory  responses.  
The   role   of   caspase-­8   as   a   key   modulator   of   gene   expression   makes   it  
functionally  analogous  to  RIPK1,  which  is  also  a  central  regulator  of  apoptosis,  necrosis  
and   gene   expression   (19).   It   is   possible   that   like   RIPK1,   distinct   post-­translational  
modifications  or  recruitment  to  distinct  complexes  mediate  the  switch  between  caspase-­
8-­dependent  apoptosis  and  gene  expression.  Caspase-­8  may  regulate  gene  expression  
through   a   RIPK1-­containing   complex   distinct   from   complex   II.   However,   since   RIPK1  
plays  a   central   scaffolding   role   in   receptor-­proximal   activation  of   the   IKK  complex,   the  
effect  of  RIPK1  deficiency  on  TLR-­induced  gene  expression  is  likely  more  profound  than  
that  of  caspase-­8.    
Like  TLR  signaling,  TNFR  activation  can  trigger  survival  and  cytokine  production,  
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apoptosis,  or  necrosis  (18,  19).  Caspase-­8  controls  cell  death   in  response  to  both  TLR  
and  TNFR  signaling  pathways.  Nevertheless,  the  common  chemokine  genes  Cxcl2  and  
Ccl22   that   are   induced   by   both   LPS   and   TNF   in   BMDMs,   required   caspase-­8   for  
maximal   induction   in   response   to  LPS  but  not  TNF.  Whether   caspase-­8  contributes   to  
TNFR-­dependent   gene   expression   in   other   cell   types   remains   to   be   determined.  
Furthermore,   although   caspase-­8-­deficient   BMDMs   had   a   defect   in   their   ability   to  
respond  to  infection  by  several  gram-­negative  bacteria  as  well  as  multiple  TLR  agonists,  
Ripk3-­/-­Casp8-­/-­  BMDMs  produced  equivalent   levels  of  cytokines   in   response   to  Sendai  
virus   infection,   which   engages   the   cytosolic   PRRs   RIG-­I   and   MDA5.   Caspase-­8   was  
previously   shown   to   negatively   regulate   type   I   IFN   in   response   to   SeV   in   human  
fibroblasts,   in   part   through   cleaving   RIPK1   and   shutting   off   RIPK1   signaling   (181).  
Nonetheless,   our   findings   suggest   that   macrophages   do   not   require   caspase-­8   for  
induction   of   inflammatory   cytokines   by   cytosolic   nucleic   acid   sensors.   Thus,   while  
caspase-­8   regulates   apoptosis   and   programmed   necrosis   downstream   of   multiple  
receptors,  in  macrophages,  caspase-­8  specifically  controls  gene  expression  in  response  
to  TLR  signaling.    
The  defect   in  production  of  IL-­6,  TNF,  IL-­12p40  and  proIL-­1β  by  Ripk3-­/-­Casp8-­/-­  
cells  in  response  to  MyD88-­dependent  TLR  agonists  such  as  CpG  and  Pam3CSK  could  
be   due   to   the   recently   reported   role   of   TRIF   participating   in   signaling   downstream   of  
classical   MyD88-­dependent   TLRs,   as   was   suggested   in   the   case   of   TLR2   (248).  
However,   TRIF   did   not   contribute   to   TLR2-­dependent   induction   of   IL-­6   or   TNF   (248),  
which   we   observed   was   affected   by   caspase-­8   deficiency.   Therefore,   caspase-­8  may  
participate  at  a  distal   step  of  TLR  signaling   in  a  manner   that  affects  both  MyD88-­  and  
TRIF-­dependent  gene  expression.  This  may  occur  through  control  of  a  shared  accessory  
factor   that   is   important   for   expression   of   these   genes.   Notably,   caspase-­8   does   not  
   85  
regulate   the   early   receptor-­proximal   events,   such   as   myddosome   formation,   IκBα  
degradation,   or  MAPK  activation.  Recruitment  of   p65   to   the  promoters  of   a  number  of  
caspase-­8-­dependent   genes   was   also   unaltered.   These   observations,   along   with   the  
finding   that   IκBα   resynthesis,   which   depends   on   NF-­κB   itself,   was   unaffected   by  
caspase-­8  deficiency,   are   consistent  with  our   transcriptional   profiling   studies   indicating  
that   over   90%   of   LPS-­induced   gene   expression   remains   unaffected   in   caspase-­8-­
deficient  cells.  However,  the  approximately  8%  of  genes  that  are  affected  include  critical  
inflammatory  mediators  and  chemokines.    
Caspase-­8   is   a   cysteine  protease   that   forms  homodimers   to   activate   apoptosis  
and  heterodimers  with  its  homolog  cFLIP  to  inhibit  apoptosis  and  necroptosis  (20,  148).  
Both   functions   of   caspase-­8   require   catalytic   activity,   however   the   caspase-­8/cFLIP  
heterodimer  does  not  need   to  undergo  self-­cleavage   to   inhibit   cell   death   (26).  Using  a  
newly-­generated   non-­cleavable   caspase-­8   knock-­in   mouse,   we   demonstrate   that   the  
catalytic,   but   not   self-­cleavage   activity   of   caspase-­8   is   required   for   maximal   cytokine  
production,  suggesting  that  an  adaptor  or  scaffolding  function  is  insufficient  and  that  the  
caspase-­8/cFLIP  heterodimer   regulates  gene  expression.  The  precise   target  or   targets  
of   caspase-­8/cFLIP   activity   that   mediate   this   gene   regulatory   function   remain   to   be  
identified.   Nevertheless,   our   findings   provide   the   first   definitive   demonstration   that   the  
enzymatic   activity   of   caspase-­8   in   TLR-­induced   gene   expression   plays   a   key   cell-­
intrinsic   role   in   TLR-­dependent   gene   expression.   Together,   these   data   provide   new  
mechanistic   insight   into   the   non-­apoptotic   function   of   caspase-­8   in   host   immune  
defense,  which  may  account   for   the   severe   susceptibility   of  mice   and   humans   lacking  
caspase-­8  to  poly-­microbial  infections.  
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Figure   20.   Ripk3-­/-­Casp8-­/-­   inflammatory   monocytes   and   neutrophils   have   a   cell-­
intrinsic  defect  in  IL-­6  and  TNF  production.  
(A)  Schematic  of  mixed  bone  marrow  chimera  experimental  set-­up.  Congenically  marked  
B6  (black),  Ripk3-­/-­  (green)  or  Ripk3-­/-­Casp8-­/-­  (orange)  bone  marrow  (BM)  were  injected  
at  a  1:1  ratio   into  lethally-­irradiated  recipient  B6.SJL  mice.  8  weeks  after  reconstitution,  
chimeras  were  orally  infected  with  Yersinia  (1x108/mouse)  and  immune  responses  were  
assayed  at  day  5  post-­infection.  (B)  Quantification  of  percentage  of  Ly6Chi  inflammatory  
monocytes  that  express  TNF  or  IL-­6  for  each  genotype  of  cells  in  the  B6:Ripk3-­/-­  (B6:R3-­/-­
),   Ripk3-­/-­:Ripk3-­/-­Casp8-­/-­   (R3-­/-­:R3-­/-­C8-­/-­)   and   B6:Ripk3-­/-­Casp8-­/-­   (B6:R3-­/-­C8-­/-­)   mixed  
chimeras,  as   indicated.  Color  scheme  of  bars   is  as   in   (A)  with  black  bars   representing  
B6,  green  bars  representing  Ripk3-­/-­,  and  orange  bars  representing  Ripk3-­/-­Casp8-­/-­  cells.      
(C)  Representative   flow  plots   of   TNF   (top   row  of   plots)   and   IL-­6   (bottom   row  of   plots)  
production   in   inflammatory   monocytes   from   mixed   chimeras   in   (B).   Flow   plots   within  
each   set   of   brackets   represent   cells   analyzed   from   the   same   mixed   bone   marrow  
recipient  mouse;;  genotypes  of   the  cells  analyzed  are   indicated  above  each  plot  R3-­/-­  –  
Ripk3-­/-­,   R3-­/-­C8-­/-­   -­   Ripk3-­/-­Casp8-­/-­.   (D)   Quantification   of   mean   fluorescence   intensity  
(MFI)  of  TNF+  and  IL-­6+  inflammatory  monocytes  from  B6:R3-­/-­,  R3-­/-­:R3-­/-­C8-­/-­and  B6:R3-­/-­
C8-­/-­    mixed  chimeras  in  (B)  and  (C).  (E)  Representative  flow  plots  of  TNF  production  in  
Ly6G+   neutrophils   from   B6:R3-­/-­,   R3-­/-­:R3-­/-­C8-­/-­   and   B6:R3-­/-­C8-­/-­      mixed   chimeras  
analyzed  as  described  in  (C).  (F)  Quantification  of  percentage  of  TNF+  neutrophils  from  
(E).   (G)  Quantification  of  bacterial  burden  per  gram   tissue   (CFU/g).  Solid  bars   indicate  
geometric  mean  of  samples.  Dotted  lines  indicate  the  limit  of  detection.    
Gating   strategy   is   described   in   detail   in   Experimental   Procedures.   Data   are  
representative  of  2-­4  independent  experiments.  *  p  <  0.05,  **  p  <  0.01,  ***  p  <  0.001  by  
Student’s  unpaired  t-­test.  
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V.  CONCLUDING  REMARKS  
  
Microbes  are  recognized  by  a  variety  of  PRRs  that  trigger  a  cascade  of  signaling  
events,   resulting   in   the  expression  of  pro-­survival  proteins  and   inflammatory  cytokines.  
Pathogens  such  as   the  gram-­negative  bacteria  Yersinia,  express  virulence   factors   that  
can   inhibit   and   manipulate   anti-­microbial   responses.   Therefore,   the   immune   system  
must   succeed   in   eliciting   an   effective   immune   response   in   the   presence   of   microbial  
inhibition.   The   Yersinia   effector   protein   YopJ   impairs   NF-­κB   and   MAPK   signaling,  
resulting   in  host  cell  death.  The  precise  mechanism  of  Yersinia-­induced  cell  death  and  
its   effect   on   disease   outcomes   remain   to   be   determined.   Death   receptor   ligation   can  
induce   two   distinct   forms   of   caspase-­8-­dependent   apoptosis   that   are   differentially  
dependent  on  the  kinase  activity  of  RIPK1  (229,  249).  Additionally,  ablation  of  caspase-­8  
elicits   RIPK3-­dependent   necrosis   (25,   26).   We   demonstrated   that   Yersinia   activated  
RIPK1  kinase-­dependent  cell  death.  Remarkably,  absence  of  both  RIPK3  and  caspase-­8  
or   FADD   abrogated   cell   death   in   response   to  Yersinia.   Yersinia-­induced   cell   death   is  
associated   with   the   activation   of   multiple   caspases.   Notably,   both   caspase-­1   and   -­3  
activation   required   caspase-­8,   RIPK1   and   FADD,   but   not   RIPK3,   implying   that   the  
activity   of   Yersinia   YopJ   elicits   both   pyroptosis   and   apoptosis.   Mice   deficient   in   both  
RIPK3  and  caspase-­8  were  highly  susceptible   to  Yersinia   infection  and  harbored  more  
bacteria   in   their   lymphoid   tissues   compared   to   RIPK3-­deficient   and   B6   mice.  
Interestingly,   this   defect   was   partially   restored   in   mice   infected   with   Yersinia   lacking  
YopJ,  suggesting  that  cell  death  has  a  host  protective  role  in  Yersinia  infection.    
Caspase-­1   is   a   critical   mediator   of   pyroptosis,   while   caspase-­3   orchestrates  
apoptotic  cell  death.  Whether  both  pyroptosis  and  apoptosis  are  activated   in   the  same  
cell   is   completely   unknown,   as   these   assays   were   performed   at   the   population   level.  
Furthermore,  the  impact  of  activating  two  distinct  forms  of  cell  death  in  the  same  cell  on  
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inflammation,   is   unclear.   Since   we   showed   that   caspase-­1   and   -­3   do   not   affect   one  
another’s  activation   in  our  experimental   system,   these  caspases  are   likely  activated   in  
parallel   pathways.   It   is   plausible   that   the   activation   of   caspase-­1   actively   represses  
caspase-­3-­dependent   apoptosis   and   vice   versa.   Single   cell   analysis   by   microscopy  
would  reveal  whether  Yersinia  induces  active  caspase-­1  and  active  caspase-­3  in  distinct  
cells.   Another   possibility   is   that   caspase-­1   and   -­3   are   activated   in   the   same   cell   in  
response   to  Yersinia   infection.   Through   cleavage   of   IL-­1   and   other   substrates,   active  
caspase-­1  may  provide  inflammatory  signals  to  an  otherwise  silent  apoptotic  cell  death.  
Further  work  will  need  to  identify  DAMPs  that  are  released  during  Yersinia-­induced  cell  
death  and  assess  whether  caspase-­1  contributes  to  the  release  of  these  DAMPs.  If  this  
is  the  case,  caspase-­1  activity  could  be  a  new  biomarker  for  immunogenic  cell  death  and  
modulating   caspase-­1   activity   could   potentially   benefit   treatment   strategies   against  
infections  or  cancer.    
Yersinia-­induced  cell  death  requires  inhibition  of  MAPK  and  NF-­κB  signaling  and  
is  concurrent  with  a  YopJ-­dependent  block  in  cFLIP  expression  (109).  We  demonstrated  
that  Ripk3-­/-­Casp8-­/-­  BMDMs  are  resistant  to  Yersinia-­induced  cell  death.  Together,  these  
data   provoke   a   model   whereby   YopJ-­dependent   inhibition   of   cFLIP   expression   and  
consequently   activity   of   the   caspase-­8/cFLIP  heterodimer   affects   two   cell   death   check  
points   (Figure   33).   First,   depletion   of   cFLIP   releases   the   break   on   caspase-­
8/FADD/RIPK1   complex   IIb   formation   and   caspase-­8   homodimerization.   Cleaved  
caspase-­8  homodimers  would   then  process  caspase-­3  and  caspase-­1,   resulting   in  cell  
death.   Second,   reduced   caspase-­8/cFLIP   activity,   derepresses   RIPK3-­mediated  
necrosis,  even  in  the  absence  of  stimulation.  Therefore,  deletion  of  both  caspase-­8  and  
RIPK3  is  required  to  protect  macrophages  from  Yersinia-­induced  cell  death.    
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How  caspase-­8  is  activated  during  Yersinia  infection  is  not  known.  A  recent  study  
demonstrated   a   novel   function   of   the   IKK   complex   in   regulating   RIPK1-­mediated   cell  
death,  implying  that  RIPK1  may  be  the  link  between  Yersinia  YopJ  and  caspase-­8  (229).  
Yersinia  YopJ  inhibits  TAK1,  which  prevents  IKKβ  phosphorylation,  NF-­κB  signaling  and  
the   block   in   expression   of   pro-­survival   proteins,   resulting   in   cell   death   (16,   108,   109).  
Dondelinger   and   colleagues   discovered   that   IKKβ   phosphorylates   RIPK1,   which  
maintains  RIPK1   in   an   inactive   conformation   and   blocks  RIPK1-­dependent   cell   death.  
Since   Yersinia-­induced   cell   death   requires   RIPK1,   it   is   possible   that   Yersinia   YopJ  
potentiates   RIPK1-­dependent   cell   death   by   inhibiting   IKKβ   phosphorylation   and  
consequently  increasing  the  cellular  pool  of  dephosphorylated  RIPK1.  Dephosphorylated  
RIPK1   would   activate   caspase-­8/FADD/RIPK1   complex   formation   and   cell   death,  
independent  of  NF-­κB  signaling.  RIPK1-­dependent  cell  death  is  fast,  as  are  the  kinetics  
of  Yersinia-­induced  cell  death,  suggesting  that  YopJ  induces  a  cell  death  pathway  that  is  
at  least  partially  independent  of  its  effect  on  pro-­survival  protein  expression  (Figure  33).  
Since  Yersinia   can   activate   different   cell   death   cascades,   what   are   the   factors  
that   determine  whether   caspase-­dependent  apoptosis  or  RIPK3-­dependent  necrosis   is  
triggered?  Active  caspase-­8  can  cleave  RIPK3  and  repress  RIPK3  necroptosis  (250).  It  
is   plausible   that   apoptosis   is   the   dominant   pathway   that   is   activated   by   Yersinia,  
because   Yersinia   infection   induces   RIPK3   cleavage   (Lance   Peterson,   unpublished).  
However,   this   doesn’t   preclude   a   role   for   RIPK3   or   RIPK3   cleavage   products   in   the  
control  of  apoptosis,  as  recent  studies  have  shown  that  mutations  in  RIPK3  can  trigger  
caspase-­8-­dependent   apoptosis   (236,   237).   Nevertheless,   Casp8DA/DA   BMDMs   that  
cannot  undergo  apoptosis,  due  to  a  mutation  in  D387,  had  a  significant  delay  in  Yersinia-­
induced  cell  death  compared  to  B6  BMDMs.  This  cell  death  was  completely  blocked  by  
the   RIPK3   kinase   inhibitor   GSK-­872,   suggesting   that   in   the   absence   of   caspase-­8-­
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dependent   apoptosis,   YopJ   potentiates   RIPK3   necrosis.  Casp1-­/-­Casp11-­/-­Casp3-­/-­   and  
Casp1-­/-­Casp11-­/-­Ripk3-­/-­  BMDMs,  are  not  protected  from  Yersinia-­induced  death  (Naomi  
Philip   and   Baofeng   Hu,   unpublished   observations),   suggesting   that   other   apoptotic  
caspases,   such   as   caspase-­7,   may   play   a   complementary   role   in   cell   death.   Since  
caspase-­3   and   -­7   share   some   substrates   and   are   activated   by   similar   stimuli,   I   would  
expect   that   caspase-­7   would   also   be   cleaved   during   Yersinia   infection.   Similarly,  
deficiency   in   all   executioner   caspases   and   RIPK3,   Casp1-­/-­Casp11-­/-­Casp3-­/-­Casp7-­/-­
Ripk3-­/-­  BMDMs  will  probably  be  protected  from  cell  death  in  response  to  Yersinia.  
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TLR4-­  and  TRIF-­deficient  macrophages  not  completely  protected  from  Yersinia-­
induced  cell  death,  suggesting  another  receptor  likely  contributes  to  cell  death  (16,  123).  
Since  TNFR1  also  activates  caspase-­8-­,  RIPK1-­  and  RIPK3-­dependent  cell  death  (233),  
TNFR1  presents  a   likely  candidate  as  a  second  death  receptor   that  mediates  Yersinia-­
induced   cell   death   in  macrophages.   Indeed,  Tnfr-­/-­   BMDMs   are   partially   protected   and  
Trif-­/-­Tnfr-­/-­   BMDMs   are   completely   resistant   to   Yersinia-­induced   cell   death   (Lance  
Peterson,   manuscript   submitted).   Intriguingly,   while   YopJ   prevents   NF-­κB   and   MAPK  
signaling,   Yersinia-­infected   BMDMs   express   and   secrete   small   amounts   of   TNF   that  
collaborates   with   the   cell-­intrinsic   activities   of   intracellular   YopJ   to   activate   cell   death  
(Lance  Peterson,  submitted).  
Murine   infections   with   YopP-­expressing   Yersinia,   a   hypercytotoxic   variant   of  
YopJ,   displayed   enhanced   bacterial   clearance   compared   to   YopJ-­expressing  Yersinia  
(89,  99).  To  test  whether  Yersinia-­induced  cell  death  impacts  immune  responses  in  vivo,  
I   infected   Ripk3-­/-­Casp8-­/-­   mice,   whose   cells   were   unable   to   undergo   cell   death   in  
response   to  Yersinia   infection.   These  mice   suffered   from   high  morbidity   and  mortality  
rates   after  Yersinia   infection,   and   had  defective   cytokine   production.  Notably,   cytokine  
responses   were   partly   restored   in  Ripk3-­/-­Casp8-­/-­   mice   that   were   infected   with   YopJ-­
deficient  Yersinia,  which  does  not  induce  cell  death.  These  findings  imply  that  cell  death  
may   contribute   to   protective   immune   responses.   However,   given   the   recent   studies  
implying   that   caspase-­8   regulates   innate   cytokine   production   (123,   124,   173,   179),   I  
considered   the   possibility   that   caspase-­8   may   play   a   cell-­intrinsic   role   in   cytokine  
generation   independently   of   cell   death.   Indeed,   using  mixed   bone  marrow   chimeras,   I  
found  that  there  was  a  smaller  proportion  of  Ripk3-­/-­Casp8-­/-­  cells  producing  inflammatory  
cytokines  compared  to  Ripk3-­/-­  cells  in  the  same  mouse.  Concomitantly,  Ripk3-­/-­Casp8-­/-­  
cells  generated  lower  amounts  of  cytokine  per  cell  compared  to  Ripk3-­/-­  cells  within  the  
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same  mouse,  suggesting  that  Ripk3-­/-­Casp8-­/-­  cells  have  a  cell-­intrinsic  defect  in  cytokine  
production.   Therefore,   to   specifically   examine   the   role   of   cell   death   on   immune  
responses   in  vivo,  we  need   to   turn   to  a  system   that   is  not  confounded  by  cell-­intrinsic  
effects  on  cytokine  generation.    
RIPK1   has   been   shown   to   trigger   formation   of   complex   IIb   containing   RIPK1,  
FADD   and   caspase-­8   that   activates   apoptosis,   as   well   as   the   RIPK1/RIPK3/MLKL  
necrosome  that  initiates  necroptosis.  I  have  demonstrated  that  RIPK1  and  RIPK1  kinase  
activity  are  both  required  for  Yersinia-­induced  cell  death.  As  a  key  regulator  of  cell  death  
pathways,  RIPK1  positions  itself  as  a  promising  target  to  test  the  role  of  cell  death  in  vivo  
(Lance   Peterson,   unpublished).   However,   Ripk1-­/-­   mice   are   post-­natal   lethal   (251),  
because,   paradoxically,   RIPK1   blocks   certain   forms   of   caspase-­8-­   and   RIPK3-­
dependent  cell  death   (29,  31)   (252).   Interestingly,  RIPK1  kinase  activity   is  dispensable  
for   viability   and   homeostasis   as  Ripk1kd/kd   (RIPK1   kinase   dead   K45A)  mice   are   viable  
and  healthy  (253).  Utilizing  a  combination  of  mixed  bone  marrow  chimeras  and  murine  
infections  with  hypo-­   versus  hypercytotoxic  Yersinia,  we  can  assess   the   impact   of   cell  
death  on  inflammation  (Lance  Peterson,  unpublished).  
A  major  gap   in  knowledge   lies   in  our  understanding  of  which  cell   types  need  to  
die  and  where  immunogenic  cell  death  needs  to  take  place  to  be  beneficial  to  the  host.  
One  approach   to  address   this  question  would  be  a  system   in  which  specific  cell   types  
are  made  resistant  to  Yersinia-­induced  cell  death.  For  instance,  generating  mixed  bone  
marrow  chimeras  from  Ripk1kd/kd  mice  and  Ccr2-­/-­  mice,  would  test  the  role  of  monocyte  
cell  death   in  vivo,  as  all  monocytes  would  be  resistant  to  Yersinia-­induced  cell  death.  A  
limitation   to   this  system   is   that   the  mixed  environment  of  other   immune  cells  may  also  
contribute   to   any   role   of   Ccr2-­dependent   monocytic   responses.   A   combination   of  
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reporter   strains   of   mice,   labeled   bacteria   and   intravital   imaging   could   be   utilized   to  
investigate  the  effect  of  cell  death  on  the  local  cellular  environment.  
What  is  the  purpose  of  a  system  that  is  set  up  to  respond  to  microbial  agents  by  
either   undergoing   immunogenic   cell   death   or   gene   expression   of   inflammatory  
mediators?   When   innate   cells   encounter   microbial   products,   there   are   a   series   of  
checkpoints  that  determine  whether  a  cell  dies,  or  activates  gene  expression.  I  propose  
that   one  major   checkpoint   occurs  along   the   steps   of   the  NF-­κB  and  MAPK  pathways.  
Ligation   of   TLRs   activates   NF-­κB   and   MAPK   signaling   and   when   these   pathways  
proceed   unimpeded,   transcription   factors   activate   cytokine   expression.   Blocking   these  
pathways,   by   a   bacterial   product   such   as   YopJ,   raises   an   alarm   within   the   cell   to  
increase   the   inflammatory   output.   One   mechanism   that   can   induce   inflammation   but  
simultaneously  override  microbial  blockade  of  inflammatory  pathways  is  the  activation  of  
regulated  cell  death.  But,  cell  death  cannot  be  the  default  pathway   in  response  to  TLR  
ligation  because  it  comes  at  a  high  cost  –  the  life  of  a  cell.  Dead  cells  must  be  replaced  
to  maintain  homeostasis  and  some  cells,   such  as  monocyte-­derived  macrophages  are  
much   easier   to   replace   than   others,   for   instance  memory   T   or   B   cells.   Therefore,   cell  
death  amplifies  inflammation  and  serves  as  an  alternative  strategy  for  immune  defense,  
when  classical  signaling  pathways  are  inhibited.  
Caspases   control   cell   death   and   survival   programs.   However,   some   caspases  
have   also   been   shown   to   have   non-­apoptotic   roles.   Caspase-­8   has   been   recently  
implicated  in  TLR  signaling,  but  how  caspase-­8  promotes  gene  expression  is  unknown.  I  
demonstrated   that   caspase-­8   has   a   cell-­intrinsic   role   in   inflammatory   gene   expression  
downstream   of   both   MyD88-­   and   TRIF-­dependent   TLR   signaling.   Importantly,   the  
enzymatic  but  not  self-­cleavage  activity  of  caspase-­8   is  necessary   for  optimal  cytokine  
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production.  These  data  attribute  a  novel  function  to  caspase-­8  in  control  of  inflammatory  
gene  expression  independent  of  its  role  in  cell  death.  
Death   receptor   signaling   induces   caspase-­8   homodimerization   and   self-­
cleavage,  releasing  the  p10  and  p20  subunits  that  subsequently  form  tetramers.  These  
self-­processing  events   stabilize   active   caspase-­8  under   cellular   conditions,   resulting   in  
cleavage   of   apoptotic   substrates.   Caspase-­8   can   also   form   heterodimers   with   its  
catalytically  dead  homolog  cFLIP.  Caspase-­8/cFLIP  heterodimers  have  catalytic  activity  
and   inhibit   apoptosis   and  programmed  necrosis,   but   the   self-­cleavage  of   caspase-­8   is  
not  required  for  these  functions.  To  test  whether  the  self-­cleavage  activity  of  caspase-­8  
is   necessary   for   gene   expression,   we   generated   Casp8DA/DA   knock-­in   mice   using  
CRISPR/Cas9.   These  mice   have   a  mutation   in   aspartate   387   to   alanine   (D387A,   also  
called  Casp8DA)  which  ablates  caspase-­8  self-­processing  activity.  In  response  to  PAMP  
stimulation,   Casp8DA/DA   macrophages   produce   equivalent   levels   of   cytokines   as   WT  
macrophages,  suggesting  that  caspase-­8  cleavage  is  not  required  for  gene  expression.  
Since  the  self-­cleavage  activity  of  caspase-­8  is  required  for  the  apoptotic  functions  of  the  
caspase-­8  homodimer,  but  not  the  caspase-­8/cFLIP  heterodimer,  these  data  implicate  a  
novel  function  for  the  caspase-­8/cFLIP  heterodimer  in  gene  expression  (Figure  20).    
Further   experiments   will   need   to   specifically   test   whether   the   caspase-­8/cFLIP  
heterodimer   mediates   gene   expression.   Unfortunately,   cFLIP-­deficient   mice   are  
embryonic   lethal   and   are   only   viable  when   bred   to  Ripk3-­/-­Casp8-­/-­  mice   (160,   254).   A  
mutation   in  human  cFLIP,  Q390D,  prevents  caspase-­8/cFLIP  dimerization   (163).  While  
this  residue  is  conserved  in  murine  cFLIP,  whether  Q390D  in  murine  cFLIP  will  interfere  
with   dimerization   needs   to   be   determined.   Since   the   cFLIP/caspase-­8   heterodimer  
inhibits   both   caspase-­8-­dependent   apoptosis   and   RIPK3-­dependent   necrosis,   these  
experiments  will  need   to  be  performed  on  a  Ripk3-­/-­Casp8DA/DA  background:  cFLIP  can  
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be  mutated   in   immortalized  Ripk3-­/-­Casp8DA/DA  BMDMs,  or  a  novel  knock-­in  mouse  can  
be   generated   using   CRISPR/Cas9   to   test   whether   blocking   cFLIP   dimerization   with  
caspase-­8  affects  gene  expression.    
A   second  approach   to   abrogate   the   caspase-­8/cFLIP  heterodimer,  would  be   to  
use   siRNA   against   cFLIP   to   knock   down   cFLIP   in  Ripk3-­/-­Casp8DA/DA   cells.   As   cFLIP-­
deficiency  potentiates  RIPK3-­necrosis,  these  experiments  will  again  need  to  be  done  in  
RIPK3-­deficient   cells   or   in   the   presence   of   RIPK3   kinase   inhibitors.   The   viral   serpin  
protease  CrmA  preferentially  inhibits  the  activity  of  caspase-­8  homodimers  compared  to  
caspase-­8/cFLIP   heterodimers   (26,   255).   Ectopic   expression   of   CrmA   in   fibroblasts  
potently   blocks   caspase-­8-­induced   apoptosis   without   potentiating   RIPK3-­dependent  
necrosis   (26).   A   third   approach   to   test   whether   caspase-­8/cFLIP   heterodimers   or  
caspase-­8  homodimers  regulate  gene  expression,  would  be  to  either  ectopically  express  
CrmA   in   B6   BMDMs   or   infect   cells   with   CrmA-­sufficient   or   -­deficient   pox   virus,   to  
specifically  target  caspase-­8  homodimers.  Since  high  levels  of  CrmA  will  inhibit  caspase-­
8/cFLIP  heterodimers,  the  concentration  of  CrmA  or  virus-­expressing  CrmA  will  need  to  
be  titrated  to  achieve  minimal  targeting  of  caspase-­8  heterodimers.  
Another   system   that   could   be   potentially   useful   to   tease   apart   the   roles   of  
caspase-­8-­containing   complexes  would   be   a   drug-­inducible   fusion   protein   dimerization  
system  (20,  148).  In  these  studies,  the  pro-­domains  of  caspase-­8  were  replaced  with  the  
FK506  binding  proteins   (FKBP),  which  bind   rapamycin  and  analogous  drugs  with  high  
affinity,   and   cFLIP   was   linked   to   FKB12   rapamycin   binding   (FRB).   These   two   distinct  
domains   allow   for   homodimerization   or   heterodimerization.   Unfortunately,   these  
experiments  generate  superphysiological  amounts  of  homodimers  and  heterodimers  that  
result   in   cell   death   (20,   148).   Low   doses   of   drug  may   have   low   cytotoxicity   and   thus  
make  it  possible  to  test  the  role  of  homodimers  versus  heterodimers  in  gene  regulation.  
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My   studies   have   shown   that   caspase-­8   is   involved   in   TLR,   but   not   TNFR  
signaling   in   macrophages.   Interestingly,   caspase-­8   does   not   associate   with   the  
myddosome,   a   macromolecular   complex   that   activates   multiple   signaling   cascades   in  
response   to   MyD88-­dependent   TLR   activation   (6,   7).   Caspase-­8-­deficient   cells   also  
have   no   defect   in   myddosome   formation.   These   data   suggest   that   caspase-­8   likely  
functions   downstream   of   the   myddosome   to   regulate   gene   expression.   Whether  
caspase-­8  promotes  NF-­κB  signaling   is  unresolved  as  studies  have  arrived  at  opposite  
conclusions   (166-­175).  Notably,  we  have  demonstrated   that  caspase-­8  does  not  affect  
early  NF-­κB  or  MAPK  signaling  events  in  macrophages,  implying  caspase-­8  plays  a  role  
in   a   distinct   pathway   or   affects   late   NF-­κB   and   MAPK   signaling.   How   TLR   signaling  
activates  caspase-­8  remains  a  major  gap  in  the  field.    
Mass  spectrometry-­based  proteomics   to  detect  specific  binding  partners  can  be  
employed  to  address  how  caspase-­8  may  be  activated  in  response  to  TLR  ligation  (256).  
Briefly,   proteins   in  TLR-­stimulated   versus  unstimulated  Ripk3-­/-­Casp8-­/-­  BMDMs  can  be  
differentially  labelled  using  stable  isotope  labelling  of  amino  acids  in  cell  culture  (SILAC).  
Cell   lysates   are   combined   at   a   1:1   ratio   and   affinity-­purified   with   caspase-­8   death  
effector   domain   (DED)  GST   fusion  proteins   followed  by   liquid   chromatography-­tandem  
mass   spectrometry   (LC-­MS/MS).   Proteins   that   interact   with   the   bait   in   a   stimulation-­
dependent   manner   will   have   more   intense   peaks   and   can   be   distinguished   from  
background   binding   proteins,   which   are   exemplified   by   their   1:1   ratio   between  
unstimulated  and  stimulated  states.  A  caveat  to  this  approach  is  that  it  assumes  that  the  
mechanism   by   which   TLRs   engage   caspase-­8   involves   interactions   with   the   DED   of  
caspase-­8.  One  argument   in   favor   of   this   is   that  Ripk3-­/-­Fadd-­/-­  BMDMs  have  a   similar  
cytokine  profile  as  Ripk3-­/-­Casp8-­/-­  BMDMs  in  response  to  TLR  ligation,  suggesting  that  a  
complex  containing  caspase-­8  and  FADD  (which  interact  via  DEDs)  likely  mediates  gene  
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expression.  FADD  also  contains  a  death  domain  (DD),  that  may  be  important  for  linking  
caspase-­8  to  known  TLR  signaling  proteins.  Peptides  identified  by  this  screen  will  need  
to  be  validated  by  i)  confirming  that  multiple  peptides  of  the  same  protein  are  enriched,  
ii)  conducting  affinity  purification  with  the  DED  of  FADD,  as  this  should  reveal  common  
candidates,  iii)  conducting  affinity  purification  with  other  fragments  of  caspase-­8  or  cFLIP  
that  may  be  involved  in  signaling,  iv)  affinity  purification  with  the  DD  of  FADD  and  v)  co-­
immunoprecipitation  of  candidate  proteins  with  caspase-­8  or  FADD.  Proteins  with  weak  
interactions  may  not  be  detected,  however  this  approach  should  reveal  candidates  that  
are  capable  of  binding  caspase-­8  and  can  be  validated  by  other  techniques  such  as  co-­
immunoprecipitation.  
As   the   enzymatic   activity   of   caspase-­8   is   necessary   for   optimal   cytokine  
responses,   we   favor   a   model   where   caspase-­8   cleaves   some   protein(s)   X   that  
subsequently   regulate(s)   gene   expression.   On   the   other   hand,   enzymatically   active  
caspase-­8   may   adopt   a   conformation   that   allows   it   to   act   as   a   signaling   platform.  
Unfortunately,   there   are   no   hard   and   fast   rules   that   define   “substrates”   versus   “non-­
substrates”,   only   “poor”,   “intermediate”   and   “good”   substrates.   A   peptide   with   the  
sequence  P4-­P3-­P2-­P1-­P1’,  with  P1-­P1’  as  a  scissile  bond,  is  a  good  caspase  substrate  if,  
first,  the  P1  residue  is  asparagine;;  second,  the  P1’  residue  is  a  neutral  amino  acid,  such  
as  glycine,  alanine  or  serine;;  third,  residues  P4-­P3-­P2  interact  favorably  with  the  catalytic  
groove   (this   depends   on   the   caspase);;   fourth,   the   substrate   cleavage   site   P4-­   P1’   is  
exposed   to   the   aqueous   environment;;   fifth,   substrates   and   caspases   must   colocalize  
(257,  258).  Finally,  high  cleavage  site  specificity  is  often  insufficient  for  proteolysis.  Many  
enzymes   including  caspase-­8  have  exosites,   that   serve  as  substrate  binding  sites  and  
are  distinct  from  the  catalytic  site  (259).  Much  less  is  known  about  caspase  exosites,  but  
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some  of   our  preliminary  data,   discussed   in  more  detail   below,   suggest   that   caspase-­8  
may  have  one  exosite  in  its  p10  subunit.    
When  caspase-­8  is  activated  by  dimerization  and  cleavage,  p102-­p202  tetramers  
bind   and   process   apoptotic   substrates.   The   catalytic   cysteine   at   residue   360   is  
necessary   for   proteolytic   activity,   and   an   aspartate   at   residue   387   is   critical   for   self-­
cleavage   between   the   p20   and   p10   subunits.   But   the   residues   required   for   substrate  
binding   (exosites)   are   not   well-­defined.   Interestingly,   thymocytes   from   BAC-­transgenic  
mice  expressing  murine  caspase-­8  D387A  undergo  delayed  Fas-­induced  apoptosis  and  
caspase-­3  activation,  suggesting  that  self-­processing  of  caspase-­8  contributes  to,  but  is  
not   necessary   for   apoptosis   in   thymocytes   ((242)   and   unpublished   data).   However,  
abrogating   self-­cleavage   activity   in   human   caspase-­8,   through   mutations   at  
complementary   as   well   as   additional   residues,   demonstrated   that   caspase-­8   self-­
processing   was   required   for   caspase-­8   activation   in   cells   (20).   One   interpretation   of  
these  data   is   that  murine   caspase-­8  may  have  additional   unknown  aspartate   residues  
that  undergo  self-­cleavage  and  that  cleavage  at  those  residues  is  sufficient  for  apoptotic  
activity.  Alternatively,  cleavage  at  D387A  of  murine  caspase-­8,  may  allow  accessibility  to  
a   substrate  binding  site  and   this   conformation   is   stabilized  by  cell   type-­specific   factors  
(Figure  34).  
To  address  whether  caspase-­8  undergoes  self-­processing  at  additional  aspartate  
residues,  we  generated  macrophage   cell-­lines   that   have   three  mutations   in   caspase-­8  
D387A,  D397A  and  D400A,   termed  Casp8D3A.  Macrophages   that  express  Casp8D3A  do  
not   undergo   caspase-­8   processing   and   have   no   detectible   caspase-­8   activity   in  
response  to  Yersinia   infection  (123).  However,  BMDMs  from  Casp8DA  mice  (expressing  
caspase-­8  D387A)  also  do  not  undergo  caspase-­8  processing  or  apoptosis,  raising  the  
possibility  that  mutations  D397A  and  D400A  do  not  alter  protein  function.  To  determine  
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the   role   of   caspase-­8   self   cleavage   in   vivo   and  whether  Casp8D3A   functions   differently  
from  Casp8DA,  we  generated  Casp8D3A   knock-­in  mice  and   compared   them   to  Casp8DA  
mice   (unpublished).   Intriguingly,   while   Casp8DA/DA   mice   are   viable   and   healthy,  
Casp8D3A/D3A  mice  are  not  viable.  Litters   from  Casp8D3A/+   x  Casp8D3A/+   crosses  bear  no  
Casp8D3A/D3A  homozygous  pups,  but  instead  only  wild  type  and  heterozygous  animals  at  
ratios   of   1:2.   Since   active   caspase-­8   protects   mice   from   RIPK3-­mediated   lethal  
inflammation  during  embryonic  development,  Casp8D3A/D3A  mice  are  likely  susceptible  for  
the   same   reasons.   Therefore,   I   hypothesize   D397   and   D400   are   critical   residues   for  
substrate  binding  and  indirectly  regulate  catalytic  activity.    
  
My   work   has   demonstrated   that   caspase-­8   regulates   gene   expression   at   the  
transcriptional   level.   Whether   caspase-­8   regulates   chromatin   accessibility   to  
transcription  factor  binding  in  a  manner  similar  to  priming  with  IFNγ  or  RNA  polymerase  
II  elongation,  is  an  open  question  (260).  To  assess  whether  caspase-­8  controls  genome-­
wide   chromatin   accessibility,   we   can   perform   assay   for   transposase   accessible  
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chromatin   with   high-­throughput   sequencing   (ATAC-­seq)   for   open   vs   closed   chromatin  
regions   (261).   Regions   that   are   identified   as   less   accessible   in   RIPK3/caspase-­8-­
deficient  macrophages  compared  to  wild  type  macrophages  will  be  validated  with  ChIP-­
qPCR  against  transcription  factors  or  histone  modifications.  Poorly  accessible  promoters  
may  display  less  H3K4me3  and  closed  enhancers  may  depict  lower  levels  of  H3K4me1.  
These  regions  may  be  associated  with  repressive  chromatin  marks  such  as  H3K27me3  
or  H3K20me3.  These  experiments  would  indirectly  test  whether  caspase-­8-­deficiency  is  
associated   with   altered   histone   demethylase,   methylase,   deacetylase   or   acetylase  
activity.  
Since   caspase-­8   controls   gene   transcription,   caspase-­8   could   regulate   RNA  
polymerase   II   (Pol   II)   elongation.   Pol   II   is   differentially   phosphorylated   and  
phosphorylation   at   serine   2   (S2)   releases   Pol   II   from   pausing.   The   complex   P-­TEFb,  
which   consists   of   cdk9   and   a   cyclin   T,   phosphorylates   Pol   II   S2   and   other   proteins  
required   for   elongation.   Caspase-­8   could   regulate   the   formation   or   recruitment   of   P-­
TEFb  to  Pol  II  via  the  cleavage  of  unknown  substrates.  
Caspase-­8  may  stabilize  interactions  between  transcription  factors.  For  instance,  
IκBβ  stabilizes  cRel:p65  dimer  formation,  which  is  required  for  optimal  transcription  of  a  
subset  of  LPS-­responsive  genes   including  Tnf,   Il1a  and   Il12b   (262).  Even-­though  cRel  
and   p65   ChIP   at   the   Tnf   promoter   was   unaffected   in   IκBβ-­deficient   macrophages,  
transcription  of  Tnf  was  significantly  reduced.  It  is  plausible  that  caspase-­8  controls  gene  
expression  via  stabilizing  dimerization  of  NF-­κB  subunits.  
The  mechanism  by  which  TLRs  activate   caspase-­8   remains  elusive.   In  T   cells,  
the   paracaspase,   MALT1,   associates   with   caspase-­8   and   cFLIP   to   regulate   T   cell  
activation   (263).   MALT1   contains   a   death   domain   and   a   paracaspase   domain.  
Therefore,  it  is  conceivable  that  MALT1  serves  as  the  link  between  TLRs  and  caspase-­8  
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activation.   TNFR1-­associated   death   domain   protein   (TRADD)   facilitates   formation   of   a  
signaling  complex  at  TNFR1  and  TLR4  through  homotypic  interaction  motifs  (264).  Thus,  
TRADD   may   activate   caspase-­8   in   response   to   TLR   stimulation.   Indeed,   TRADD-­
deficient  macrophages  produce  lower  amounts  of  IL-­6  and  TNF  in  response  to  LPS.  
An   important   area   that   requires   further   study   is   understanding   how   caspase-­8  
serves   to   modulate   only   8%   of   the   LPS   response.   Caspase-­8   may   behave   as   an  
intermediate   tier   or   stimulus-­specific   transcription   factor,   whose   chromatin   binding   is  
regulated  by  pioneer  or   lineage  determining   transcription   factors,   similar   to  JunB   (265,  
266).      JunB-­deficient   macrophages   have   defects   in   M1   and   M2   polarization   and  
associated  cytokine  production  (267,  268).   Interestingly,   I   found   that  RIPK3/caspase-­8-­
deficient   macrophages   express   lower   levels   of   Junb   transcript   compared   to   Ripk3-­/-­  
BMDMs  in  response  to  LPS  stimulation.  However,  these  differences  at  the  mRNA  level  
did   not   translate   to   differences   in   JunB   protein   as   measured   by   western   blotting  
(unpublished).   Nevertheless,   GSEA   analysis   that   compared   a   JunB-­dependent   LPS  
responsive   gene   set  with   a   rank-­ordered   list   of   caspase-­8-­dependent   genes   (from  our  
RNA-­seq)   revealed   significant   correlation   and   enrichment   of   caspase-­8-­dependent  
genes  in  the  JunB  gene  set  (unpublished).  Thus,  it  is  possible  that  caspase-­8  regulates  
JunB   expression   and   that   small   differences   (that   may   not   be   detectible   by   western  
blotting),  together  with  differences  in  other  regulators,  have  a  cumulative  effect  on  gene  
expression.    
To  further  understand  the  basis  for  the  specificity  of  caspase-­8-­dependent  gene  
expression,   I   chose   to  model   these   data   on   the   theory   of   scale-­free   networks   (Figure  
35).   Scale-­free   networks   are   characterized   by   nodes   and   hubs   (269,   270).  Nodes   are  
defined   as   elements   that   have   interactions   or   edges   with   other   elements   within   the  
network.  There  is  an  inverse  correlation  between  the  frequency  of  a  node  being  within  a  
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network  and  the  number  of  node  edges.  Nodes  with  a  large  number  of  edges  are  known  
as  hubs  and  disruptions  at  hubs,  but  not  at  nodes,  significantly   impact   the  network.  As  
biological   systems   are   not   binary   in   nature,   I   hypothesize   that   there   is   a   hierarchy   to  
network  hubs;;  major  hubs  function  as  on/off  switches,  while  intermediate  hubs  serve  as  
an  analog  dial  to  fine  tune  responses.  I  propose  that  caspase-­8  acts  as  an  intermediate  
signaling   hub   modulating   multiple   nodes   that   each   affect   distinct   aspects   of   TLR  
signaling.   Since   caspase-­8-­deficient   cells   are   capable   of   producing   a   low   level   of  
cytokines  and  only  8%  of  the  LPS  response  is  impacted,  caspase-­8  is  not  a  major  hub.  
Proteins  upstream  in  signaling  pathways,  such  as  TRIF  or  MyD88  would  be  classified  as  
major   hubs,   as   they   are   required   for   signal   transduction.   Finally,   scale-­free   networks  
highlight  the  robustness  of  biological  networks.  Disturbing  one  node  such  as  STAT5A  or  
IRF1   may   not   have   a   significant   impact   on   cytokine   production   (unpublished),   but  
removing  a  hub,  such  as  caspase-­8,  substantially  alters  signaling  outputs.    
To  conclude,  my  studies  have  shed  light  on  the  mechanisms  by  which  the  gram-­
negative   pathogen   Yersinia   induces   cell   death   and   caspase-­1   activation   in  
macrophages.  I  have  used  Yersinia  as  a  model  to  elucidate  the  impact  of  cell  death  on  
immune  responses   in  vivo.  These  data  suggest  that  inflammatory  cell  death  may  be  an  
effective  host  defense  response   to  pathogens   that  actively  subvert   immune  signaling.   I  
have   also   investigated   the   non-­apoptotic   function   of   caspase-­8   and   have   ascribed   a  
novel  role  for  caspase-­8  enzymatic  activity   in  regulating   inflammatory  gene  expression.  
Caspase-­8   positions   itself   as   an   important   signaling   hub   that   likely   fine   tunes   innate  
immune  responses,  ensuring  that  anti-­pathogen  responses  are  appropriately  regulated.  
As  many  of   the  pathways  and  proteins   I  examined  are  conserved   in  humans,  my  work  
may  offer  rational  strategies  for  therapeutics  that  target  autoimmunity,  inflammatory  and  
infectious  disease,  and  cancer.  
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VI.  APPENDIX  I  SUPPLEMENTARY  CODE  
  
This   appendix   contains   all   the   code   used   to   analyze   the  RNA-­seq   data   in   this   thesis.  
Briefly,  B6,  Ripk3-­/-­  and  Ripk3-­/-­Casp8-­/-­  BMDMs  were  stimulated  with  LPS  for  6hrs  or  left  
untreated.  RNA  was  isolated  using  the  RNeasy  Mini  Kit  (Qiagen)  and  processed  as  per  
manufacturer’s   instructions.   mRNA-­seq   libraries   were   prepared   using   the   TruSeq  
Stranded   Total   RNA   LT   Kit   with   Ribo-­Zero   Gold,   according   to   the   manufacturer’s  
instructions.  Samples  were  run  on  Illumina  NextSeq  500  to  generate  between  151  base-­
pair,   paired-­end   reads   with   a   Q30   score   of   ~80%,   resulting   in   25-­50   million  
fragments/sample.   All   data   processing   and   analyses   were   carried   out   using   the   R  
programming   language   (Version   3.2.2)   and   the   RStudio   interface   (Version   0.99.489),  
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Set-­up  and   QC  
  
To  start  off,  I  read  in  a  file  that  describes  the  design  of  the  study.  This  file  sets  treatment  




Then  I  read  in  my  raw  data.  Fastq  files  were  previously  aligned  to  the  mouse  genome  
Mus_musculus.GRCm38  to  generate  BAM  files.  Reads  were  then  aligned  to  exons  and  




Normalize  unfiltered  data  based  on  mean-­variance  relationship  and  generate  log2  counts  






Filter  data  to  only  keep  those  genes  that  had  >10  reads  per  million  mapped  reads  in  
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Annotate  expression  data  using  the  updated  mouse  database,  insert  EntrezIDs  and  filter  










myAnnot.unfiltered <- AnnotationDbi::select(org.Mm.eg.db, 
keys=rownames(exprs.matrix.unfiltered), keytype="ENSEMBL", 
columns=c("ENTREZID", "GENENAME", "SYMBOL", "CHR")) 
myAnnot.filtered <- AnnotationDbi::select(org.Mm.eg.db, 
keys=rownames(exprs.matrix.filtered), keytype="ENSEMBL", 
columns=c("ENTREZID", "GENENAME", "SYMBOL", "CHR")) 
resultTable.unfiltered <- merge(myAnnot.unfiltered, 
exprs.matrix.unfiltered, by.x="ENSEMBL", by.y=0) resultTable.filtered <- 
merge(myAnnot.filtered, exprs.matrix.filtered, by.x="ENSEMBL", by.y=0) 
head(resultTable.unfiltered) 
dim(resultTable.unfiltered) dim(resultTable.filtered) 
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#add  more  appropriate  sample  names  as  column  headers  
colnames(resultTable.unfiltered)  <-­  c("Ensembl",  "Entrez",  "Name",  "Symbol",  "Chr",  sampleLabels)  
colnames(resultTable.filtered)  <-­  c("Ensembl",  "Entrez",  "Name",  "Symbol",  "Chr",  sampleLabels)  
#now  write  these  annotated  datasets  out  
write.table(resultTable.unfiltered,  "normalizedUnfilteredRNAseq.txt",  sep="\t",  quote=FALSE)  
write.table(resultTable.filtered,  "normalizedFilteredRNAseq.txt",  sep="\t",  quote=FALSE)  
head(resultTable.unfiltered)  
head(resultTable.filtered)  
#remove   all  genes   on   X   and   Y   chromosomes   using   dplyr   filter  function   as   mixed  
sex   BMDMs   were   used  
class(resultTable.filtered)  dim(resultTable.filtered)  
myDataX.filter  <-­  resultTable.filtered  %>%  
filter(Chr!="X")  head(myDataX.filter)  
myDataXY.filter  <-­  myDataX.filter  %>%  
filter(Chr!="Y")  head(myDataXY.filter)  dim(myDataXY.filter)  
write.table(myDataXY.filter,  "normalizedFilteredXYRNAseq.txt",  sep="\t",  quote=FALSE)  
  
Since  RNA-­seq  may  bring  up  multiple  gene  segments  per  gene  ID,  collapse  expression  
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Principal  component  analysis  of  these  data  portrays  variables  that  account  for  
most  of  the  variation  in  the  data  
 






































































































Figure 1: Samples group by genotype and treatment.
Principal component analysis of these data portrays variables that account for most of the
variation in the data
Figure 2: LPS accounts for over 95% of the variance.





















data.frame  <-­  as.data.frame(pca.res$x)  ggplot(data.frame,  aes(x=PC1,  y=PC2,  
color=myGroups))  +  
geom_point(size=5)  +  
scale_colour_manual(values=c("#000000",  "#AAAAAA",  "#E36B09",  "#FFCC66",  "#297A18",  
"#6EF054"))  +  
theme(legend.position="right",  legend.key=element_rect(fill=NA))  +  
#remove  axis  ticks  and  tick  text  
theme(axis.ticks  =  element_blank(),axis.text  =  element_blank())  +  
#change  background  and  gridlines  
theme(panel.background  =  element_rect(fill  =  NA,  colour  =  "black"),  panel.grid.major  =  

















Now we can visualize how the samples contribute to PC1 and PC2
data.frame <- as.data.frame(pca.res$x)
ggplot(data.frame, aes(x=PC1, y=PC2, color=myGroups)) +
geom_point(size=5) +
scale_colour_manual(values=c("#000000", "#AAAAAA", "#E36B09", "#FFCC66", "#297A18", "#6EF054")) +
theme(legend.position="right", legend.key=element_rect(fill=NA)) +
#remove axis ticks and tick text
theme(axis.ticks = element_blank(),axis.text = element_blank()) +
#change background and gridlines
theme(panel.background element_rect(fill = NA, colour = "black"),
panel.grid.major = element_line(colour = NA),
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Identification  of  Differentially  Expressed  Genes  
 
I  fit  a  linear  model  to  the  data  and  set  up  contrast  matrices  of  the  analyses  I’m  
interested  in.  
 
fit  <-­  lmFit(myCollapsed,  design)  
#  set  up  a  contrast  matrix  comparing  UT  and  LPS  in  B6  BMDMs  =  "LPS-­responsive  genes"  
contrast.matrix.UT.LPS.B6  <-­  makeContrasts(B6UT.v.B6LPS  =  B6.LPS_6hr  -­  B6.untreated,  
levels=design)  
#  extract  the  linear  model  fit  for  the  contrast  matrix  that  you  just  defined  above  
fitsUT.LPS.B6  <-­  contrasts.fit(fit,  contrast.matrix.UT.LPS.B6)  
#get  bayesian  stats  for  your  linear  model  fit  
ebFitUT.LPS.B6  <-­  eBayes(fitsUT.LPS.B6)  
  
Here,  I  pull  out  probeIDs  from  all  genes  in  the  Venn  diagram  and  combine  them  with  












Figure 3: LPS-treatment contributes to the largest variation between samples (96%), where B6 and Ripk3-/-
cluster together and are separated from the corresponding Ripk3-/-Casp8-/- samples.
Ide tifi ti f i  rentially Expressed Genes
I fit a linear model to the data and set up contrast matrices of the analyses I’m interested in.
fit <- lmFit(myCollapsed, design)
# set up a contrast matrix comparing UT and LPS in B6 BMDMs = "LPS-responsive genes"
contrast.matrix.UT.LPS.B6 <- makeContrasts(B6UT.v.B6LPS = B6.LPS_6hr - B6.untreated, levels=design)
# extract the linear model fit for the contrast matrix that you just defined above
fitsUT.LPS.B6 <- contrasts.fit(fit, contrast.matrix.UT.LPS.B6)
#get bayesian stats for your linear model fit
ebFitUT.LPS.B6 <- eBayes(fitsUT.LPS.B6)
Here, I pull out probeIDs from all genes in the Venn diagram and combine them with expres-
sion data into one file.
# use the  decideTests  function to show Venn diagram for all diffexp genes
resultsUT.LPS.B6 <- decideTests(ebFitUT.LPS.B6, method="global",
adjust.method="BH", p.value=0.05, lfc=0.59)
diffProbesUT.LPS.B6 <- which(resultsUT.LPS.B6[,1] !=0)
myEset.ALL <- new("ExpressionSet", exprs = myCollapsed)
# retrieve expression data for the probes from above and export into excel table





   124  
 
Now,  use  LPS-­responsive  genes  (diffDataUT.LPS.B6)  as  input  gene  list  to  determine  
which  genes  are  caspase-­8  and/or   RIPK3-­dependent.  
 
  
fit  <-­  lmFit(diffDataUT.LPS.B6,  design)  
#  set  up  contrast  matrices  based  on  the  pairwise  comparisons  of  interest  
contrast.matrix.LPS.ofB6LPSR3  <-­  makeContrasts(R3.v.B6  =  Ripk3.LPS_6hr  -­  B6.LPS_6hr,  
levels=design)  contrast.matrix.LPS.ofB6LPSR3C8  <-­  makeContrasts(R3C8.v.R3  =  
Ripk3_Casp8.LPS_6hr  -­  Ripk3.LPS_6hr,  
R3C8.v.B6  =  Ripk3_Casp8.LPS_6hr  -­  B6.LPS_6hr,  levels=design)  
  
#  extract  the  linear  model  fit  for  the  contrast  matrix  that  you  just  defined  above  fitsLPS.ofB6LPSR3  <-­  
contrasts.fit(fit,  contrast.matrix.LPS.ofB6LPSR3)  fitsLPS.ofB6LPSR3C8  <-­  contrasts.fit(fit,  
contrast.matrix.LPS.ofB6LPSR3C8)  
  
#get  bayesian  stats  for  your  linear  model  fit  ebFitLPS.ofB6LPSR3  <-­  
eBayes(fitsLPS.ofB6LPSR3)  ebFitLPS.ofB6LPSR3C8  <-­  eBayes(fitsLPS.ofB6LPSR3C8)  
  
resultsLPS.ofB6LPSR3  <-­  decideTests(ebFitLPS.ofB6LPSR3,  method="global",  
adjust.method="BH",  p.value=0.05,  lfc=0.59)  resultsLPS.ofB6LPSR3C8  <-­  
decideTests(ebFitLPS.ofB6LPSR3C8,  method="global",  
adjust.method="BH",  p.value=0.05,  lfc=0.59)  
  
diffProbesLPS.ofB6LPSR3  <-­  which(resultsLPS.ofB6LPSR3[,1]   !=0)  




myEset.ALL  <-­  new("ExpressionSet",  exprs  =  diffDataUT.LPS.B6)  
  
#  retrieve  expression  data  for  the  probes  from  above  diffData.LPS.ofB6LPSR3  <-­  
myEset.ALL[resultsLPS.ofB6LPSR3[,1]  !=0]  diffData.LPS.ofB6LPSR3C8  <-­  
myEset.ALL[resultsLPS.ofB6LPSR3C8[,1]  !=0  |  
resultsLPS.ofB6LPSR3C8[,2]  !=0]  
  
#pull  the  expression  data  back  out  of  the  eset  object  diffData.LPS.ofB6LPSR3  <-­  
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#combine  probeIDs,  gene  symbols  and  expression  data  for  differentially  expressed  genes  into  one  
file  
#  62  genes  of  6379  were  RIPK3-­dependent:  
write.table(cbind(diffProbesLPS.ofB6LPSR3,  diffData.LPS.ofB6LPSR3),  
"DiffGenesLPSofB6.B6vsR3.xls",  sep="\t",  quote=FALSE)  
#  527  genes  of  6379  were  RIPK3/caspase-­8-­dependent,  8.3%,  Fig3C:  
write.table(cbind(diffProbesLPS.ofB6LPSR3C8,  diffData.LPS.ofB6LPSR3C8),  
"DiffGenesLPSofB6.vsR3C8.xls",  sep="\t",  quote=FALSE)  
  













write.table(LPS.R3C8only, "LPS.onlyR3C8notR3.xls", sep="\t", quote=FALSE) 
 




vLPSR3.R3C8 <- venneuler(c(A=14, B=479, "A&B"=48)) 
plot(vLPSR3.R3C8, 
col=c("pink", "brown")) 
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Generate  heatmap  of  caspase-­8-­dependent  genes  regulated  by  LPS  
treatment.  
  





mycl <- cutree(hr, k=6)
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#now  find  out  what  your  clusters  are  










0 2 4 6 8 10
#The numbers next to the color boxes correspond to the cluster numbers in  mycl .
#clusters 2,1,6,3,4,5 from top down for diffData.LPS.ofB6LPSR3C8.AVG
#select sub-clusters of co-regulated transcripts for downstream analysis c(2)=cluster 1
clid <- c(2)
ysub <- diffData.LPS.subset.AVG[names(mycl[mycl%in%clid]),]
hrsub <- hclust(as.dist(1-cor(t(ysub), method="pearson")), method="average")
clusterIDs <- data.frame(Labels=rev(hrsub$labels[hrsub$order]))
clusterIDs <- as.vector(t(clusterIDs))
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#retrieve gene symbols for selected cluster for downstream applications (i.e. GO enrichment in DAVID)
write.table(clusterIDs, "LPSinducedR3C8.cluster1.xls", sep="\t", quote=FALSE)
#select sub-clusters of co-regulated transcripts for downstream analysis c(3)=cluster 2
clid <- c(3)
ysub <- diffData.LPS.subset.AVG[names(mycl[mycl%in%clid]),]
hrsub <- hclust(as.dist(1-cor(t(ysub), method="pearson")), method="average")
clusterIDs <- data.frame(Labels=rev(hrsub$labels[hrsub$order]))
clusterIDs <- as.vector(t(clusterIDs))
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#retrieve gene symbols for selected cluster for downstream applications 
(i.e. GO enrichment in DAVID) 
write.table(clusterIDs,  "LPSinducedR3C8.cluster1.xls",  sep="\t",  quote=FALSE)  
  
#select sub-clusters of co-regulated transcripts for downstream 
analysis c(3)=cluster 2 
clid  <-­  c(3)  
ysub  <-­  diffData.LPS.subset.AVG[names(mycl[mycl%in%clid]),]  
hrsub  <-­  hclust(as.dist(1-­cor(t(ysub),  method="pearson")),  method="average")  clusterIDs  <-­  
data.frame(Labels=rev(hrsub$labels[hrsub$order]))  
clusterIDs  <-­  as.vector(t(clusterIDs))  
heatmap.2(ysub,  Rowv=as.dendrogram(hrsub),  Colv=NA,  labRow=NA,  col=myheatcol,  
scale="row",  density.info="none",  trace="none",  RowSideColors=mycolhc[mycl%in%clid],  
margins=c(12,25),  cexCol=1)  
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#retrieve gene symbols for selected cluster for downstream applications (i.e. GO enrichment in DAVID)
write.table(clusterIDs, "LPSinducedR3C8.cluster2.xls", sep="\t", quote=FALSE)
Generate heatmap of subset of cluster 2.
#read in your data from a text file that contains genes symbols as rows, and samples as columns.
#This file MUST be a dataframe, NOT a data matrix
myDiffGenes.LPS <- read.delim("LPS.Cluster2.txt", header=TRUE)
head(myDiffGenes.LPS)
colnames(myDiffGenes.LPS)
#use the dplyr  mutate  command to get averages and fold changes for all your replicates
myDiffGenes.LPS <- mutate(myDiffGenes.LPS,
B6.untreated.AVG = (B6.untreated.1 + B6.untreated.2)/2,
Ripk3.untreated.AVG = (Ripk3.untreated.1 + Ripk3.untreated.2)/2,
Ripk3_Casp8.untreated.AVG = (Ripk3_Casp8.untreated.1 + Ripk3_Casp8.untreated.2)/2,
B6.LPS_6hr.AVG = (B6.LPS_6hr.1 + B6.LPS_6hr.2)/2,
Ripk3.LPS_6hr.AVG = (Ripk3.LPS_6hr.1 + Ripk3.LPS_6hr.2)/2,
Ripk3_Casp8.LPS_6hr.AVG = (Ripk3_Casp8.LPS_6hr.1 + Ripk3_Casp8.LPS_6hr.2)/2,
12
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#retrieve gene symbols for selected cluster for downstream applications 
(i.e. GO enrichment in DAVID) 
write.table(clusterIDs,  "LPSinducedR3C8.cluster2.xls",  sep="\t",  quote=FALSE)  
  
Generate  heatmap  of  subset  of  cluster   2.  
 
#read in your data from a text file that contains genes symbols as rows, 
and samples as columns. 
#This file MUST be a dataframe, NOT a data matrix myDiffGenes.LPS  <-­  
read.delim("LPS.Cluster2.txt",  header=TRUE)  head(myDiffGenes.LPS)  
colnames(myDiffGenes.LPS)  
#use the dplyr 'mutate' command to get averages and fold changes for all 
your replicates 
myDiffGenes.LPS  <-­  mutate(myDiffGenes.LPS,  
B6.untreated.AVG  =  (B6.untreated.1  +  B6.untreated.2)/2,  Ripk3.untreated.AVG  =  
(Ripk3.untreated.1  +  Ripk3.untreated.2)/2,  
Ripk3_Casp8.untreated.AVG  =  (Ripk3_Casp8.untreated.1  +  Ripk3_Casp8.untreated.2)/2,  
B6.LPS_6hr.AVG  =  (B6.LPS_6hr.1  +  B6.LPS_6hr.2)/2,  
Ripk3.LPS_6hr.AVG  =  (Ripk3.LPS_6hr.1  +  Ripk3.LPS_6hr.2)/2,  Ripk3_Casp8.LPS_6hr.AVG  =  
(Ripk3_Casp8.LPS_6hr.1  +  Ripk3_Casp8.LPS_6hr.2)/2,  
LogFC.B6.LPS_6hr.vs.B6.untreated  =  (B6.LPS_6hr.AVG  -­  B6.untreated.AVG),  
LogFC.Ripk3.LPS_6hr.vs.Ripk3.untreated  =  (Ripk3.LPS_6hr.AVG  -­  Ripk3.untreated.AVG),  
LogFC.Ripk3_Casp8.LPS_6hr.vs.Ripk3_Casp8.untreated  =  
(Ripk3_Casp8.LPS_6hr.AVG  -­  Ripk3_Casp8.untreated.AVG),  
LogFC.Ripk3.LPS_6hr.vs.B6.LPS_6hr  =  (Ripk3.LPS_6hr.AVG  -­  B6.LPS_6hr.AVG),  
LogFC.Ripk3_Casp8.LPS_6hr.vs.Ripk3.LPS_6hr  =  
(Ripk3_Casp8.LPS_6hr.AVG  -­  Ripk3.LPS_6hr.AVG),  
LogFC.Ripk3_Casp8.LPS_6hr.vs.B6.LPS_6hr  =  (Ripk3_Casp8.LPS_6hr.AVG  -­  B6.LPS_6hr.AVG),  
LogFC.Ripk3_Casp8.untreated.vs.Ripk3.untreated  =  
(Ripk3_Casp8.untreated.AVG  -­  Ripk3.untreated.AVG),  LogFC.Ripk3.untreated.vs.B6.untreated  
=  (Ripk3.untreated.AVG  -­  B6.untreated.AVG),  LogFC.Ripk3_Casp8.untreated.vs.B6.untreated  =  




FC.Ripk3.LPS_6hr.vs.Ripk3.untreated  =  (2^(LogFC.Ripk3.LPS_6hr.vs.Ripk3.untreated)))  
  
head(myDiffGenes.LPS)  
#use dplyr "arrange" and "select" functions to sort by LogFC column of 
interest (arrange) 
myDiffGenes.LPS  <-­  myDiffGenes.LPS  %>%  
arrange(desc(LogFC.Ripk3_Casp8.LPS_6hr.vs.Ripk3.LPS_6hr))  head(myDiffGenes.LPS)  
write.table(myDiffGenes.LPS,  "myGOCluster2.xls",  sep="\t",  quote=FALSE)  
  
#Generate heatmap of Cluster2 subset 
mySelectedHeatmap  <-­  read.delim("LPS.Cluster2.heatmap.txt",  sep="\t",  stringsAsFactors  =  
FALSE,  header=TRUE,  row.names=1)  
head(mySelectedHeatmap)  dim(mySelectedHeatmap)  colnames(mySelectedHeatmap)  <-­  
myGroups  
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mySelectedHeatmap.AVG  <-­  avearrays(mySelectedHeatmap,  
ID=colnames(mySelectedHeatmap))  
head(mySelectedHeatmap.AVG)  dim(mySelectedHeatmap.AVG)  
mySelectedHeatmap.AVG  <-­  mySelectedHeatmap.AVG[,c(4,5,6)]  mySelectedHeatmap  <-­  
as.matrix(mySelectedHeatmap.AVG)  
  
hr  <-­  hclust(as.dist(1-­cor(t(mySelectedHeatmap),  method="pearson")),  method="average")  hc  <-­  
hclust(as.dist(1-­cor(mySelectedHeatmap,  method="spearman")),  method="complete")  
dim(mySelectedHeatmap)  
mycl  <-­  cutree(hr,  k=1)  
mycolhc  <-­  rainbow(length(unique(mycl)),  start=0.1,  end=0.9)  mycolhc  <-­  
mycolhc[as.vector(mycl)]  
myheatcol  <-­  greenred(75)  
#Rowv=NA maintains the order of the rows you have in your data table. 
heatmap.2(mySelectedHeatmap,  Rowv=NA,  Colv=NA,  col=myheatcol,  scale="row",  
density.info="none",  trace="none",  RowSideColors=mycolhc,  labRow=NULL,  
cexRow=1.5,  cexCol=1,  margins=c(12,25),  key=T)  
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All analyses were carried out on the following system:
sessionInfo()
R version 3.2.2 (2015-08-14) Platform: x86_64-apple-darwin13.4.0 (64-bit) Running under: OS X 10.10.5
(Yosemite)
locale: [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8
attached base packages: [1] stats4 parallel stats graphics grDevices utils datasets [8] methods base
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All  analyses  were  carried  out  on  the  following  system:  
  
 sessionInfo()                                                                    
 
R version 3.2.2 (2015-08-14) Platform: x86_64-apple-darwin13.4.0 
(64-bit) Running under: OS X 10.10.5 (Yosemite) 
locale:  [1]  en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-
8/en_US.UTF-8 attached base packages: [1] stats4 parallel stats 
graphics grDevices utils datasets [8] methods base other attached 
packages: [1] venneuler_1.1-0 rJava_0.9-7 
[3] devtools_1.9.1 knitr_1.12 
[5] rmarkdown_0.9.2 gplots_2.17.0 
[7] RColorBrewer_1.1-2 ggvis_0.4.2 
[9] dplyr_0.4.3 reshape2_1.4.1 
[11] ggplot2_1.0.1 WGCNA_1.48 
[13] fastcluster_1.1.16 dynamicTreeCut_1.62 
[15] org.Mm.eg.db_3.2.3 RSQLite_1.0.0 
[17] DBI_0.3.1 AnnotationDbi_1.32.0 
[19] ShortRead_1.28.0 GenomicAlignments_1.6.1 
[21] SummarizedExperiment_1.0.1 Biobase_2.30.0 
[23] Rsamtools_1.22.0 GenomicRanges_1.22.1 
[25] GenomeInfoDb_1.6.1 Biostrings_2.38.2 
[27] XVector_0.10.0 IRanges_2.4.5 
[29] S4Vectors_0.8.4 BiocParallel_1.4.0 
[31] BiocGenerics_0.16.1 edgeR_3.12.0 
[33] limma_3.26.3 Rsubread_1.20.2 
loaded via a namespace (and not attached):  
[1] splines_3.2.2 foreach_1.4.3 gtools_3.5.0  
[4] Formula_1.2-1 shiny_0.12.2 assertthat_0.1 
[7] latticeExtra_0.6-26 yaml_2.1.13 impute_1.44.0  
[10] lattice_0.20-33 digest_0.6.8 colorspace_1.2-6 
[13] htmltools_0.2.6 httpuv_1.3.3 preprocessCore_1.32.0  
[16] plyr_1.8.3 zlibbioc_1.16.0 xtable_1.8-0  
[19] GO.db_3.2.2 scales_0.3.0 gdata_2.17.0 
[22] lazyeval_0.1.10 nnet_7.3-11 proto_0.3-10  
[25] survival_2.38-3 magrittr_1.5 mime_0.4 
[28] memoise_0.2.1 evaluate_0.8 doParallel_1.0.10  
[31] MASS_7.3-45 hwriter_1.3.2 foreign_0.8-66  
[34] tools_3.2.2 formatR_1.2.1 matrixStats_0.15.0  
[37] stringr_1.0.0 munsell_0.4.2 cluster_2.0.3 
[40] lambda.r_1.1.7 caTools_1.17.1 futile.logger_1.4.1  
[43] grid_3.2.2 iterators_1.0.8 labeling_0.3 
[46] bitops_1.0-6 gtable_0.1.2 codetools_0.2-14  
[49] R6_2.1.1 gridExtra_2.0.0 Hmisc_3.17-0 
[52] futile.options_1.0.0 KernSmooth_2.23-15 stringi_1.0-1  
[55] Rcpp_0.12.2 rpart_4.1-10 acepack_1.3-3.3 
     




1.   Philip   NH   &   Brodsky   IE   (2012)   Cell   death   programs   in   Yersinia   immunity   and  
pathogenesis.  Front  Cell  Infect  Microbiol  2:149.  
2.   Janeway  CA,   Jr.   &  Medzhitov   R   (2002)   Innate   immune   recognition.  Annu  Rev  
Immunol  20:197-­216.  
3.   Iwasaki  A  &  Medzhitov  R   (2010)  Regulation  of  adaptive   immunity  by   the   innate  
immune  system.  Science  327(5963):291-­295.  
4.   Kagan  JC  &  Barton  GM  (2015)  Emerging  principles  governing  signal  transduction  
by  pattern-­recognition  receptors.  Cold  Spring  Harb  Perspect  Biol  7(3):a016253.  
5.   Kagan  JC,  et  al.  (2008)  TRAM  couples  endocytosis  of  Toll-­like  receptor  4  to  the  
induction  of  interferon-­beta.  Nat  Immunol  9(4):361-­368.  
6.   Lin   SC,   Lo   YC,   &  Wu   H   (2010)   Helical   assembly   in   the   MyD88-­IRAK4-­IRAK2  
complex  in  TLR/IL-­1R  signalling.  Nature  465(7300):885-­890.  
7.   Motshwene  PG,  et  al.  (2009)  An  oligomeric  signaling  platform  formed  by  the  Toll-­
like  receptor  signal  transducers  MyD88  and  IRAK-­4.  J  Biol  Chem  284(37):25404-­
25411.  
8.   Green   DR,   Ferguson   T,   Zitvogel   L,   &   Kroemer   G   (2009)   Immunogenic   and  
tolerogenic  cell  death.  Nat  Rev  Immunol  9(5):353-­363.  
9.   Kono  H  &  Rock  KL  (2008)  How  dying  cells  alert   the   immune  system  to  danger.  
Nat  Rev  Immunol  8(4):279-­289.  
10.   Kroemer  G,  Galluzzi  L,  Kepp  O,  &  Zitvogel  L   (2013)   Immunogenic  cell  death   in  
cancer  therapy.  Annu  Rev  Immunol  31:51-­72.  
11.   Zitvogel   L,   Kepp   O,   &   Kroemer   G   (2010)   Decoding   cell   death   signals   in  
inflammation  and  immunity.  Cell  140(6):798-­804.  
12.   Torchinsky   MB,   Garaude   J,   Martin   AP,   &   Blander   JM   (2009)   Innate   immune  
recognition   of   infected   apoptotic   cells   directs   T(H)17   cell   differentiation.  Nature  
458(7234):78-­82.  
13.   Green  DR  &  Llambi  F   (2015)  Cell  Death  Signaling.  Cold  Spring  Harb  Perspect  
Biol  7(12).  
14.   Haase  R,  et  al.  (2003)  A  dominant  role  of  Toll-­like  receptor  4   in  the  signaling  of  
apoptosis  in  bacteria-­faced  macrophages.  J  Immunol  171(8):4294-­4303.  
15.   Ruckdeschel   K,   et   al.   (2004)   Signaling   of   apoptosis   through   TLRs   critically  
involves   toll/IL-­1   receptor  domain-­containing  adapter   inducing   IFN-­beta,  but  not  
MyD88,  in  bacteria-­infected  murine  macrophages.  J  Immunol  173(5):3320-­3328.  
16.   Zhang  Y  &  Bliska  JB  (2003)  Role  of  Toll-­like   receptor  signaling   in   the  apoptotic  
response  of  macrophages  to  Yersinia  infection.  Infect  Immun  71(3):1513-­1519.  
17.   Kaiser  WJ   &  Offermann  MK   (2005)   Apoptosis   induced   by   the   toll-­like   receptor  
adaptor   TRIF   is   dependent   on   its   receptor   interacting   protein   homotypic  
interaction  motif.  J  Immunol  174(8):4942-­4952.  
18.   Chan  FK,  Luz  NF,  &  Moriwaki  K  (2015)  Programmed  necrosis  in  the  cross  talk  of  
cell  death  and  inflammation.  Annu  Rev  Immunol  33:79-­106.  
19.   Weinlich   R   &   Green   DR   (2014)   The   two   faces   of   receptor   interacting   protein  
kinase-­1.  Mol  Cell  56(4):469-­480.  
20.   Oberst   A,   et   al.   (2010)   Inducible   dimerization   and   inducible   cleavage   reveal   a  
requirement   for   both   processes   in   caspase-­8   activation.   J   Biol   Chem  
285(22):16632-­16642.  
   134  
21.   Kantari   C   &  Walczak  H   (2011)   Caspase-­8   and   bid:   caught   in   the   act   between  
death  receptors  and  mitochondria.  Biochim  Biophys  Acta  1813(4):558-­563.  
22.   Feoktistova   M,   et   al.   (2011)   cIAPs   block   Ripoptosome   formation,   a  
RIP1/caspase-­8  containing  intracellular  cell  death  complex  differentially  regulated  
by  cFLIP  isoforms.  Mol  Cell  43(3):449-­463.  
23.   He   S,   Liang   Y,   Shao   F,   &   Wang   X   (2011)   Toll-­like   receptors   activate  
programmed   necrosis   in  macrophages   through   a   receptor-­interacting   kinase-­3-­
mediated  pathway.  Proc  Natl  Acad  Sci  U  S  A  108(50):20054-­20059.  
24.   Kaiser  WJ,   et   al.   (2013)  Toll-­like   receptor   3-­mediated  necrosis   via  TRIF,  RIP3,  
and  MLKL.  J  Biol  Chem  288(43):31268-­31279.  
25.   Kaiser   WJ,   et   al.   (2011)   RIP3   mediates   the   embryonic   lethality   of   caspase-­8-­
deficient  mice.  Nature  471(7338):368-­372.  
26.   Oberst   A,   et   al.   (2011)   Catalytic   activity   of   the   caspase-­8-­FLIP(L)   complex  
inhibits  RIPK3-­dependent  necrosis.  Nature  471(7338):363-­367.  
27.   Yeh  WC,   et   al.   (1998)   FADD:   essential   for   embryo   development   and   signaling  
from  some,  but  not  all,  inducers  of  apoptosis.  Science  279(5358):1954-­1958.  
28.   Kang  TB,  et  al.  (2004)  Caspase-­8  serves  both  apoptotic  and  nonapoptotic  roles.  
J  Immunol  173(5):2976-­2984.  
29.   Dillon   CP,   et   al.   (2014)   RIPK1   blocks   early   postnatal   lethality   mediated   by  
caspase-­8  and  RIPK3.  Cell  157(5):1189-­1202.  
30.   Gunther   C,   et   al.   (2011)   Caspase-­8   regulates   TNF-­alpha-­induced   epithelial  
necroptosis  and  terminal  ileitis.  Nature  477(7364):335-­339.  
31.   Rickard   JA,   et   al.   (2014)   RIPK1   regulates   RIPK3-­MLKL-­driven   systemic  
inflammation  and  emergency  hematopoiesis.  Cell  157(5):1175-­1188.  
32.   Welz  PS,  et  al.  (2011)  FADD  prevents  RIP3-­mediated  epithelial  cell  necrosis  and  
chronic  intestinal  inflammation.  Nature  477(7364):330-­334.  
33.   Murphy   JM,   et   al.   (2013)   The   pseudokinase  MLKL  mediates   necroptosis   via   a  
molecular  switch  mechanism.  Immunity  39(3):443-­453.  
34.   Sun  L,  et  al.  (2012)  Mixed  lineage  kinase  domain-­like  protein  mediates  necrosis  
signaling  downstream  of  RIP3  kinase.  Cell  148(1-­2):213-­227.  
35.   Wu  J,  et  al.  (2013)  Mlkl  knockout  mice  demonstrate  the  indispensable  role  of  Mlkl  
in  necroptosis.  Cell  Res  23(8):994-­1006.  
36.   Dondelinger  Y,  et  al.   (2014)  MLKL  compromises  plasma  membrane   integrity  by  
binding  to  phosphatidylinositol  phosphates.  Cell  Rep  7(4):971-­981.  
37.   Quarato   G,   et   al.   (2016)   Sequential   Engagement   of   Distinct   MLKL  
Phosphatidylinositol-­Binding  Sites  Executes  Necroptosis.  Mol  Cell  61(4):589-­601.  
38.   Wang   H,   et   al.   (2014)  Mixed   lineage   kinase   domain-­like   protein  MLKL   causes  
necrotic  membrane  disruption  upon  phosphorylation  by  RIP3.  Mol  Cell  54(1):133-­
146.  
39.   Cai  Z,  et  al.  (2014)  Plasma  membrane  translocation  of  trimerized  MLKL  protein  is  
required  for  TNF-­induced  necroptosis.  Nat  Cell  Biol  16(1):55-­65.  
40.   Chen  X,  et  al.   (2014)  Translocation  of  mixed   lineage  kinase  domain-­like  protein  
to  plasma  membrane  leads  to  necrotic  cell  death.  Cell  Res  24(1):105-­121.  
41.   Lamkanfi   M   &   Dixit   VM   (2014)   Mechanisms   and   functions   of   inflammasomes.  
Cell  157(5):1013-­1022.  
42.   Vanaja  SK,  Rathinam  VA,  &  Fitzgerald  KA  (2015)  Mechanisms  of  inflammasome  
activation:  recent  advances  and  novel  insights.  Trends  Cell  Biol  25(5):308-­315.  
43.   Davis   BK,   Wen   H,   &   Ting   JP   (2011)   The   inflammasome   NLRs   in   immunity,  
inflammation,  and  associated  diseases.  Annu  Rev  Immunol  29:707-­735.  
   135  
44.   Aachoui   Y,   et   al.   (2013)  Caspase-­11   protects   against   bacteria   that   escape   the  
vacuole.  Science  339(6122):975-­978.  
45.   Hornung  V,  et  al.  (2009)  AIM2  recognizes  cytosolic  dsDNA  and  forms  a  caspase-­
1-­activating  inflammasome  with  ASC.  Nature  458(7237):514-­518.  
46.   Kayagaki   N,   et   al.   (2011)   Non-­canonical   inflammasome   activation   targets  
caspase-­11.  Nature  479(7371):117-­121.  
47.   Mariathasan   S,   et   al.   (2004)   Differential   activation   of   the   inflammasome   by  
caspase-­1  adaptors  ASC  and  Ipaf.  Nature  430(6996):213-­218.  
48.   Martinon  F,  Petrilli  V,  Mayor  A,  Tardivel  A,  &  Tschopp  J  (2006)  Gout-­associated  
uric  acid  crystals  activate  the  NALP3  inflammasome.  Nature  440(7081):237-­241.  
49.   Amer   A,   et   al.   (2006)   Regulation   of   Legionella   phagosome   maturation   and  
infection  through  flagellin  and  host  Ipaf.  J  Biol  Chem  281(46):35217-­35223.  
50.   Franchi  L,  et  al.  (2006)  Cytosolic  flagellin  requires  Ipaf  for  activation  of  caspase-­1  
and   interleukin   1beta   in   salmonella-­infected   macrophages.   Nat   Immunol  
7(6):576-­582.  
51.   Miao  EA,  et  al.  (2006)  Cytoplasmic  flagellin  activates  caspase-­1  and  secretion  of  
interleukin  1beta  via  Ipaf.  Nat  Immunol  7(6):569-­575.  
52.   Miao   EA,   et   al.   (2010)   Innate   immune   detection   of   the   type   III   secretion  
apparatus   through   the   NLRC4   inflammasome.   Proc   Natl   Acad   Sci   U   S   A  
107(7):3076-­3080.  
53.   Chavarria-­Smith   J   &   Vance   RE   (2015)   The   NLRP1   inflammasomes.   Immunol  
Rev  265(1):22-­34.  
54.   Boyden   ED   &   Dietrich   WF   (2006)   Nalp1b   controls   mouse   macrophage  
susceptibility  to  anthrax  lethal  toxin.  Nat  Genet  38(2):240-­244.  
55.   Zamboni   DS   &   Lima-­Junior   DS   (2015)   Inflammasomes   in   host   response   to  
protozoan  parasites.  Immunol  Rev  265(1):156-­171.  
56.   Rathinam  VA,  et  al.  (2010)  The  AIM2  inflammasome  is  essential  for  host  defense  
against  cytosolic  bacteria  and  DNA  viruses.  Nat  Immunol  11(5):395-­402.  
57.   Ataide  MA,  et  al.  (2014)  Malaria-­induced  NLRP12/NLRP3-­dependent  caspase-­1  
activation  mediates  inflammation  and  hypersensitivity  to  bacterial  superinfection.  
PLoS  Pathog  10(1):e1003885.  
58.   Elinav  E,  et  al.  (2011)  NLRP6  inflammasome  regulates  colonic  microbial  ecology  
and  risk  for  colitis.  Cell  145(5):745-­757.  
59.   Normand   S,   et   al.   (2011)   Nod-­like   receptor   pyrin   domain-­containing   protein   6  
(NLRP6)   controls   epithelial   self-­renewal   and   colorectal   carcinogenesis   upon  
injury.  Proc  Natl  Acad  Sci  U  S  A  108(23):9601-­9606.  
60.   Vladimer   GI,   et   al.   (2012)   The   NLRP12   inflammasome   recognizes   Yersinia  
pestis.  Immunity  37(1):96-­107.  
61.   Wlodarska  M,  et  al.  (2014)  NLRP6  inflammasome  orchestrates  the  colonic  host-­
microbial   interface   by   regulating   goblet   cell  mucus   secretion.  Cell   156(5):1045-­
1059.  
62.   Gurung   P,   et   al.   (2012)   Toll   or   interleukin-­1   receptor   (TIR)   domain-­containing  
adaptor   inducing   interferon-­beta   (TRIF)-­mediated   caspase-­11   protease  
production   integrates   Toll-­like   receptor   4   (TLR4)   protein-­   and   Nlrp3  
inflammasome-­mediated   host   defense   against   enteropathogens.   J   Biol   Chem  
287(41):34474-­34483.  
63.   Wang   S,   et   al.   (1998)   Murine   caspase-­11,   an   ICE-­interacting   protease,   is  
essential  for  the  activation  of  ICE.  Cell  92(4):501-­509.  
   136  
64.   Hagar  JA,  Powell  DA,  Aachoui  Y,  Ernst  RK,  &  Miao  EA  (2013)  Cytoplasmic  LPS  
activates   caspase-­11:   implications   in   TLR4-­independent   endotoxic   shock.  
Science  341(6151):1250-­1253.  
65.   Kayagaki  N,  et  al.  (2013)  Noncanonical  inflammasome  activation  by  intracellular  
LPS  independent  of  TLR4.  Science  341(6151):1246-­1249.  
66.   Broz  P,  et  al.  (2012)  Caspase-­11  increases  susceptibility  to  Salmonella  infection  
in  the  absence  of  caspase-­1.  Nature  490(7419):288-­291.  
67.   Case   CL,   et   al.   (2013)   Caspase-­11   stimulates   rapid   flagellin-­independent  
pyroptosis   in   response   to   Legionella   pneumophila.  Proc   Natl   Acad   Sci   U   S   A  
110(5):1851-­1856.  
68.   Casson   CN,   et   al.   (2013)   Caspase-­11   activation   in   response   to   bacterial  
secretion  systems  that  access  the  host  cytosol.  PLoS  Pathog  9(6):e1003400.  
69.   Rathinam   VA,   et   al.   (2012)   TRIF   licenses   caspase-­11-­dependent   NLRP3  
inflammasome  activation  by  gram-­negative  bacteria.  Cell  150(3):606-­619.  
70.   Coll  NS,  Epple  P,  &  Dangl  JL  (2011)  Programmed  cell  death  in  the  plant  immune  
system.  Cell  Death  Differ  18(8):1247-­1256.  
71.   Kepp   O,   et   al.   (2009)   Disruption   of   the   PP1/GADD34   complex   induces  
calreticulin  exposure.  Cell  Cycle  8(23):3971-­3977.  
72.   Obeid   M,   et   al.   (2007)   Calreticulin   exposure   dictates   the   immunogenicity   of  
cancer  cell  death.  Nat  Med  13(1):54-­61.  
73.   Ahrens  S,  et  al.  (2012)  F-­actin  is  an  evolutionarily  conserved  damage-­associated  
molecular   pattern   recognized   by   DNGR-­1,   a   receptor   for   dead   cells.   Immunity  
36(4):635-­645.  
74.   Sancho   D,   et   al.   (2009)   Identification   of   a   dendritic   cell   receptor   that   couples  
sensing  of  necrosis  to  immunity.  Nature  458(7240):899-­903.  
75.   Apetoh  L,  et  al.  (2007)  Toll-­like  receptor  4-­dependent  contribution  of  the  immune  
system  to  anticancer  chemotherapy  and  radiotherapy.  Nat  Med  13(9):1050-­1059.  
76.   O'Connor  W,  Jr.,  et  al.   (2009)  A  protective  function  for   interleukin  17A  in  T  cell-­
mediated  intestinal  inflammation.  Nat  Immunol  10(6):603-­609.  
77.   Sonnenberg  GF,  et  al.  (2010)  Pathological  versus  protective  functions  of  IL-­22  in  
airway  inflammation  are  regulated  by  IL-­17A.  J  Exp  Med  207(6):1293-­1305.  
78.   Ye  P,  et  al.  (2001)  Requirement  of  interleukin  17  receptor  signaling  for  lung  CXC  
chemokine   and   granulocyte   colony-­stimulating   factor   expression,   neutrophil  
recruitment,  and  host  defense.  J  Exp  Med  194(4):519-­527.  
79.   Miao   EA,   et   al.   (2010)   Caspase-­1-­induced   pyroptosis   is   an   innate   immune  
effector   mechanism   against   intracellular   bacteria.   Nat   Immunol   11(12):1136-­
1142.  
80.   Brydges   SD,   et   al.   (2013)   Divergence   of   IL-­1,   IL-­18,   and   cell   death   in   NLRP3  
inflammasomopathies.  J  Clin  Invest  123(11):4695-­4705.  
81.   Upton  JW,  Kaiser  WJ,  &  Mocarski  ES  (2010)  Virus  inhibition  of  RIP3-­dependent  
necrosis.  Cell  Host  Microbe  7(4):302-­313.  
82.   Inoue  M,  Williams  KL,  Gunn  MD,  &  Shinohara  ML  (2012)  NLRP3  inflammasome  
induces   chemotactic   immune   cell   migration   to   the   CNS   in   experimental  
autoimmune  encephalomyelitis.  Proc  Natl  Acad  Sci  U  S  A  109(26):10480-­10485.  
83.   Yatim  N,  et  al.  (2015)  RIPK1  and  NF-­kappaB  signaling  in  dying  cells  determines  
cross-­priming  of  CD8(+)  T  cells.  Science  350(6258):328-­334.  
84.   Viboud  GI  &  Bliska  JB  (2005)  Yersinia  outer  proteins:  role  in  modulation  of  host  
cell  signaling  responses  and  pathogenesis.  Annu  Rev  Microbiol  59:69-­89.  
85.   Cornelis   GR   (2006)   The   type   III   secretion   injectisome.   Nat   Rev   Microbiol  
4(11):811-­825.  
   137  
86.   Mills  SD,  et  al.  (1997)  Yersinia  enterocolitica  induces  apoptosis  in  macrophages  
by  a  process  requiring  functional  type  III  secretion  and  translocation  mechanisms  
and  involving  YopP,  presumably  acting  as  an  effector  protein.  Proc  Natl  Acad  Sci  
U  S  A  94(23):12638-­12643.  
87.   Monack   DM,   Mecsas   J,   Ghori   N,   &   Falkow   S   (1997)   Yersinia   signals  
macrophages   to   undergo   apoptosis   and   YopJ   is   necessary   for   this   cell   death.  
Proc  Natl  Acad  Sci  U  S  A  94(19):10385-­10390.  
88.   Ruckdeschel   K,   et   al.   (1998)   Yersinia   enterocolitica   impairs   activation   of  
transcription  factor  NF-­kappaB:  involvement  in  the  induction  of  programmed  cell  
death   and   in   the   suppression   of   the   macrophage   tumor   necrosis   factor   alpha  
production.  J  Exp  Med  187(7):1069-­1079.  
89.   Brodsky  IE  &  Medzhitov  R  (2008)  Reduced  secretion  of  YopJ  by  Yersinia  limits  in  
vivo  cell  death  but  enhances  bacterial  virulence.  PLoS  Pathog  4(5):e1000067.  
90.   Ruckdeschel   K,   Richter   K,   Mannel   O,   &   Heesemann   J   (2001)   Arginine-­143   of  
Yersinia   enterocolitica   YopP   crucially   determines   isotype-­related   NF-­kappaB  
suppression  and  apoptosis  induction  in  macrophages.  Infect  Immun  69(12):7652-­
7662.  
91.   Zauberman   A,   et   al.   (2006)   Interaction   of   Yersinia   pestis   with   macrophages:  
limitations  in  YopJ-­dependent  apoptosis.  Infect  Immun  74(6):3239-­3250.  
92.   Zheng  Y,  et  al.  (2011)  A  Yersinia  effector  with  enhanced  inhibitory  activity  on  the  
NF-­kappaB   pathway   activates   the   NLRP3/ASC/caspase-­1   inflammasome   in  
macrophages.  PLoS  Pathog  7(4):e1002026.  
93.   Bergsbaken   T   &  Cookson  BT   (2007)  Macrophage   activation   redirects   yersinia-­
infected  host  cell  death  from  apoptosis  to  caspase-­1-­dependent  pyroptosis.  PLoS  
Pathog  3(11):e161.  
94.   Ruckdeschel  K,   et   al.   (2001)  Yersinia   outer   protein  P   of  Yersinia   enterocolitica  
simultaneously   blocks   the   nuclear   factor-­kappa   B   pathway   and   exploits  
lipopolysaccharide   signaling   to   trigger   apoptosis   in   macrophages.   J   Immunol  
166(3):1823-­1831.  
95.   Ruckdeschel   K,   et   al.   (1997)   Interaction   of   Yersinia   enterocolitica   with  
macrophages   leads   to  macrophage   cell   death   through  apoptosis.   Infect   Immun  
65(11):4813-­4821.  
96.   Zheng  Y,  Lilo  S,  Mena  P,  &  Bliska  JB  (2012)  YopJ-­induced  caspase-­1  activation  
in  Yersinia-­infected  macrophages:   independent  of  apoptosis,   linked   to  necrosis,  
dispensable  for  innate  host  defense.  PLoS  One  7(4):e36019.  
97.   Monack  DM,  Mecsas  J,  Bouley  D,  &  Falkow  S  (1998)  Yersinia-­induced  apoptosis  
in   vivo   aids   in   the   establishment   of   a   systemic   infection   of   mice.   J   Exp   Med  
188(11):2127-­2137.  
98.   Bergman  MA,  Loomis  WP,  Mecsas  J,  Starnbach  MN,  &  Isberg  RR  (2009)  CD8(+)  
T  cells  restrict  Yersinia  pseudotuberculosis  infection:  bypass  of  anti-­phagocytosis  
by  targeting  antigen-­presenting  cells.  PLoS  Pathog  5(9):e1000573.  
99.   Zauberman  A,  et  al.  (2009)  Yersinia  pestis  endowed  with  increased  cytotoxicity  is  
avirulent   in   a   bubonic   plague   model   and   induces   rapid   protection   against  
pneumonic  plague.  PLoS  One  4(6):e5938.  
100.   Grabenstein   JP,   Marceau   M,   Pujol   C,   Simonet   M,   &   Bliska   JB   (2004)   The  
response   regulator   PhoP   of   Yersinia   pseudotuberculosis   is   important   for  
replication  in  macrophages  and  for  virulence.  Infect  Immun  72(9):4973-­4984.  
101.   Heath  WR   &   Carbone   FR   (2001)   Cross-­presentation,   dendritic   cells,   tolerance  
and  immunity.  Annu  Rev  Immunol  19:47-­64.  
   138  
102.   Orth  K,  et  al.  (2000)  Disruption  of  signaling  by  Yersinia  effector  YopJ,  a  ubiquitin-­
like  protein  protease.  Science  290(5496):1594-­1597.  
103.   Palmer  LE,  Pancetti  AR,  Greenberg  S,  &  Bliska  JB  (1999)  YopJ  of  Yersinia  spp.  
is   sufficient   to   cause   downregulation   of   multiple   mitogen-­activated   protein  
kinases  in  eukaryotic  cells.  Infect  Immun  67(2):708-­716.  
104.   Sweet   CR,   Conlon   J,   Golenbock   DT,   Goguen   J,   &   Silverman   N   (2007)   YopJ  
targets   TRAF   proteins   to   inhibit   TLR-­mediated   NF-­kappaB,   MAPK   and   IRF3  
signal  transduction.  Cell  Microbiol  9(11):2700-­2715.  
105.   Zhou  H,  et  al.   (2005)  Yersinia  virulence  factor  YopJ  acts  as  a  deubiquitinase  to  
inhibit  NF-­kappa  B  activation.  J  Exp  Med  202(10):1327-­1332.  
106.   Mittal   R,   Peak-­Chew   SY,   &   McMahon   HT   (2006)   Acetylation   of   MEK2   and   I  
kappa   B   kinase   (IKK)   activation   loop   residues   by   YopJ   inhibits   signaling.  Proc  
Natl  Acad  Sci  U  S  A  103(49):18574-­18579.  
107.   Mukherjee  S,  et  al.  (2006)  Yersinia  YopJ  acetylates  and  inhibits  kinase  activation  
by  blocking  phosphorylation.  Science  312(5777):1211-­1214.  
108.   Paquette   N,   et   al.   (2012)   Serine/threonine   acetylation   of   TGFbeta-­activated  
kinase   (TAK1)   by   Yersinia   pestis   YopJ   inhibits   innate   immune   signaling.   Proc  
Natl  Acad  Sci  U  S  A  109(31):12710-­12715.  
109.   Zhang  Y,   Ting  AT,  Marcu  KB,  &  Bliska   JB   (2005)   Inhibition   of  MAPK  and  NF-­
kappa  B  pathways  is  necessary  for  rapid  apoptosis  in  macrophages  infected  with  
Yersinia.  J  Immunol  174(12):7939-­7949.  
110.   Grobner   S,   et   al.   (2007)   Catalytically   active   Yersinia   outer   protein   P   induces  
cleavage  of  RIP  and  caspase-­8  at   the   level  of   the  DISC  independently  of  death  
receptors  in  dendritic  cells.  Apoptosis  12(10):1813-­1825.  
111.   Denecker   G,   et   al.   (2001)   Yersinia   enterocolitica   YopP-­induced   apoptosis   of  
macrophages   involves   the   apoptotic   signaling   cascade   upstream   of   bid.   J   Biol  
Chem  276(23):19706-­19714.  
112.   Grobner   S,   et   al.   (2006)   Yersinia   YopP-­induced   apoptotic   cell   death   in  murine  
dendritic   cells   is   partially   independent   from   action   of   caspases   and   exhibits  
necrosis-­like  features.  Apoptosis  11(11):1959-­1968.  
113.   Vance   RE,   Isberg   RR,   &   Portnoy   DA   (2009)   Patterns   of   pathogenesis:  
discrimination  of  pathogenic  and  nonpathogenic  microbes  by  the  innate  immune  
system.  Cell  Host  Microbe  6(1):10-­21.  
114.   Schroder  K  &  Tschopp  J  (2010)  The  inflammasomes.  Cell  140(6):821-­832.  
115.   Brodsky   IE,   et   al.   (2010)   A   Yersinia   effector   protein   promotes   virulence   by  
preventing   inflammasome  recognition  of   the   type  III  secretion  system.  Cell  Host  
Microbe  7(5):376-­387.  
116.   Bauernfeind   FG,   et   al.   (2009)   Cutting   edge:   NF-­kappaB   activating   pattern  
recognition   and   cytokine   receptors   license  NLRP3   inflammasome   activation   by  
regulating  NLRP3  expression.  J  Immunol  183(2):787-­791.  
117.   Ratner  D,  et  al.  (2016)  Manipulation  of  IL-­1beta  and  IL-­18  production  by  Yersinia  
pestis  effectors  YopJ  and  YopM  and  redundant  impact  on  virulence.  J  Biol  Chem.  
118.   Schoberle  TJ,  Chung  LK,  McPhee  JB,  Bogin  B,  &  Bliska  JB  (2016)  Uncovering  
an   Important   Role   for   YopJ   in   the   Inhibition   of   Caspase-­1   in   Activated  
Macrophages   and   Promoting   Yersinia   pseudotuberculosis   Virulence.   Infect  
Immun.  
119.   Chung   LK,   et   al.   (2014)   IQGAP1   is   important   for   activation   of   caspase-­1   in  
macrophages   and   is   targeted   by   Yersinia   pestis   type   III   effector   YopM.  MBio  
5(4):e01402-­01414.  
   139  
120.   LaRock  CN  &  Cookson  BT   (2012)   The  Yersinia   virulence   effector   YopM   binds  
caspase-­1  to  arrest  inflammasome  assembly  and  processing.  Cell  Host  Microbe  
12(6):799-­805.  
121.   Lilo   S,   Zheng   Y,   &   Bliska   JB   (2008)   Caspase-­1   activation   in   macrophages  
infected  with  Yersinia  pestis  KIM   requires   the   type   III   secretion  system  effector  
YopJ.  Infect  Immun  76(9):3911-­3923.  
122.   Greten  FR,  et  al.  (2007)  NF-­kappaB  is  a  negative  regulator  of  IL-­1beta  secretion  
as   revealed   by   genetic   and   pharmacological   inhibition   of   IKKbeta.   Cell  
130(5):918-­931.  
123.   Philip   NH,   et   al.   (2014)  Caspase-­8  mediates   caspase-­1   processing   and   innate  
immune   defense   in   response   to   bacterial   blockade   of   NF-­kappaB   and   MAPK  
signaling.  Proc  Natl  Acad  Sci  U  S  A  111(20):7385-­7390.  
124.   Weng   D,   et   al.   (2014)   Caspase-­8   and   RIP   kinases   regulate   bacteria-­induced  
innate   immune   responses   and   cell   death.   Proc   Natl   Acad   Sci   U   S   A  
111(20):7391-­7396.  
125.   Broz  P,   von  Moltke   J,   Jones   JW,  Vance  RE,  &  Monack  DM   (2010)  Differential  
requirement   for   Caspase-­1   autoproteolysis   in   pathogen-­induced   cell   death   and  
cytokine  processing.  Cell  Host  Microbe  8(6):471-­483.  
126.   Sander   LE,   et   al.   (2011)   Detection   of   prokaryotic   mRNA   signifies   microbial  
viability  and  promotes  immunity.  Nature  474(7351):385-­389.  
127.   Jung   C,   et   al.   (2012)   Yersinia   pseudotuberculosis   disrupts   intestinal   barrier  
integrity  through  hematopoietic  TLR-­2  signaling.  J  Clin  Invest  122(6):2239-­2251.  
128.   Meinzer  U,  et  al.   (2012)  Yersinia  pseudotuberculosis  effector  YopJ  subverts  the  
Nod2/RICK/TAK1   pathway   and   activates   caspase-­1   to   induce   intestinal   barrier  
dysfunction.  Cell  Host  Microbe  11(4):337-­351.  
129.   Lemaitre  N,  Sebbane  F,  Long  D,  &  Hinnebusch  BJ  (2006)  Yersinia  pestis  YopJ  
suppresses  tumor  necrosis  factor  alpha  induction  and  contributes  to  apoptosis  of  
immune  cells  in  the  lymph  node  but  is  not  required  for  virulence  in  a  rat  model  of  
bubonic  plague.  Infect  Immun  74(9):5126-­5131.  
130.   Lathem   WW,   Price   PA,   Miller   VL,   &   Goldman   WE   (2007)   A   plasminogen-­
activating   protease   specifically   controls   the   development   of   primary   pneumonic  
plague.  Science  315(5811):509-­513.  
131.   Dessein  R,  et  al.  (2009)  Toll-­like  receptor  2   is  critical  for   induction  of  Reg3  beta  
expression   and   intestinal   clearance   of   Yersinia   pseudotuberculosis.   Gut  
58(6):771-­776.  
132.   Dube  PH,  Revell  PA,  Chaplin  DD,  Lorenz  RG,  &  Miller  VL  (2001)  A  role  for  IL-­1  
alpha   in   inducing   pathologic   inflammation   during   bacterial   infection.   Proc   Natl  
Acad  Sci  U  S  A  98(19):10880-­10885.  
133.   Cerretti  DP,   et   al.   (1992)  Molecular   cloning  of   the   interleukin-­1   beta   converting  
enzyme.  Science  256(5053):97-­100.  
134.   Thornberry  NA,  et  al.  (1992)  A  novel  heterodimeric  cysteine  protease  is  required  
for  interleukin-­1  beta  processing  in  monocytes.  Nature  356(6372):768-­774.  
135.   Yuan  J,  Shaham  S,  Ledoux  S,  Ellis  HM,  &  Horvitz  HR  (1993)  The  C.  elegans  cell  
death   gene   ced-­3   encodes   a   protein   similar   to   mammalian   interleukin-­1   beta-­
converting  enzyme.  Cell  75(4):641-­652.  
136.   van  Raam  BJ  &  Salvesen  GS   (2012)  Proliferative  versus  apoptotic   functions  of  
caspase-­8   Hetero   or   homo:   the   caspase-­8   dimer   controls   cell   fate.   Biochim  
Biophys  Acta  1824(1):113-­122.  
   140  
137.   Eckhart   L,   et   al.   (2008)   Identification  of  novel  mammalian  caspases   reveals  an  
important   role   of   gene   loss   in   shaping   the   human   caspase   repertoire.  Mol  Biol  
Evol  25(5):831-­841.  
138.   Wachmann   K,   et   al.   (2010)   Activation   and   specificity   of   human   caspase-­10.  
Biochemistry  49(38):8307-­8315.  
139.   Chang   DW,   Xing   Z,   Capacio   VL,   Peter   ME,   &   Yang   X   (2003)   Interdimer  
processing  mechanism  of  procaspase-­8  activation.  EMBO  J  22(16):4132-­4142.  
140.   Hoffmann   JC,   Pappa   A,   Krammer   PH,   &   Lavrik   IN   (2009)   A   new   C-­terminal  
cleavage   product   of   procaspase-­8,   p30,   defines   an   alternative   pathway   of  
procaspase-­8  activation.  Mol  Cell  Biol  29(16):4431-­4440.  
141.   Boatright  KM,  et  al.  (2003)  A  unified  model  for  apical  caspase  activation.  Mol  Cell  
11(2):529-­541.  
142.   Pop   C,   Fitzgerald   P,   Green   DR,   &   Salvesen   GS   (2007)   Role   of   proteolysis   in  
caspase-­8  activation  and  stabilization.  Biochemistry  46(14):4398-­4407.  
143.   Murphy   BM,   Creagh   EM,   &   Martin   SJ   (2004)   Interchain   proteolysis,   in   the  
absence  of  a  dimerization  stimulus,  can   initiate  apoptosis-­associated  caspase-­8  
activation.  J  Biol  Chem  279(35):36916-­36922.  
144.   Sohn  D,  Schulze-­Osthoff  K,  &  Janicke  RU  (2005)  Caspase-­8  can  be  activated  by  
interchain  proteolysis  without  receptor-­triggered  dimerization  during  drug-­induced  
apoptosis.  J  Biol  Chem  280(7):5267-­5273.  
145.   Cowling  V  &  Downward  J  (2002)  Caspase-­6   is   the  direct  activator  of  caspase-­8  
in   the   cytochrome   c-­induced   apoptosis   pathway:   absolute   requirement   for  
removal  of  caspase-­6  prodomain.  Cell  Death  Differ  9(10):1046-­1056.  
146.   Medema  JP,  et  al.  (1997)  Cleavage  of  FLICE  (caspase-­8)  by  granzyme  B  during  
cytotoxic  T  lymphocyte-­induced  apoptosis.  Eur  J  Immunol  27(12):3492-­3498.  
147.   Hughes  MA,  et  al.  (2009)  Reconstitution  of  the  death-­inducing  signaling  complex  
reveals  a  substrate  switch  that  determines  CD95-­mediated  death  or  survival.  Mol  
Cell  35(3):265-­279.  
148.   Pop   C,   et   al.   (2011)   FLIP(L)   induces   caspase   8   activity   in   the   absence   of  
interdomain   caspase   8   cleavage   and   alters   substrate   specificity.   Biochem   J  
433(3):447-­457.  
149.   Bertin  J,  et  al.  (1997)  Death  effector  domain-­containing  herpesvirus  and  poxvirus  
proteins  inhibit  both  Fas-­  and  TNFR1-­induced  apoptosis.  Proc  Natl  Acad  Sci  U  S  
A  94(4):1172-­1176.  
150.   Goltsev  YV,  et  al.  (1997)  CASH,  a  novel  caspase  homologue  with  death  effector  
domains.  J  Biol  Chem  272(32):19641-­19644.  
151.   Han  DK,   et   al.   (1997)  MRIT,   a   novel   death-­effector   domain-­containing   protein,  
interacts  with  caspases  and  BclXL  and  initiates  cell  death.  Proc  Natl  Acad  Sci  U  
S  A  94(21):11333-­11338.  
152.   Hu  S,  Vincenz  C,  Ni  J,  Gentz  R,  &  Dixit  VM  (1997)  I-­FLICE,  a  novel   inhibitor  of  
tumor   necrosis   factor   receptor-­1-­   and   CD-­95-­induced   apoptosis.   J   Biol   Chem  
272(28):17255-­17257.  
153.   Inohara  N,  Koseki  T,  Hu  Y,  Chen  S,  &  Nunez  G  (1997)  CLARP,  a  death  effector  
domain-­containing   protein   interacts   with   caspase-­8   and   regulates   apoptosis.  
Proc  Natl  Acad  Sci  U  S  A  94(20):10717-­10722.  
154.   Irmler  M,  et  al.  (1997)  Inhibition  of  death  receptor  signals  by  cellular  FLIP.  Nature  
388(6638):190-­195.  
155.   Rasper  DM,  et  al.  (1998)  Cell  death  attenuation  by  'Usurpin',  a  mammalian  DED-­
caspase  homologue  that  precludes  caspase-­8  recruitment  and  activation  by   the  
CD-­95  (Fas,  APO-­1)  receptor  complex.  Cell  Death  Differ  5(4):271-­288.  
   141  
156.   Srinivasula   SM,   et   al.   (1997)   FLAME-­1,   a   novel   FADD-­like   anti-­apoptotic  
molecule   that   regulates   Fas/TNFR1-­induced   apoptosis.   J   Biol   Chem  
272(30):18542-­18545.  
157.   Thome  M,  et  al.  (1997)  Viral  FLICE-­inhibitory  proteins  (FLIPs)  prevent  apoptosis  
induced  by  death  receptors.  Nature  386(6624):517-­521.  
158.   Varfolomeev  EE,  et  al.  (1998)  Targeted  disruption  of  the  mouse  Caspase  8  gene  
ablates   cell   death   induction   by   the   TNF   receptors,   Fas/Apo1,   and   DR3   and   is  
lethal  prenatally.  Immunity  9(2):267-­276.  
159.   Yeh  WC,   et   al.   (2000)   Requirement   for   Casper   (c-­FLIP)   in   regulation   of   death  
receptor-­induced   apoptosis   and   embryonic   development.   Immunity   12(6):633-­
642.  
160.   Dillon   CP,   et   al.   (2012)   Survival   function   of   the   FADD-­CASPASE-­8-­cFLIP(L)  
complex.  Cell  Rep  1(5):401-­407.  
161.   Tschopp  J,  Thome  M,  Hofmann  K,  &  Meinl  E  (1998)  The  fight  of  viruses  against  
apoptosis.  Curr  Opin  Genet  Dev  8(1):82-­87.  
162.   Boatright   KM,   Deis   C,   Denault   JB,   Sutherlin   DP,   &   Salvesen   GS   (2004)  
Activation  of  caspases-­8  and  -­10  by  FLIP(L).  Biochem  J  382(Pt  2):651-­657.  
163.   Micheau  O,  et  al.  (2002)  The  long  form  of  FLIP  is  an  activator  of  caspase-­8  at  the  
Fas  death-­inducing  signaling  complex.  J  Biol  Chem  277(47):45162-­45171.  
164.   Yu  JW,  Jeffrey  PD,  &  Shi  Y  (2009)  Mechanism  of  procaspase-­8  activation  by  c-­
FLIPL.  Proc  Natl  Acad  Sci  U  S  A  106(20):8169-­8174.  
165.   Stoven   S,   et   al.   (2003)   Caspase-­mediated   processing   of   the   Drosophila   NF-­
kappaB  factor  Relish.  Proc  Natl  Acad  Sci  U  S  A  100(10):5991-­5996.  
166.   Dohrman   A,   et   al.   (2005)   Cellular   FLIP   (long   form)   regulates   CD8+   T   cell  
activation   through   caspase-­8-­dependent   NF-­kappa   B   activation.   J   Immunol  
174(9):5270-­5278.  
167.   Golks  A,  Brenner  D,  Krammer  PH,  &  Lavrik  IN  (2006)  The  c-­FLIP-­NH2  terminus  
(p22-­FLIP)  induces  NF-­kappaB  activation.  J  Exp  Med  203(5):1295-­1305.  
168.   Kataoka  T,  et  al.  (2000)  The  caspase-­8  inhibitor  FLIP  promotes  activation  of  NF-­
kappaB  and  Erk  signaling  pathways.  Curr  Biol  10(11):640-­648.  
169.   Koenig   A,   et   al.   (2014)   The   c-­FLIPL   cleavage   product   p43FLIP   promotes  
activation   of   extracellular   signal-­regulated   kinase   (ERK),   nuclear   factor   kappaB  
(NF-­kappaB),  and  caspase-­8  and  T  cell  survival.  J  Biol  Chem  289(2):1183-­1191.  
170.   Lemmers  B,  et  al.   (2007)  Essential   role   for  caspase-­8   in  Toll-­like   receptors  and  
NFkappaB  signaling.  J  Biol  Chem  282(10):7416-­7423.  
171.   Rathore   N,   Matta   H,   &   Chaudhary   PM   (2004)   An   evolutionary   conserved  
pathway   of   nuclear   factor-­kappaB   activation   involving   caspase-­mediated  
cleavage  and  N-­end  rule  pathway-­mediated  degradation  of  IkappaBalpha.  J  Biol  
Chem  279(38):39358-­39365.  
172.   Su   H,   et   al.   (2005)   Requirement   for   caspase-­8   in   NF-­kappaB   activation   by  
antigen  receptor.  Science  307(5714):1465-­1468.  
173.   Allam   R,   et   al.   (2014)   Mitochondrial   apoptosis   is   dispensable   for   NLRP3  
inflammasome   activation   but   non-­apoptotic   caspase-­8   is   required   for  
inflammasome  priming.  EMBO  Rep  15(9):982-­990.  
174.   Beisner  DR,  Ch'en  IL,  Kolla  RV,  Hoffmann  A,  &  Hedrick  SM  (2005)  Cutting  edge:  
innate   immunity   conferred   by   B   cells   is   regulated   by   caspase-­8.   J   Immunol  
175(6):3469-­3473.  
175.   Ch'en   IL,   et   al.   (2008)  Antigen-­mediated  T   cell   expansion   regulated   by   parallel  
pathways  of  death.  Proc  Natl  Acad  Sci  U  S  A  105(45):17463-­17468.  
   142  
176.   Carlile   GW,   Smith   DH,   &  Wiedmann  M   (2004)   Caspase-­3   has   a   nonapoptotic  
function  in  erythroid  maturation.  Blood  103(11):4310-­4316.  
177.   Fernando  P,   Kelly   JF,   Balazsi   K,   Slack  RS,   &  Megeney   LA   (2002)  Caspase   3  
activity   is   required   for  skeletal  muscle  differentiation.  Proc  Natl  Acad  Sci  U  S  A  
99(17):11025-­11030.  
178.   Oomman   S,   Strahlendorf   H,   Dertien   J,   &   Strahlendorf   J   (2006)   Bergmann   glia  
utilize  active  caspase-­3  for  differentiation.  Brain  Res  1078(1):19-­34.  
179.   Gurung  P,  et  al.   (2014)  FADD  and  caspase-­8  mediate  priming  and  activation  of  
the  canonical  and  noncanonical  Nlrp3   inflammasomes.  J   Immunol  192(4):1835-­
1846.  
180.   Man  SM,  et  al.  (2013)  Salmonella  infection  induces  recruitment  of  Caspase-­8  to  
the   inflammasome   to   modulate   IL-­1beta   production.   J   Immunol   191(10):5239-­
5246.  
181.   Rajput  A,  et  al.  (2011)  RIG-­I  RNA  helicase  activation  of  IRF3  transcription  factor  
is   negatively   regulated   by   caspase-­8-­mediated   cleavage   of   the   RIP1   protein.  
Immunity  34(3):340-­351.  
182.   Shenderov  K,  et  al.   (2014)  Cutting  edge:  Endoplasmic  reticulum  stress   licenses  
macrophages   to   produce   mature   IL-­1beta   in   response   to   TLR4   stimulation  
through   a   caspase-­8-­   and   TRIF-­dependent   pathway.   J   Immunol   192(5):2029-­
2033.  
183.   Lakhani   SA,   et   al.   (2006)   Caspases   3   and   7:   key   mediators   of   mitochondrial  
events  of  apoptosis.  Science  311(5762):847-­851.  
184.   Rongvaux   A,   et   al.   (2014)   Apoptotic   caspases   prevent   the   induction   of   type   I  
interferons  by  mitochondrial  DNA.  Cell  159(7):1563-­1577.  
185.   Henao-­Mejia  J,  et  al.   (2016)  Generation  of  Genetically  Modified  Mice  Using   the  
CRISPR-­Cas9   Genome-­Editing   System.  Cold   Spring   Harb   Protoc   2016(2):pdb  
prot090704.  
186.   Tapia   K,   et   al.   (2013)   Defective   viral   genomes   arising   in   vivo   provide   critical  
danger   signals   for   the   triggering   of   lung   antiviral   immunity.   PLoS   Pathog  
9(10):e1003703.  
187.   Edmonson  MN,  et  al.   (2011)  Bambino:  a  variant  detector  and  alignment  viewer  
for   next-­generation   sequencing   data   in   the   SAM/BAM   format.   Bioinformatics  
27(6):865-­866.  
188.   Keane  TM,  et  al.   (2011)  Mouse  genomic  variation  and   its  effect  on  phenotypes  
and  gene  regulation.  Nature  477(7364):289-­294.  
189.   Zhang   J,   et   al.   (2012)   The   genetic   basis   of   early   T-­cell   precursor   acute  
lymphoblastic  leukaemia.  Nature  481(7380):157-­163.  
190.   Benavente  CA,  et  al.   (2013)  Cross-­species  genomic  and  epigenomic   landscape  
of  retinoblastoma.  Oncotarget  4(6):844-­859.  
191.   Ghosn  EE,  et  al.  (2010)  Two  physically,  functionally,  and  developmentally  distinct  
peritoneal  macrophage  subsets.  Proc  Natl  Acad  Sci  U  S  A  107(6):2568-­2573.  
192.   Yount  JS,  Kraus  TA,  Horvath  CM,  Moran  TM,  &  Lopez  CB  (2006)  A  novel  role  for  
viral-­defective   interfering   particles   in   enhancing   dendritic   cell   maturation.   J  
Immunol  177(7):4503-­4513.  
193.   Black  DS  &  Bliska  JB  (1997)  Identification  of  p130Cas  as  a  substrate  of  Yersinia  
YopH   (Yop51),   a   bacterial   protein   tyrosine   phosphatase   that   translocates   into  
mammalian  cells  and  targets  focal  adhesions.  EMBO  J  16(10):2730-­2744.  
194.   Simonet  M  &  Falkow  S  (1992)  Invasin  expression  in  Yersinia  pseudotuberculosis.  
Infect  Immun  60(10):4414-­4417.  
   143  
195.   Zhang  Y,  Murtha  J,  Roberts  MA,  Siegel  RM,  &  Bliska  JB  (2008)  Type  III  secretion  
decreases   bacterial   and   host   survival   following   phagocytosis   of   Yersinia  
pseudotuberculosis  by  macrophages.  Infect  Immun  76(9):4299-­4310.  
196.   Portnoy   DA,   Wolf-­Watz   H,   Bolin   I,   Beeder   AB,   &   Falkow   S   (1984)  
Characterization  of  common  virulence  plasmids  in  Yersinia  species  and  their  role  
in  the  expression  of  outer  membrane  proteins.  Infect  Immun  43(1):108-­114.  
197.   Hoiseth   SK   &   Stocker   BA   (1981)   Aromatic-­dependent   Salmonella   typhimurium  
are  non-­virulent  and  effective  as  live  vaccines.  Nature  291(5812):238-­239.  
198.   Blasi  E,  et  al.  (1985)  Selective  immortalization  of  murine  macrophages  from  fresh  
bone  marrow  by  a  raf/myc  recombinant  murine  retrovirus.  Nature  318(6047):667-­
670.  
199.   Ramirez-­Carrozzi  VR,  et  al.   (2009)  A  unifying  model   for   the  selective  regulation  
of   inducible   transcription   by   CpG   islands   and   nucleosome   remodeling.   Cell  
138(1):114-­128.  
200.   Sun   Y,   et   al.   (2015)   Immunostimulatory   Defective   Viral   Genomes   from  
Respiratory  Syncytial  Virus  Promote  a  Strong   Innate  Antiviral  Response  during  
Infection  in  Mice  and  Humans.  PLoS  Pathog  11(9):e1005122.  
201.   Shi  W  (2015)  A  Bioconductor  R  pipeline  for  analysis  of  RNA-­seq  data.  
202.   Liao   Y,   Smyth   GK,   &   Shi   W   (2013)   The   Subread   aligner:   fast,   accurate   and  
scalable  read  mapping  by  seed-­and-­vote.  Nucleic  Acids  Res  41(10):e108.  
203.   Liao  Y,  Smyth  GK,  &  Shi  W  (2014)   featureCounts:  an  efficient  general  purpose  
program   for   assigning   sequence   reads   to   genomic   features.   Bioinformatics  
30(7):923-­930.  
204.   Law  CW,  Chen  Y,  Shi  W,  &  Smyth  GK   (2014)   voom:  Precision  weights  unlock  
linear  model  analysis  tools  for  RNA-­seq  read  counts.  Genome  Biol  15(2):R29.  
205.   Ritchie  ME,  et  al.  (2015)  limma  powers  differential  expression  analyses  for  RNA-­
sequencing  and  microarray  studies.  Nucleic  Acids  Res  43(7):e47.  
206.   Huang   da  W,   Sherman   BT,   &   Lempicki   RA   (2009)   Systematic   and   integrative  
analysis   of   large   gene   lists   using   DAVID   bioinformatics   resources.  Nat   Protoc  
4(1):44-­57.  
207.   Huang   da   W,   Sherman   BT,   &   Lempicki   RA   (2009)   Bioinformatics   enrichment  
tools:   paths   toward   the   comprehensive   functional   analysis   of   large   gene   lists.  
Nucleic  Acids  Res  37(1):1-­13.  
208.   Mootha   VK,   et   al.   (2003)   PGC-­1alpha-­responsive   genes   involved   in   oxidative  
phosphorylation   are   coordinately   downregulated   in   human   diabetes.  Nat  Genet  
34(3):267-­273.  
209.   Subramanian  A,  et  al.  (2005)  Gene  set  enrichment  analysis:  a  knowledge-­based  
approach  for  interpreting  genome-­wide  expression  profiles.  Proc  Natl  Acad  Sci  U  
S  A  102(43):15545-­15550.  
210.   Medzhitov  R  (2007)  Recognition  of  microorganisms  and  activation  of  the  immune  
response.  Nature  449(7164):819-­826.  
211.   Broz  P  &  Monack  DM  (2013)  Newly  described  pattern  recognition  receptors  team  
up  against  intracellular  pathogens.  Nat  Rev  Immunol  13(8):551-­565.  
212.   Orth   K,   et   al.   (1999)   Inhibition   of   the   mitogen-­activated   protein   kinase   kinase  
superfamily  by  a  Yersinia  effector.  Science  285(5435):1920-­1923.  
213.   Palmer   LE,   Hobbie   S,   Galan   JE,   &   Bliska   JB   (1998)   YopJ   of   Yersinia  
pseudotuberculosis   is   required   for   the   inhibition   of   macrophage   TNF-­alpha  
production  and  downregulation  of  the  MAP  kinases  p38  and  JNK.  Mol  Microbiol  
27(5):953-­965.  
   144  
214.   Muzio   M,   et   al.   (1996)   FLICE,   a   novel   FADD-­homologous   ICE/CED-­3-­like  
protease,   is   recruited   to   the   CD95   (Fas/APO-­1)   death-­-­inducing   signaling  
complex.  Cell  85(6):817-­827.  
215.   Vandenabeele  P,  Declercq  W,  Van  Herreweghe  F,  &  Vanden  Berghe  T   (2010)  
The   role   of   the   kinases   RIP1   and   RIP3   in   TNF-­induced   necrosis.   Sci   Signal  
3(115):re4.  
216.   Feoktistova  M,  Geserick  P,  Panayotova-­Dimitrova  D,  &  Leverkus  M  (2012)  Pick  
your   poison:   the   Ripoptosome,   a   cell   death   platform   regulating   apoptosis   and  
necroptosis.  Cell  Cycle  11(3):460-­467.  
217.   Green   DR,   Oberst   A,   Dillon   CP,   Weinlich   R,   &   Salvesen   GS   (2011)   RIPK-­
dependent  necrosis  and   its   regulation  by  caspases:  a  mystery   in   five  acts.  Mol  
Cell  44(1):9-­16.  
218.   Degterev  A,  et  al.  (2008)  Identification  of  RIP1  kinase  as  a  specific  cellular  target  
of  necrostatins.  Nat  Chem  Biol  4(5):313-­321.  
219.   Kang  TB,  Yang  SH,  Toth  B,  Kovalenko  A,  &  Wallach  D  (2013)  Caspase-­8  blocks  
kinase   RIPK3-­mediated   activation   of   the   NLRP3   inflammasome.   Immunity  
38(1):27-­40.  
220.   Vince  JE,  et  al.  (2012)  Inhibitor  of  apoptosis  proteins  limit  RIP3  kinase-­dependent  
interleukin-­1  activation.  Immunity  36(2):215-­227.  
221.   Antonopoulos   C,   El   Sanadi   C,   Kaiser  WJ,  Mocarski   ES,   &   Dubyak  GR   (2013)  
Proapoptotic   chemotherapeutic   drugs   induce   noncanonical   processing   and  
release  of  IL-­1beta  via  caspase-­8  in  dendritic  cells.  J  Immunol  191(9):4789-­4803.  
222.   McPhee  JB,  Mena  P,  Zhang  Y,  &  Bliska  JB  (2012)  Interleukin-­10  induction  is  an  
important   virulence   function   of   the  Yersinia   pseudotuberculosis   type   III   effector  
YopM.  Infect  Immun  80(7):2519-­2527.  
223.   Bossaller  L,  et  al.   (2012)  Cutting  edge:  FAS   (CD95)  mediates  noncanonical   IL-­
1beta   and   IL-­18   maturation   via   caspase-­8   in   an   RIP3-­independent   manner.   J  
Immunol  189(12):5508-­5512.  
224.   Park   JM,   et   al.   (2005)   Signaling   pathways   and   genes   that   inhibit   pathogen-­
induced   macrophage   apoptosis-­-­CREB   and   NF-­kappaB   as   key   regulators.  
Immunity  23(3):319-­329.  
225.   Chun   HJ,   et   al.   (2002)   Pleiotropic   defects   in   lymphocyte   activation   caused   by  
caspase-­8  mutations   lead   to   human   immunodeficiency.  Nature   419(6905):395-­
399.  
226.   Su   HC   &   Lenardo   MJ   (2008)   Genetic   defects   of   apoptosis   and   primary  
immunodeficiency.  Immunol  Allergy  Clin  North  Am  28(2):329-­351,  ix.  
227.   Bolze   A,   et   al.   (2010)   Whole-­exome-­sequencing-­based   discovery   of   human  
FADD  deficiency.  Am  J  Hum  Genet  87(6):873-­881.  
228.   Ch'en  IL,  Tsau  JS,  Molkentin  JD,  Komatsu  M,  &  Hedrick  SM  (2011)  Mechanisms  
of  necroptosis  in  T  cells.  J  Exp  Med  208(4):633-­641.  
229.   Dondelinger  Y,  et  al.   (2015)  NF-­kappaB-­Independent  Role  of   IKKalpha/IKKbeta  
in   Preventing   RIPK1   Kinase-­Dependent   Apoptotic   and   Necroptotic   Cell   Death  
during  TNF  Signaling.  Mol  Cell  60(1):63-­76.  
230.   Salmena  L,  et  al.   (2003)  Essential  role  for  caspase  8   in  T-­cell  homeostasis  and  
T-­cell-­mediated  immunity.  Genes  Dev  17(7):883-­895.  
231.   Ramirez-­Carrozzi   VR,   et   al.   (2006)   Selective   and   antagonistic   functions   of  
SWI/SNF   and   Mi-­2beta   nucleosome   remodeling   complexes   during   an  
inflammatory  response.  Genes  Dev  20(3):282-­296.  
232.   Besnault-­Mascard   L,   et   al.   (2005)   Caspase-­8   sumoylation   is   associated   with  
nuclear  localization.  Oncogene  24(20):3268-­3273.  
   145  
233.   Oberst   A   &   Green   DR   (2011)   It   cuts   both   ways:   reconciling   the   dual   roles   of  
caspase  8  in  cell  death  and  survival.  Nat  Rev  Mol  Cell  Biol  12(11):757-­763.  
234.   Kato  H,  et  al.  (2005)  Cell  type-­specific  involvement  of  RIG-­I  in  antiviral  response.  
Immunity  23(1):19-­28.  
235.   Yount   JS,   Gitlin   L,   Moran   TM,   &   Lopez   CB   (2008)   MDA5   participates   in   the  
detection   of   paramyxovirus   infection   and   is   essential   for   the   early   activation   of  
dendritic   cells   in   response   to   Sendai   Virus   defective   interfering   particles.   J  
Immunol  180(7):4910-­4918.  
236.   Mandal   P,   et   al.   (2014)   RIP3   induces   apoptosis   independent   of   pronecrotic  
kinase  activity.  Mol  Cell  56(4):481-­495.  
237.   Newton  K,  et  al.  (2014)  Activity  of  protein  kinase  RIPK3  determines  whether  cells  
die  by  necroptosis  or  apoptosis.  Science  343(6177):1357-­1360.  
238.   Remijsen   Q,   et   al.   (2014)   Depletion   of   RIPK3   or   MLKL   blocks   TNF-­driven  
necroptosis  and  switches  towards  a  delayed  RIPK1  kinase-­dependent  apoptosis.  
Cell  Death  Dis  5:e1004.  
239.   Donepudi  M,  Mac  Sweeney  A,  Briand  C,  &  Grutter  MG  (2003)   Insights   into   the  
regulatory  mechanism  for  caspase-­8  activation.  Mol  Cell  11(2):543-­549.  
240.   Zhang   DW,   et   al.   (2009)   RIP3,   an   energy   metabolism   regulator   that   switches  
TNF-­induced  cell  death  from  apoptosis  to  necrosis.  Science  325(5938):332-­336.  
241.   Wu   YT,   et   al.   (2011)   zVAD-­induced   necroptosis   in   L929   cells   depends   on  
autocrine  production  of  TNFalpha  mediated  by   the  PKC-­MAPKs-­AP-­1  pathway.  
Cell  Death  Differ  18(1):26-­37.  
242.   Kang   TB,   et   al.   (2008)   Mutation   of   a   self-­processing   site   in   caspase-­8  
compromises  its  apoptotic  but  not  its  nonapoptotic  functions  in  bacterial  artificial  
chromosome-­transgenic  mice.  J  Immunol  181(4):2522-­2532.  
243.   Gringhuis  SI,   et   al.   (2012)  Dectin-­1   is   an   extracellular   pathogen   sensor   for   the  
induction   and   processing   of   IL-­1beta   via   a   noncanonical   caspase-­8  
inflammasome.  Nat  Immunol  13(3):246-­254.  
244.   Maelfait   J,   et   al.   (2008)   Stimulation   of   Toll-­like   receptor   3   and   4   induces  
interleukin-­1beta  maturation  by  caspase-­8.  J  Exp  Med  205(9):1967-­1973.  
245.   Moriwaki  K,  et  al.  (2014)  The  necroptosis  adaptor  RIPK3  promotes  injury-­induced  
cytokine  expression  and  tissue  repair.  Immunity  41(4):567-­578.  
246.   Cuda  CM,  et  al.   (2014)  Caspase-­8  acts  as  a  molecular   rheostat   to   limit  RIPK1-­  
and  MyD88-­mediated  dendritic  cell  activation.  J  Immunol  192(12):5548-­5560.  
247.   Cuda  CM,  et  al.  (2015)  Conditional  deletion  of  caspase-­8  in  macrophages  alters  
macrophage  activation  in  a  RIPK-­dependent  manner.  Arthritis  Res  Ther  17:291.  
248.   Nilsen  NJ,  et  al.  (2015)  A  role  for  the  adaptor  proteins  TRAM  and  TRIF  in  toll-­like  
receptor  2  signaling.  J  Biol  Chem  290(6):3209-­3222.  
249.   Wang   L,   Du   F,   &   Wang   X   (2008)   TNF-­alpha   induces   two   distinct   caspase-­8  
activation  pathways.  Cell  133(4):693-­703.  
250.   Feng   S,   et   al.   (2007)   Cleavage   of   RIP3   inactivates   its   caspase-­independent  
apoptosis  pathway  by  removal  of  kinase  domain.  Cell  Signal  19(10):2056-­2067.  
251.   Kelliher   MA,   et   al.   (1998)   The   death   domain   kinase   RIP   mediates   the   TNF-­
induced  NF-­kappaB  signal.  Immunity  8(3):297-­303.  
252.   Takahashi  N,   et   al.   (2014)  RIPK1  ensures   intestinal   homeostasis   by   protecting  
the  epithelium  against  apoptosis.  Nature  513(7516):95-­99.  
253.   Berger   SB,   et   al.   (2014)   Cutting   Edge:   RIP1   kinase   activity   is   dispensable   for  
normal  development  but  is  a  key  regulator  of  inflammation  in  SHARPIN-­deficient  
mice.  J  Immunol  192(12):5476-­5480.  
   146  
254.   Weinlich   R,   et   al.   (2013)   Protective   roles   for   caspase-­8   and   cFLIP   in   adult  
homeostasis.  Cell  Rep  5(2):340-­348.  
255.   Zhou   Q,   et   al.   (1997)   Target   protease   specificity   of   the   viral   serpin   CrmA.  
Analysis  of  five  caspases.  J  Biol  Chem  272(12):7797-­7800.  
256.   Blagoev   B,   et   al.   (2003)   A   proteomics   strategy   to   elucidate   functional   protein-­
protein  interactions  applied  to  EGF  signaling.  Nat  Biotechnol  21(3):315-­318.  
257.   Pop   C   &   Salvesen   GS   (2009)   Human   caspases:   activation,   specificity,   and  
regulation.  J  Biol  Chem  284(33):21777-­21781.  
258.   Timmer   JC   &   Salvesen   GS   (2007)   Caspase   substrates.   Cell   Death   Differ  
14(1):66-­72.  
259.   Xu  G,   et   al.   (2001)   Covalent   inhibition   revealed   by   the   crystal   structure   of   the  
caspase-­8/p35  complex.  Nature  410(6827):494-­497.  
260.   Qiao   Y,   et   al.   (2013)   Synergistic   activation   of   inflammatory   cytokine   genes   by  
interferon-­gamma-­induced  chromatin   remodeling  and   toll-­like  receptor  signaling.  
Immunity  39(3):454-­469.  
261.   Buenrostro  JD,  Wu  B,  Chang  HY,  &  Greenleaf  WJ  (2015)  ATAC-­seq:  A  Method  
for  Assaying  Chromatin  Accessibility  Genome-­Wide.  Curr  Protoc  Mol  Biol  109:21  
29  21-­29.  
262.   Rao   P,   et   al.   (2010)   IkappaBbeta   acts   to   inhibit   and   activate   gene   expression  
during  the  inflammatory  response.  Nature  466(7310):1115-­1119.  
263.   Kawadler   H,   Gantz   MA,   Riley   JL,   &   Yang   X   (2008)   The   paracaspase   MALT1  
controls  caspase-­8  activation  during  lymphocyte  proliferation.  Mol  Cell  31(3):415-­
421.  
264.   Chen  NJ,  et  al.  (2008)  Beyond  tumor  necrosis  factor  receptor:  TRADD  signaling  
in  toll-­like  receptors.  Proc  Natl  Acad  Sci  U  S  A  105(34):12429-­12434.  
265.   Smale  ST  &  Natoli  G   (2014)  Transcriptional   control  of   inflammatory   responses.  
Cold  Spring  Harb  Perspect  Biol  6(11):a016261.  
266.   Smale   ST,   Tarakhovsky   A,   &   Natoli   G   (2014)   Chromatin   contributions   to   the  
regulation  of  innate  immunity.  Annu  Rev  Immunol  32:489-­511.  
267.   Fontana   MF,   et   al.   (2015)   Myeloid   expression   of   the   AP-­1   transcription   factor  
JUNB   modulates   outcomes   of   type   1   and   type   2   parasitic   infections.  Parasite  
Immunol  37(9):470-­478.  
268.   Fontana   MF,   et   al.   (2015)   JUNB   is   a   key   transcriptional   modulator   of  
macrophage  activation.  J  Immunol  194(1):177-­186.  
269.   Albert  R   (2005)  Scale-­free  networks   in  cell  biology.  J  Cell  Sci  118(Pt  21):4947-­
4957.  
270.   Brodsky   IE   &  Medzhitov  R   (2009)   Targeting   of   immune   signalling   networks   by  
bacterial  pathogens.  Nat  Cell  Biol  11(5):521-­526.  
  
